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Abstract 
Prostate cancer (PC), is initially androgen dependent due to the androgenic nature of the 
organ. Hence, initial therapy comprises androgen depletion via chemical castration in 
conjunction with an anti-androgen therapeutic. However, patients relapse and the tumours 
aggressively re-grow in a castrate resistant (CRPC) manner.  
In CRPC, androgen receptor (AR) signaling remains functional via numerous mechanisms 
hence the AR remains a viable therapeutic target. However, treatment with current AR 
targeting therapeutics also results in relapse indicating the potential of targeting AR signaling 
indirectly by targeting AR co-factors.  Recently, KMT5A, a lysine methyltransferase, has 
been identified as an AR co-activator exclusively in models of CRPC. A number of KMT5A 
inhibitors have been identified recent years, which would enhance the possibility of targeting 
KMT5A in PC.  
This thesis aims to determine the signature of genes that are regulated directly by KMT5A or 
by combined activities of AR and KMT5A in PC cell lines and to further identify biomarkers 
for KMT5A activity. These aims were approached using Illumina Human HT-12 arrays to 
detect KMT5A gene expression profiles in an in vitro cell line model of androgen 
independent PC (LNCaP-AI cells). Microarray data analysis revealed a number of androgen- 
regulated genes to be modulated by KMT5A concurrently, and other genes that were found to 
be regulated by KMT5A activity, and a further cohort of genes that were found to be 
regulated solely by KMT5A. 
CDC20 was selected for further study from the identified KMT5A regulated genes as a 
possible biomarker for KMT5A activity in aggressive PC. KMT5A was found to regulate 
CDC20 mRNA and protein expression. The enzymatic activity of KMT5A was demonstrated 
to affect CDC20 expression through the enrichment of the H4K20me1 mark at the CDC20 
promoter in androgen-sensitive (LNCaP) and androgen-independent (LNCaP-AI) cells. The 
regulation of CDC20 by KMT5A expression, therefore identifies CDC20 as putative 
biomarker for KMT5A activity. KMT5A was also shown to influence CDC20 expression via 
p53. Knockdown of KMT5A inhibited the mono-methylation of p53 at K382 to enhance p53 
activity, demonstrated by increased p21 expression which negatively regulated CDC20 
ii 
 
expression. These findings were confirmed using commercially available KMT5A inhibitors 
Ryuvidine and UNC0379.  
In summary, KMT5A inhibition in PC cells using small molecule inhibitors may provide 
benefit to patients that have relapsed on AR- targeting therapeutics and as such requires 
further investigation as a potential therapeutic target. CDC20 was identified as a putative 
biomarker for KMT5A activity which may prove useful to detect effective KMT5A inhibition 
in these studies. 
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1.1. The prostate 
1.1.1. Function of the prostate 
In the adult male, the prostate gland is a pyramid-shaped organ weighing 30-40 g. About the 
size of a walnut, it lies below the urinary bladder and is located in front of the rectum in the 
pelvis. The base contacts the bladder and the apex contacts the urethra. The prostate is 
responsible for secreting a milky, alkaline fluid containing  secretory proteins that help to 
nurture and protect the sperm as well as maintaining its viability and motility (Abate-Shen 
and Shen, 2000; McNeal, 2006a). 
1.1.2. Zonal anatomy of the prostate  
The prostate gland contains three major glandular regions  which differ histologically and 
biologically: the peripheral zone, the central zone, and the transition zone ( Figure 
1.1)(McNeal, 2006b; Shah, 2012) 
 •Transition zone:  forms about 5-10 % of the prostate volume, and surrounds the urethra 
between bladder neck and colliculus. A detectable increase in this zone volume occurs in 
benign prostatic hyperplasia (BPH) accompanied by lower urinary tract symptoms (LUTS) 
(McNeal, 2006a).  
•Central zone:  forms about 25 % of the prostate volume. The central zone forms a funnel 
(sagittal section) or ring-like (horizontal) zone that contains the ejaculatory ducts. This zone is 
relatively resistant to carcinoma and other disease (McNeal, 2006a). 
•Peripheral zone:  forms about 70 % of the prostate volume. The anterior fibromuscular 
stroma forms about 5 % of the prostate volume, and is located anterior to the urethra and 
extends into the transition zone (McNeal, 2006a). 
There are also several important non glandular regions concentrated in the anteromedial 
portion of the gland. Each glandular zone has specific architectural and stromal features. In all 
zones, both ducts and acini are lined by secretory epithelium. In each zone, there is a layer of 
basal cells beneath the secretory lining, as well as interspersed endocrine-paracrine cells 
(Benninghoff, 1988). 
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Figure 1-1 Zonal anatomy of the prostate gland. Schematic illustrating the 
anatomy of the human prostate, adapted from (McLaughlin et al., 2005). 
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1.1.3. Histology of the prostate 
The prostate epithelium comprises the prostatic ducts with four cell types, including basal, 
secretory luminal, neuroendocrine and stem cells. The stromal part of the prostate consists of 
smooth muscle, vascular endothelial cells, nerve cells, fibroblasts, inflammatory cells, soluble 
factors and insoluble matrix (Josson et al., 2010). The secretory luminal cells are androgen- 
dependent cells which are responsible for the secretion of the secretory proteins into the 
luminal duct. The basal cells are located between the luminal cells and the basement 
membrane, and although they are regarded as androgen-independent, they are thought to be 
the site of the putative prostate stem cells. 
Following androgen deprivation therapy, stem cells are suggested to play a role in  androgen 
independent prostate cancer (PC) growth and development (Richardson et al., 2004). In the 
case of androgen dependent PC models, studies showed that androgen depletion will reduce 
the putative stem cells proportion in the tumour cells population, and with the progression of 
the disease into the androgen independent stage, the ratio of androgen- independent stem cells 
will be highly increased, and that androgen replacement prior to the progression of the disease 
might enhance the susceptibility of hormonal manipulation of the androgen dependent tumour 
(Hussain et al., 2013).  
Neuroendocrine cells are the third most common cell type of prostatic epithelium. 
Neuroendocrine cells have been regarded as part of the diffuse APUD (Amine Precursor 
Uptake and Decarboxylation) system, elements of which display epithelial, endocrine as well 
as neuronal characteristics with nerve-like dendritic processes. It also considered as androgen 
independent cells (Szczyrba et al., 2016)(Figure 1.2). 
Prostate specific antigen (PSA) screening test is used for detection of PC. KLK3 is an 
androgen regulated gene encoding a serine protease that is a major prostate secreted protein 
that maintains fluidity in the seminal fluid. Serum PSA levels can be used as a tumour marker 
for PC.  The age-specific cut-off PSA measurements recommended by the Prostate Cancer 
Risk Management Programme are as follows: aged 50−59 years ≥ 3.0 ng/ml; aged 60−69 
years ≥ 4.0 ng/ml and aged 70 years and older ≥ 5.0 ng/ml, according to the referral 
guidelines for suspected cancer issued by NHS in 2005. However, a widespread controversy 
about PSA screening test has been developed (Hamdy et al., 2016). Two large-scale 
randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in 
the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in 
Europe were done to assess whether screening reduces prostate cancer mortality. The age of 
the participants at enrolment varies by country between 50–74 years. A PSA test is the 
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principal screening method at all centres, and several centres also use digital rectal 
examination and/or transrectal ultrasound as additional screening tests. The results showed 
that organized screening reduces PC mortality but is associated with over diagnosis. 
Opportunistic PSA testing had little if any effect on PC mortality and resulted in more over 
diagnosis, with almost twice the number of men needed to be diagnosed to save one man from 
dying from PC compared to men offered an organized biennial screening program (Godtman 
et al., 2015). 
 
 
 
 
 
 
Figure 1-2 Schematic overview of cells in the prostate epithelium. 
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1.2. Androgen receptor 
1.2.1. Structure of androgen receptor 
The effect of androgen is mediated through the androgen receptor (AR) and plays a crucial 
role in controlling the embryonic development and adult function of the prostate, as well as 
growth of PC.  AR is a transcription factor that regulates gene expression in response to its 
ligand in target cells. It is a member of the nuclear receptors superfamily of transcription 
factors (Shah, 2012; El-Amm, 2013; Gelman, 2002) and categorized as NR3C4 (nuclear 
receptor subfamily 3, group C, member 4) (Fang et al, 2003; Lu et al., 2006). The AR gene is 
composed of eight exons that encode four functional domains (Shah, 2012; El-Amm, 2013):  
• The NH2-terminal transactivation domain (NTD). 
• The central DNA-binding domain (DBD) 
• Hinge region. 
• COOH-terminal ligand-binding domain (LBD).  
The eight exons in AR encode a protein of ~919 amino acids (Koochekpour, 2010). The AF-1 
and AF-2 transactivation domains are located in the NTD and the LBD respectively and are 
required for optimal transactivation (Figure 1.3) (Shafi et al., 2013).  
AR is expressed as two isoforms: the first is the predominant isoform B (110 kDa) and the 
second is the less dominant isoform A (∼80 kDa). Additional novel AR splice variants have 
been described in androgen-insensitive PC cell lines designated as AR1, AR2, AR3, AR4, and 
A5A, AR6 (Hu et al., 2009; Koochekpour, 2010) and androgen receptor splice variant 7 
messenger RNA (AR-V7) which was identified  in circulating tumour cells from patients 
receiving enzalutamide or abiraterone. Although multiple androgen-receptor variants have 
been discovered, AR-V7 is the only known androgen-receptor variant encoding a functional 
protein product that is detectable in clinical specimens (Antonarakis et al., 2014). The amino 
acid length of the AR protein varies between individuals due to difference in the numbers of 
polyglutamine (for most men 19–25) and polyglycine repeats. The polyglutamine length has 
been inversely associated with AR transcriptional activity. Both repeats are encoded within 
exon 1 in the amino terminal domain. Higher levels of transcriptional activity in multiple cell 
types are a result of shorter glutamine repeats (Beisel et al., 2002) (Figure 1.3).
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Figure 1-3 Schematic representation of the androgen receptor gene and 
protein, with indications of its specific domains and splice variants.U: 
unique N- or C-terminal sequence. Adapted from (Guo and Qiu, 2011; 
Lonergan and Tindall, 2011).
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1.2.2. Mechanism of action  
The majority of testosterone entering the cell is converted by membrane-bound enzyme 5α-
reductase to 5α-dihydrotestosterone (DHT) in the cytoplasm. DHT is a more potent form of 
androgen that has a higher binding affinity for the AR (Feldman and Feldman, 2001). AR 
becomes detached from heat shock proteins (HSP) that were bound to prevent unnecessary 
activation of AR and to stabilise the receptor. AR then undergoes a conformational changes, 
dimer formation and nuclear translocation for subsequent DNA interaction.  
There are different regions of the AR that are involved in dimerization. These include, DBD –
mediated dimerization which facilitates AR binding to DNA elements known as androgen 
responsive elements (AREs) in target gene promoter and regulates transcription (Feldman and 
Feldman, 2001; Li and Al-Azzawi, 2009). AR (LBD and DBD) domains in addition to AR 
protein-protein interaction play an important role in the androgen regulated gene expression. 
AR protein-protein interaction is mediated by DBD interaction in AR homodimers, a process 
which usually follows an interaction between AR coactivator grooves in the LBD with the 
FQNLF motif in the N-terminal domain (N/C interaction) occurring in the cytoplasm, prior to 
DBD interaction, an initial step for nuclear N/C interaction (van Royen et al., 2012). 
In the nucleus, the AR dimer binds to AREs in the target genes and initiates the recruitment of 
a number of cofactors that are necessary for regulation of gene expression. AR transcriptional 
activity is controlled by the co-regulators which impact on AR binding capacity and ligand 
selectivity (Li and Al-Azzawi, 2009). The function of AR can be regulated by these co-
regulators either by inhibiting (co-repressors) such as Calreticulin, Cyclin D1, HBO1,  or 
promoting (co-activator) transcriptional activity such as ARA24, STUB1, NCOR2, ART-27, 
TF11F, Zimp, CBP,  AES, TFIIH, STAT3, BRCA1, DAXX, BRCA2, SRC1, GSN, Rb, 
PIAS1, p300, ARIP4, ARIP3/PIASXa, ARA55/HIC-5, TRAP220, ARA70/NCOA4, TIP60, 
TIF2/GRIP1/SRC2, ARA54, AIB3/ASC-2, CYCLIN D1, ARA160/TMF1, NCOR1, 
AIB1/SRC3/ NCOA3. These co- regulators have a role in DNA modification at the promoter 
of target genes either directly by modification of histones or indirectly through the recruitment 
of chromatin-modifying complexes which also play a role in the recruitment of the basal 
transcriptional machinery (Heemers and Tindall, 2007; Li and Al-Azzawi, 2009) (Figure 1.4). 
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Figure 1-4 Mechanism of androgen receptor action. Testosterone is 
converted to DHT by 5-alpha reductase in the membrane of the cell. DHT then 
binds to the AR, HSPs dissociate, and conformational changes take place to allow 
homo-dimerization, phosphorylation and translocation into the nucleus where AR 
binds to sequences in the DNA, termed androgen response elements to activate 
transcription. Adapted from (Li and Al-Azzawi, 2009).
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1.3. Prostate Diseases 
1.3.1. Benign prostatic hyperplasia (BPH) 
BPH is a pathological condition of the prostate that is caused by changes in the epithelial and 
stromal cells of the prostate, due to the effect of DHT on the aging prostate. BPH commonly 
arises in the transition zone and occurs in about 70 % of men over 70 years old. Increased 
pressure produced by increased stromal tissue content, which can reach up to 60 % of the 
prostate size, results in obstruction of the urinary flow and is considered as the major 
symptom of the disease (Foster, 2000). To prevent the disease progression, 5α-reductase 
inhibitors such as finasteride are often used to reduce the conversion of testosterone to DHT 
and thus the proliferative potential of the transition zone. In addition to this, selective α1-
adrenergic inhibitors such as alfuzosin are used to relax the smooth muscle, thereby reducing 
the constriction of the urethra (Bechis et al., 2014) (Figure 1.5.A). 
 
 
1.3.2. Prostatic Intraepithelial Neoplasia (PIN) 
Malignant transformation of cells is a gradual process which starts within benign cells which 
evolves into a malignant form. PIN is a pre-malignant condition of the prostate cells that has 
been defined as “neoplastic growth of epithelial cells within pre-existing benign prostatic 
acini or ducts.” (Kim and Yang,2002). It is considered as the intermediate stage between 
benign epithelium and invasive carcinoma (Ayala and Ro, 2007). PIN can be identified 
histologically by the changes in the ductal structure as it becomes darker and thicker than the 
normal surrounding ducts with some intra-luminal growth abnormalities which can also be 
detected (Ayala and Ro, 2007).Three grades of PIN have been identified based on the 
histological changes that take place starting from low grade PIN to high grade PIN (HGPIN) 
(McNeal and Bostwick, 1986). As with PC, the severity and incidence of HGPIN is increased 
with age and they are both more likely to develop within the peripheral zone of the prostate 
(Ayala and Ro, 2007) (Figure 1.5.B). 
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1.3.3. Prostate Cancer 
Adenocarcinomas comprise the majority (more than 95 %) of PC. Transitional cell 
carcinomas account for approximately 4.5 %, with the remainder being rare neuro-endocrine 
carcinomas or sarcomas (Kumar and Anderson, 2002; Swallow et al., 2012). Prostate 
adenocarcinoma cells are characterised by enlarged, hyperchromatic nuclei with projecting 
nucleoli and profuse cytoplasm. In PC, the basal cell layer is frequently absent, while it is 
present in the normal glands and in BPH glands.  
About 10% of PCs occur within the central zone, 20 % originate in the transition zone and 
70% are found in the peripheral zone. High-grade PIN is associated with invasive PC in 80 % 
of cases, whereas low-grade has this association in only 20% of cases (Kumar and Anderson, 
2002; Swallow et al., 2012). PC can be classified histologically into 5 grades: Grade 1( only 
individual discrete well-formed glands), Grade 2 (predominantly well-formed glands with 
lesser component of poorly formed/fused/cribriform glands), Grade 3 (predominantly poorly 
formed/ fused/cribriform glands with lesser component of well-formed glands), Grade 4 ( 
Only poorly formed/fused/cribriform glands or- predominantly well-formed glands and lesser 
component lacking glands - predominantly lacking glands and lesser component of well-
formed glands), and Grade5 (lack of gland formation (or with necrosis) with or without 
poorly formed/fused/cribriform glands)(Epstein et al., 2016) (Figure 1.5.C). 
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Figure1-5 Prostate diseases. (A)Benign prostatic hyperplasia ( 
www.sciencephoto.com) (B)Prostatic Intraepithelial Neoplasia 
(library.med.utah.edu)(C) Prostate Cancer (www.proteinatlas.org). 
A 
B 
C 
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1.3.4. Castration resistant prostate cancer 
Although chemical or surgical castration, which can reduce serum testosterone levels to <50 
ng/dl, has remained the most effective treatment for this disease for more than 60 years, recent 
studies indicate that PCs may generate intra-tumour androgenic steroids or become 
hypersensitive to low steroid levels through AR gene mutations or amplification of  the AR 
gene supporting continued tumour growth. AR-regulated genes contribute in several cellular 
processes that participate in PC initiation and progression. For patients with advanced PC, 
blocking AR signalling through specific inhibitors such as bicalutamide (Casodex) and 
enzalutamide or by androgen deprivation with abiraterone has been utilized as standard 
treatments (Attard et al., 2009; Cheng et al., 2015).  
In most patients the treatment is initially effective, but the diseases will develop into a lethal 
form that is known as castration resistant PC (CRPC). CRPC is characterized as showing an 
increase in serum PSA levels before the onset of additional symptoms (Andersen et al., 2010).  
The molecular mechanisms of castration resistance have been investigated recently and 
indicate that AR signalling continues in CRPC and plays an essential role in the progression 
of the disease (Sung  and Cheung., 2013) The role of AR in CRPC is supported by  research 
showing that the same genes which are elevated by androgens in androgen-dependent PC 
xenografts are also found increased in CRPC. This suggests that the AR in CRPC can be 
activated in the absence of testicular androgens and lead to recommencement of tumour 
growth (Sung  and Cheung., 2013). 
A recent study refers to the role of the glucocorticoid receptor (GR) in activation of a subset 
of target genes that is similar to those target genes of AR and maintenance of the resistant 
phenotype. AR mediated a negative feedback on GR, which was inhibited by the effect of 
anti-androgens and leads to up- regulation of GR. The study referred to the effect of using 
dexamethasone (GR agonist) in conferring enzalutamide resistance, while using GR 
antagonist to re-establish the sensitivity to enzalutamide.  These findings may explain the 
continued expression of AR target genes which play a role in CRPC by GR activation acting 
as  an AR mimic (Arora et al., 2013). 
Previously, MYB (a proto-oncogene protein, a member of the MYB (myeloblastosis) family 
of transcription factors) was found to interact with androgen-receptor (AR) in prostate cancer 
cells, and facilitates the nuclear localization of AR in a ligand-independent manner. It 
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additionally been suggest to play critical role in the CR progression of PC. Overexpression of 
MYB in mice models was found to significantly increased the tumour growth, while 
castration of the same mice models with overexpression of MYB have a slight effect of 
tumour growth (Srivastava et al., 2016). 
Additionally, a high-throughput genetic screen was performed to identify kinases that enable 
tumour formation by androgen-dependent prostate epithelial cells under androgen-deprived 
conditions. A mitotic-related serine/threonine kinase, NEK6, was identified as a mediator of 
androgen-independent tumour growth. Silencing NEK6 in CRPC cells was enough to restore 
the sensitivity to castration in a mouse xenograft model system. NEK6 was found to be 
overexpressed in a subset of human prostate cancers, and that NEK6 signalling was 
established  as a central mechanism mediating castration-resistant prostate cancer(Choudhury 
et al., 2016).  
 
1.3.5. Risk factors of prostate cancer 
There are many risk factors that could help to explain the high prevalence of PC. These 
factors are summarized as follow: 
1. Family history (Agalliu et al., 2013). 
2. Diet (Kristal et al., 2010). 
3. Genetic and environmental factors (Virlogeux et al., 2015). 
4. Chemicals (Koutros et al., 2013). 
 5.  Social status (Henry and O'Mahony, 1999). 
1.3.6. Treatment of prostate cancer  
There are a number of options for treatment of early stage PC: surgery, hormone therapy, 
radiotherapy, observation also known as active surveillance or watchful waiting (Postma, 
2006), also chemotherapy (Figure 1.6.). 
1. Radical prostatectomy: for elderly men with stable health conditions or young patients 
with more than 10 years life expectancy, surgical removal of the prostate gland is usually the 
most preferable treatment method (Henry and O'Mahony, 1999).Radical prostatectomy was 
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also suggested to reduce mortality among men with localized prostate cancer (Bill-Axelson et 
al., 2014) 
2. Hormone therapy: hormone therapy has been suggested as an adjuvant in combination 
with radiotherapy as it helps to increase survival rate of patients (Polkinghorn et al., 
2013).Depleting androgens involves the use of chemicals that interfere with the 
hypothalamic-pituitary-gonadal axis that controls prostate growth. The anterior pituitary gland 
is responsible for synthesis and releasing of luteinising hormone (LH) controlled by the 
hypothalamic luteinising hormone releasing hormone (LHRH) secreted in a pulsatile fashion. 
In the testis, the release of the testosterone by the Leydig cells is stimulated by the pituitary 
LH   (Feldman and Feldman, 2001). In the prostate, as previously mentioned, testosterone is 
reduced to DHT by the effect 5α- reductase. DHT then binds to the AR to induce transcription 
of androgen regulated genes to induce growth, proliferation and differentiation of PC cell. 
Therefore, LHRH agonists are used as one of PC possible therapies. However, the continuous 
administration of an LHRH agonist, which generally has substitutions of amino acids for 
glycine at six positions, increasing its affinity for the receptor and stability of binding makes 
LH release refractory to hypothalamic regulation. There is an initial rise in LH and 
testosterone levels, whilst LHRHR levels fall due to being continuously occupied; LH and 
testosterone levels begin to decline within three to four weeks. To prevent the initial flare in 
testosterone, either oestrogen or an anti-androgen pre-treatment can be used. LHRH agonists 
are considered as the standard of care in hormonal therapy because these agents have the 
potential of reversibility and enable the use of intermittent androgen-deprivation therapy 
(ADT), avoid the physical and psychological discomfort associated with orchiectomy, have a 
lower risk of cardiotoxicity than observed with diethylstilbestrol, andresult in equivalent 
oncologic efficacy) have been shown to lead to a survival benefit in men with CRPC (Henry 
and O'Mahony, 1999; Schweizer and Antonarakis, 2014). 
Another aspect of hormone therapy of PC is by using of anti-androgens such as FlutamideTM 
and BicalutamideTM which competitively bind to the AR and prevent the activation of the 
receptor (Di Lorenzo et al., 2005), thereby inhibiting the effect of androgens.  
Additional example of hormonal therapy of PC is Abiraterone acetate, which is a small 
molecular inhibitor that has been shown to have anti-tumour effects in CRPC. Castration is 
known to block gonadal testosterone generation. However, it has been suggested that 
androgens from non-gonadal sources drive the AR in CRPC. Abiraterone targets CYP17, a 
microsomal enzyme that has a key role in the synthesis of androgen by catalysing two 
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independent steroid reactions (Attard et al., 2008). Abiraterone has been shown to have 
significant anti-tumour activity in CRPC (Payton, 2012). 
3. Radiation therapy: Radiotherapy is recommended if the tumour extends beyond the 
capsule or has invaded the seminal vesicle. It can be delivered in two forms: 
* External beam irradiation: such as three-dimensional conformal radiation therapy which is 
suitable for fit elderly and young adult patients with more than 10 years life expectancy, it 
offers  equivalent  overall survival prospects to radical surgery (Henry and O'Mahony, 1999). 
* Brachytherapy:  implanting  radioactive seeds into the prostate gland under CT scan or 
ultrasound guidance, these seeds remain in situ and give a permanent intense local dose of 
radiation (Henry and O'Mahony, 1999). It allows for delivery of high doses of radiation to the 
prostate with relatively minimal dose to surrounding normal tissues (Kumar et al., 2016) 
4. Active surveillance:  usually suitable for older men, patients with advanced incurable 
disease and also patients with important co-morbidities. Presently, participants treated with 
active surveillance are selected based on specific criteria including localized disease, low 
KLK3 level, and  Gleason score of 6 or lower (Postma, 2006).  
5. Chemotherapy: Cytotoxic chemotherapy is rising as an effective treatment method for 
men with PC. In 2004, two important Phase III studies showed for the first time that 
chemotherapy provided a survival benefits in patients with CRPC. Both studies utilised 
docetaxel-based regimens; docetaxel plus prednisone became the standard first line therapy of 
CRPC. As a result of these studies, many researchers have tested this agent both in 
combination with other established agents and with novel chemotherapeutic and targeted 
therapies (Petrylak, 2005).  Furthermore, cabazitaxel has demonstrated its efficacy in patients 
pre-treated with docetaxel (Schweizer and Antonarakis, 2014). Another example is using 
mitoxantrone with a corticosteroid for patients with symptomatic hormone-refractory PC 
(SHRPC) which gives significant palliation with minimal toxicity. Estramustine can also be 
used combined with a variety of microtubular inhibitors (Gilligan and Kantoff, 2002). 
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Figure 1-6 Treatment of prostate cancer with stages. Adapted from 
(www.medscape.org). 
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1.4. Mechanisms of androgen independence in PC 
Various mechanisms can account for how PC can grow independently of androgens, these 
include: 
1. Intra-tumour androgens: through in situ metabolism and synthesis of androgens to 
overcome the low levels of circulating androgen by increasing the activity of  the 5-α 
reductase enzyme which is responsible for converting testosterone to DHT (Feldman and 
Feldman, 2001). 
2. AR amplification and hypersensitivity pathway: AR gene amplification is thought to be 
one of the methods by which cells become hypersensitive to androgen. Androgen independent 
cells in CRPC have been found to be activated by about four times less DHT than androgen 
dependent cells due to increased AR expression and stability (Gregory et al., 2001). Patients 
with AR amplification have been found to have a greater  survival rate than those with non-
AR amplified tumours, as they are found to better respond to second line total androgen 
blockade therapy (Palmberg et al., 2000). 
3. Promiscuous pathway: This could result from mutations in the AR LBD, that enable it 
bind to alternative ligands such as the AR antagonists flutamide and bicalutamide, or to 
progesterone to alternatively activate the AR. Gene amplification and point mutations have 
been frequently detected in PC and are associated with increased AR transcriptional activity 
and also correlate with tumour aggressiveness (Robinson et al., 2015; Munkley et al., 2016). 
Reducing its expression in PC cell lines decreases AR-dependent proliferation and inhibits the 
ability of AR either to activate or to repress target genes (Feldman and Feldman, 2001; 
Agoulnik et al., 2006; Mitsiades, 2013). 
4. Qualitative changes in the coregulatory components of the AR complex: AR 
coactivators and corepressors that modulate the transcriptional response can be dysregulated 
in cancer. For example, all three steroid receptor coactivators (SRC) of the p160 family (SRC-
1, SRC-2, and SRC-3) have been reported to be overexpressed in PC. SRC3 located on human 
chromosome 20q21 is more frequently amplified while amplification of either SRC1 or SRC2 
is rare in cancer (Xu et al., 2009). 
5. Activation of the AR complex by other signalling pathways (outlaw pathway): here AR 
can be activated independently of its ligand. In the absence of androgens, many factors have 
Chapter 1: Introduction 
 
 
19 
 
been found to activate AR such as insulin, fibroblast and epidermal growth factors (IGF, KGF 
and EGF). In addition, receptor tyrosine kinases (RTKs) are also found to be correlated with 
the phosphorylation of AR by either the AKT (protein kinase B) or the mitogen-activated 
protein kinase (MAPK) pathways, producing a ligand-independent activated AR (Feldman 
and Feldman, 2001; Mitsiades, 2013) ( Figure 1.7).
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Figure 1-7 Mechanisms of androgen independence in PC. The 
hypersensitive pathway (AR gene amplification). The promiscuous pathway, the 
specificity of the AR is extended so that it can be activated by non-androgenic 
molecules. The outlaw pathway, receptor tyrosine kinases (RTKs) are activated, 
and the AR is phosphorylated by either the AKT (protein kinase B) or the mitogen-
activated protein kinase (MAPK) pathway producing a ligand-independent AR. 
Adapted from Feldman and Feldman (2001). 
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1.5. Post-translational modification of the AR 
The AR is regulated by a number of PTMs including: phosphorylation, acetylation, 
methylation, sumoylation and ubiquitination. These modifications impact the AR through 
various mechanisms such as, modulating AR stability, localisation, structure or the AR 
interacting partners (Gioeli and Paschal, 2012) (Figure 1.8).  
 
Figure 1-8 Androgen receptor post translational modifications sites. 
Adapted from: https://commons.wikimedia.org 
 
 Phosphorylation 
Phosphorylation of the AR plays an important role in regulating AR activity through 
increasing or decreasing  protein interaction with AR domains (Gioeli and Paschal, 2012). 
The AR can be phosphorylated on serine, threonine and tyrosine residues by a number of 
kinases. For example, Cdk1, Cdk5 and Cdk9 mediate the phosphorylation of the AR on serine 
81 (S81) which is known to be essential in regulating the activity and localisation of the AR. 
Considering both pARser81 and pARser213 in combination may serve as a prognostic 
biomarker for CRPC and potential novel therapeutic targets (McAllister et al., 2016). 
Furthermore, AR phosphorylation at S256 and S308 are increased during AR nuclear 
localisation, whilst it is mainly phosphorylated at S94 when the AR is located in the 
cytoplasm. In addition to enhancing ligand-dependent activation, phosphorylation can 
enhance ligand independent activation of the AR which is mediated by the EGF family of 
receptor tyrosine kinases (Ferraldeschi et al., 2015). Moreover, phosphorylation can also 
cause upregulated AR activation by increasing AR-co-activator activity or by modifying AR 
itself, mediated by Aurora Kinase A (Aurora A) and Cdk1(Gioeli and Paschal, 2012). De-
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phosphorylation of the AR can be mediated by either altering the accessibility of the 
phosphosites or by the effect of Protein phosphatase 1 and 2A (PP1a, PP2A) which has been 
suggested to cause a site specific AR de-phosphorylation (Gioeli and Paschal, 2012). 
 Acetylation 
AR acetylation is also an important regulator of AR activity, a process that is mediated by 
p300 and p300/CREB binding protein (CBP)-associated factor at lysine residues K630, K632 
and K633 within the KLKK motif. Furthermore, it has been suggested that AR acetylation is a 
key regulator of PC cell apoptosis and growth (Fu et al., 2003).  The AR undergoes de-
acetylation by SIRT1 and the histone deactylases, HDAC1(Gioeli and Paschal, 2012). 
 Sumoylation 
Sumoylation is the covalent attachment of a small ubiquitin-like modifier (SUMO) through an 
iso-peptide linkage on lysine residues.  This process is catalysed by three enzymes, E1, E2 
and E3. AR sumoylation results in alteration in AR transcriptional regulation, nucleo-
cytoplasmic localisation, DNA replication and repair, cell cycle, and apoptosis. Two 
sumoylation sites, K386 and K520, have been identified which reside in the AR NTD (Van 
der Steen et al., 2013). Sumoylation of AR at its NTD weakens the interaction with LBD, a 
process necessary for transcriptional activation of AR (Coffey and Robson, 2012). AR 
sumoylation is mainly enhanced in the presence of androgen which would be explained by 
increasing the nuclear localisation of AR where the sumoylation enzymes are mostly present 
especially E1 and E2 (Coffey and Robson, 2012; Van der Steen et al., 2013). The role of AR 
variants  SUMOylation in CRPC are currently being investigated (Kounatidou and Gaughan, 
2016) 
 
 Ubiquitination 
Ubiquitination is the process of covalently attaching a highly conserved small protein, 
ubiquitin (Ub) to the substrate protein. An isopeptide bond links the C-terminal glycine 
residue of Ub to a lysine residue in the target protein which could lead to substrate 
inactivation through proteasomal-mediated degradation. For example, AR ubiquitination by 
CHIP, SPOP and MDM2 marks the AR for proteolysis by the proteasome. In addition to 
protein stability, ubiquitination also regulates the activity of its substrate protein (Coffey and 
Robson, 2012; Van der Steen et al., 2013). It is suggested that AR- Ub on androgen-
responsive genes promoters may prepare the promoter for the subsequent transcription 
process (Coffey and Robson, 2012). 
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It has previously been suggested that resveratrol, a polyphenol with antioxidant properties, 
has anti-cancerous effects in PCa by inducing apoptosis and inhibiting cell proliferation, and  
might indeed regulate ARV7 protein levels via the ubiquitin degradation pathway in CRPC 
(Cavero, 2016). 
Methylation 
The most recently described PTM of the AR is the methylation process. It has been found that 
the AR can be regulated indirectly through histone methylations and de-methylation, a 
process that can regulate AR transcription (Coffey and Robson, 2012). Two lysine residues, 
K630 and K632 which are located  in the AR hinge region are subject to methylation  which  
overlap with the acetylation sites (Van der Steen et al., 2013). SET9 has been described as 
one methyltransferase that catalyses AR methylation to facilitate N/C terminal domains 
interaction enabling the AR to interact with AREs in response to androgens. Moreover, SET9 
regulates the chromatin structure at AR regulated genes to modulate AR transcriptional 
activity (Gaughan et al., 2011; Ko et al., 2011). Knockdown of SET9 results in reduced AR 
binding to its target gene promoter KLK3 (Van der Steen et al., 2013).  Demethylation of the 
AR is mediated by the demethylase family members (KDM4A, KDM4B, KDM4C and 
KDM4D) which are considered as AR co-activators as demethylation of AR  facilitates its 
acetylation at the same lysine residues (Van der Steen et al., 2013).  In addition, a histone 
lysine methyl transferase (HMT), KMT5A, was identified as a putative AR regulatory protein 
by siRNA library screening.  (Coffey et al, un-published data).  
 
1.6. KMT5A (SET8, Pre-SET7) 
1.6.1. KMT5A structure and isoforms 
SETD8, which is the gene that encodes the KMT5A protein, is located on chromosome 
12q24.31. KMT5A is a member of the SET domain methyltransferase family that uses the 
cofactor S-adenosylmethionine (AdoMet) to catalyse the methylation of selected lysine 
residues in proteins. The SET methyltransferases were first discovered in Drosophila and 
took their name from the suppressor of variegation genes, Su (var)3-9, Enhancer of zeste and 
Trithorax (Couture et al., 2005). 
In particular, KMT5A is responsible for catalysing the majority of mono-methylation on 
histone H4 at lysine 20 (K20). Its specific function as a mono-methyltransferase is due to an 
evolutionarily conserved tyrosine residue in the enzymatic site of the SET domain, which 
hydrogen bonds with mono-methylated lysine residues, thereby inhibiting addition of further 
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methyl groups (guowei, 2002). Being a methyltransferase, KMT5A specificity to only mono-
methylate H4K20 was explained by crystallographic studies, which referred to KMT5A 
recognition channel as being too narrow to accommodate tri-methylated species (Beck, 2012).   
KMT5A protein consist of 393 amino acids ( www.uniprot.org ) comprising the following 
distinct functional domains (guowei, 2002): 
 The histone binding domain (HBD): located between residues 51-194 (Couture et al.,
2005; Yin et al., 2008a). 
 The enzymatically active SET domain: this conserved domain located between residues
195-393 (Couture et al., 2005; Yin et al., 2008a). The SET domain contains what is known as 
the inserted SET or iSET region in its structure. Both the sequence and the structure of iSET 
have a key role in determining the substrate specificity of the methyltransferase (Couture et 
al., 2005).  
 Two PCNA integrated peptides (PIP) domains:  which target KMT5A for degradation
during the S phase of the cell cycle. The PIP 1 box is located between residues 51-58, and the 
PIP 2 box is located between residues 178-185. When these regions are deleted KMT5A 
protein level is stabilised during S phase (Beck, 2012) (Figure 1.9). 
KMT5A protein resolves as a doublet on standard SDS-PAGE. PCR in the human 
osteosarcoma derived cell line U2OS, revealed that there are two isoforms of KMT5A, 
produced by alternative splicing. In addition to the known isoform within SETD8 exon 2, a 
second isoform for human KMT5A exist. The two isoforms are referred to as KMT5Aa and 
KMT5Ab (Abbas et al., 2010b). The larger isoform is migrate as 42 kDa protein, and the 
second isoform is around 3 kDa smaller as it lacks the first 41 amino acids in the KMT5A N-
terminus (http://www.uniprot.org/uniprot/Q9NQR1 ). 
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Figure 1-9 KMT5A protein structure. KMT5A consists of 393 amino acids and 
has two distinct functional domains; the histone binding domain (HBD) (residue 
51-194) and the SET domain or enzymatic domain (residues 195-393). There are 
two PIP boxes in its structure located in the HBD. PIP 1 box located between 
residues 51-58, while PIP 2 box located between 178-185 amino acid residues, 
through which KMT5A is targeted for degradation. 
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1.6.2. Post-translational modifications and regulation of KMT5A expression level 
The level of KMT5A fluctuates during the individual phases of the cell cycle. This regulation 
is seen at the protein level whereby protein destruction and stabilisation play key roles. 
Specifically, KMT5A is significantly increased during late S phase and the G2/M transition as 
the enzyme is specifically localized to mitotic chromosomes, then the levels of KMT5A 
decline during the transition to G1 (Rice et al., 2002). 
During M phase (specifically from prophase to metaphase), KMT5A becomes phosphorylated 
(Georgi et al., 2002). The predominant site of KMT5A phosphorylation during mitosis is at 
serine 29 (S29). The cdk1/cyclin B complex  recognizes a short conserved region containing a 
Cdk phosphorylation consensus sequence, to induce the S29 phosphorylation of KMT5A 
specifically in the transition from prophase to anaphase (Brustel et al., 2011). Importantly, 
this phosphorylation event has two functional consequences. Firstly, phosphorylation of 
KMT5A results in its removal from mitotic chromosomes and relocation to the 
extrachromosomal space, subsequent to global accumulation of H4K20me1 in G2 phase. 
Secondly, phosphorylation of KMT5A stabilizes KMT5A levels by directly inhibiting its 
ubiquitination and degradation by the APCcdh1 E3 ubiquitin ligase (Wu et al., 2010).  
During early anaphase, it was found that KMT5A is dephosphorylated by the Cdc14 
phosphatase resulting in anaphase promoting complex (APCcdh1)-mediated ubiquitination and 
degradation of KMT5A consistent with the observed decrease in KMT5A levels at G1 phase 
(Wu et al., 2010). 
It was previously reported that endogenous KMT5A levels during G1phase are sustained, 
although greatly reduced compared to G2/M until cells begin to transition through S phase 
(Wu and Rice, 2011).  Prior to S phase at the G1/S transition, KMT5A is ubiquitinated by the 
SCFSkp2 ubiquitin ligase resulting in the degradation of KMT5A. SCFSkp2 remains active 
during DNA replication suggesting that it may also participate in KMT5A degradation during 
S phase (Yin et al., 2008a).  
KMT5A was recently reported to be recruited to DNA replication foci via interaction with the 
proliferating cell nuclear antigen (PCNA) and importantly, this recruitment was shown to be 
required for proper DNA replication (Wu and Rice, 2011). Interestingly, the KMT5A protein 
is virtually undetectable during S phase despite relatively high levels of KMT5A transcription 
indicating that KMT5A must be rapidly degraded following its recruitment to replication foci. 
Several reports demonstrate that the CRL4cdt2 ubiquitin ligase complex is specifically 
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responsible for the degradation of chromatin-bound KMT5A during S phase (Wu et al., 
2010). 
Fluctuations in the level of H4K20me1 during the cell cycle, which peaks during mitosis 
appears to be consistent with the expression and localization of KMT5A. The resulting Lys-
20 methylation can be preserved beyond a single round of cell division, suggesting that 
KMT5A imprints an epigenetic inscription in transcriptional silencing (Couture et al., 2005) 
(Figure 1.10). 
 
Figure 1-10 KMT5A levels of activity during cell cycle. KMT5A degraded by 
the SCFskp2 ubiquitin ligase to allow the entrance into S phase, which results in 
removal of KMT5A from chromatin. KMT5A degradation is mainly mediated by 
the CRLcdt2 ubiquitin ligase during S-phase to prevent DNA re-replication and 
defective chromatin condensation. Cyclin B/CDK1 then catalyse the increase in 
KMT5A expression for mitotic entry mainly at the transition between S and G2 
phase. APCcdh1 catalyse KMT5A degradation to mediate a proper transition from 
metaphase to anaphase. 
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1.6.3. Functions of KMT5A 
1.6.3.1. Methylation of H4K20  
 The specific mono-methylation of lysine 20 of histone H4 (H4K20) has been found in a large 
number of species, which would indicate that this methylation is an evolutionarily conserved 
process. This process plays an essential role in cell cycle dependent transcriptional silencing 
and mitotic regulation in metazoans (Couture et al., 2005). The mono-, di- and tri-methylation 
of H4K20 is mainly catalysed by histone methyltransferases that belong to the SET domain 
family of proteins. However, Dot1 can also catalyse this activity although it is not a SET 
domain family member (Balakrishnan and Milavetz, 2010). 
The main SET domain containing H4K20 methyltransferases are KMT5A (responsible for 
generating H4K20me1), Suv4-20 (Suv4-20h1/KMT5B), (responsible for generating 
H4K20me2) and Suv4-20h2/KMT5C (responsible for generating H4K20me3) (Fang et al., 
2002; Pannetier et al., 2008).  
In vivo studies suggest that the loss of KMT5A reduces the creation of H4K20me1 as well as 
subsequent methylated states, i.e. H4K20me2 and H4K20me3. This suggests that in order for 
enzymatic activity to be accomplished, the KMT5B and KMT5C methyltransferases require a 
template in the form of H4K20me1 for catalysing di- and tri-methylation (Balakrishnan and 
Milavetz, 2010). 
Histone H4 inserts in the substrate-binding cleft of KMT5A as an extended parallel β strand, 
while, residues located N-terminal to Lys-20 in H4 are involved in an extensive array of salt 
bridge, hydrogen bond, and van der Waals interactions with KMT5A while the residues C-
terminal to Lys-20 residues bind through mainly hydrophobic interactions. Mutational 
analysis of both histone H4 and the substrate-binding cleft indicated that interactions with 
residues in the N and C termini of the H4 peptide are important to produce the substrate 
specificity (Couture et al., 2005).   
KMT5A, independent of its methyltransferase activity, has also been suggested to play a part 
in creating a trans-tail histone code by recruiting a H3K4 methyltransferase to mark distinct 
regions of silent chromatin within the mammalian epigenome (Sims et al., 2006). The histone 
methyltransferase KMT5A specifically mono-methylates H4K20 to maintain silent chromatin 
and effect chromatin compaction as a prerequisite for mitotic chromosome separation (Lee 
and Zhou, 2010), also the studies on KMT5A showed that it has a role in transcriptional 
silencing in metazoans (Couture et al., 2005). In addition, Ash1, which is a multi-catalytic 
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histone methyltransferase, can methylate K20 in H4 and lysine residues 4 and 9 in H3. 
Transcriptional activation by Ash1 relates to methylation of these three lysine residues at 
Ash1 target gene promoters (Beisel et al., 2002). Hence, there is still a debate in the field of 
chromatin biology about the preferential localization of this histone modification, despite the 
evidence of the distribution of these proteins throughout chromatin (Balakrishnan and 
Milavetz, 2010). 
Lysine methylation can be reversed in humans by two demethylase families, firstly the 
Jumonji C and secondly the lysine-specific demethylase families. Deregulated expression 
observed for several histone demethylases in cancer  and the regulatory role of histone 
demethylases in controlling  the function of steroid receptors, including both the oestrogen 
receptor and AR, suggest a significant role in development and progression of tumours such 
as prostate and breast (Stratmann and Haendler, 2012). 
1.6.3.2. Methylations of non-histone proteins 
KMT5A catalytic activity is not restricted to histone proteins, as like many other 
methyltransferases, KMT5A can methylate non-histone proteins including: 
p53 
The tumour suppressor p53 is a key transcription factor induced in response to DNA damage 
and recognized as a binding partner for L3MBTL1 and as a methylation substrate of KMT5A. 
p53 is methylated on lysine 382 by KMT5A which is shown to inhibit the transcription of a 
number of target genes, including the CDK inhibitor, p21. In normal cell cycle conditions, 
this methylation is essential to inhibit the transcription of p21 and allow the cell cycle to 
progress (Jørgensen et al., 2013). The inhibitory consequence of p53 methylation at K382 by 
KMT5A on p53 transcriptional activity can be explained by this specific methylation site 
being located within the binding site of L3MBTL1 (West et al., 2010). p53 K382me1 has 
been found to be attenuated at the promoter of some cell cycle arrest and apoptosis genes, 
while it is enriched at the promoter of GADD45 (p53 dependent DNA repair genes), which 
may indicate a shift in the transcriptional program of p53 K382me1 toward DNA repair in 
tumour cells (Shi et al., 2007). 
Numb 
Numb initially known as the determinant of cell fate in Drosophila, has four main isoforms 
(p65, p66, p70, and p71) which all contain a C-terminal proline-rich region (PRR) and an N-
terminal phospho-tyrosine binding (PTB) domain. The differences between theses domains 
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are short sequence that may be present or absent in the PRR and/or PTB regions. KMT5A has 
been found to methylate Numb in its phospho-tyrosine-binding (PTB) domain, which leads to  
inhibition of p53-dependent apoptosis, while demethylation of Numb promotes p53-
dependent apoptosis (Dhami et al., 2013). 
1.6.3.3. DNA damage and repair 
Following the formation of a DNA double strand break (DSBs), which is one of the cytotoxic 
types of DNA damage that if improperly repaired may lead to oncogenic chromosomal 
rearrangement, the DNA damage repair (DDR) pathway is activated to recruit a number of 
proteins required for efficient DNA repair to take place. Previous studies have reported the 
role of KMT5A in the mono-methylation of H4K20 across the genome which is required for 
53BP1 to bind to the chromatin. Following DNA damage, H4K20me1 has been shown to be 
associated with the accessibility of DNA damage foci for DNA repair proteins recruitment 
(Houston et al., 2008). However, the mechanism by which this occur is not clear. Following 
DSB formation, the first event in DNA damage repair (DDR) is the phosphorylation of 
ϒH2AX at serine 139 by ATM, ATR, and DNA-PK. This is followed by MDC1 binding (a 
direct ϒH2AX reader) and RNF8 mediated ubiquitination of histones and non-histone proteins 
at the site of damage. In turn, this results in the recruitment of important repair proteins 
including BRCA1 and 53BP1. 53BP1 is one of the key factors found at DSBs as it acts as 
scaffold for other proteins to accumulate for non-homologous end joining (NHEJ) and DNA 
repair. The localization of 53BP1 to the DSBs is affected by several determinates including 
the ubiquitin signalling mediated by RNF8/RNF168, as well as H4K20 me1 (Dulev et al., 
2014). Notably, depleting KMT5A in embryonic stem cells leads to massive DNA damage 
and γH2AX foci formation (Oda et al., 2009; Yu et al., 2013).  
 Furthermore, KMT5A is required for DNA replication fork progression (Jørgensen et al., 
2007). KMT5A is recruited to DNA replication foci, via the interaction with PCNA, during S-
phase, which is essential for proper DNA replication.  KMT5A is also suggested to repress 
the genes required for DNA replication initiation, which would prevent S phase entry 
(Jørgensen et al., 2007; Tardat et al., 2007). This might be mediated by Chk1 as suggested by 
depletion of KMT5A by small interference RNA, which results in accumulation of the cells at 
S phase of the cell cycle (Oda et al., 2009; Yu et al., 2013).  
1.6.3.4. Epithelial-mesenchymal progression  
TWIST is a helix-loop-helix transcriptional factor that play a vital role in facilitating the 
epithelial-mesenchymal transition (EMT) but the molecular events leading to this are still not 
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fully understood (Yang et al., 2012b). KMT5A is substantially associated with TWIST, and 
together are responsible for promoting EMT and facilitating the invasive potential of breast 
cancer cells both in vitro and in vivo. Interestingly, TWIST can also regulate AR expression 
via binding to E-boxes in the AR promoter region. Furthermore, silencing of TWIST induces 
cell-cycle arrest at the G1 phase and cellular apoptosis in the AR-expressing LNCaP cell line 
as well as castration-resistant LNCaP derivatives. Castration mediated oxidative stress causes 
Twist1 overexpression to promote AR expression which could result in the acquisition of 
castration resistance (Shiota, 2010). 
 
In addition to the essential role of TWIST in moderating the behaviour of mesenchymal cells, 
Twist1 is also an oncogene in a number of aggressive tumours including gastric, liver and 
breast cancers. The oncogenic role of Twist1 to enable the pathological EMT of cells within a 
primary tumour similar to its function in development, and not by facilitating cell 
transformation. During EMT, tumour cells acquire properties to aid them to migrate away 
from the primary tumour, and then enter the blood/  lymphatic systems, and finally, settle into 
secondary tumour sites (Stratmann and Haendler, 2012).  
Studies have shown that TWIST knockdown leads to reduced level of expression of N-
cadherin which inhibited the migration rate of the PC cell line, PC-3 cells. In addition to 
promoting the hallmark changes associated with EMT, such as N-cadherin up-regulation and 
E-cadherin down-regulation, Twist1 also increases the angiogenic factor, VEGF in prostate 
and bladder cancers and Twist 1 level correlate with metastasis (Qin et al., 2012). 
KMT5A acts as a dual epigenetic modifier on the promoters of the TWIST target genes E-
cadherin and N-cadherin through mono-methylation activity on H4K20. KMT5A expression 
is negatively correlated with E-cadherin and positively correlated with metastasis and the 
expression of TWIST and N-cadherin in breast cancer samples (Yang et al., 2012b).  
Metastatic PC cells have a particular preference to migrate to bone sites. The sensitivity of 
androgen independent PC cells to anticancer drugs was increased by down-regulation of 
Twist1. In addition, migration and invasion was suppressed, which may suggest inactivation 
of Twist1 as a potential strategy to control  the growth and metastasis of these cells (Qin et 
al., 2012). 
1.6.3.5. Chromatin compaction  
During cell proliferation, the accurate copying of the chromosomes usually occurs during S 
phase followed during meiosis by compaction of the chromatin, a process suggested to be 
controlled by changing in the activity of KMT5A during cell cycle progression (Brustel et al., 
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2011). The expression levels of KMT5A are regulated by the E3 ubiquitin ligase CRL4Cdt2 
which targets KMT5A on the chromatin for destruction, an event that is accompanied by 
DNA replication. KMT5A binds to the chromatin via PCNA where binding occurs at a 
specific degron sequence in KMT5A to results in a reduction of H4K20me1. Mutations in this 
degron result in premature chromatin compaction, H4K20m1 accumulation and G2 arrest 
(Centore et al., 2010). 
The precise mechanism for how KMT5A mono-methylates H4K20 is not fully understood, 
but possible mechanisms are derived based on nucleosome structural studies. One of the 
suggested mechanisms is particle contact between histone H2A and K20 on the H4 N-
terminal tail to result in H4K20me1 affecting the chromatin structure. Another possibility is 
that H4-K20me1 mark is a binding site for chromatin condensation-related proteins, such as 
L3MBTL1 which can trigger local chromatin compaction in association with the mitotic 
chromosome, by interacting with methylated lysines on two close nucleosomes in vitro 
(Brustel et al., 2011). 
1.6.3.6. Gene transcription 
The mono-methylation activity of KMT5A against H4K20 was always thought of as a 
transcription suppression process and many articles are supportive of this understanding. 
Analyzing of H4K20me1 associated genes on chromosome 21 and 22 in human cells showed 
an enrichment of H4K20me1 on the first half of gene bodies of specific genes. Regardless of 
basal expression levels of these genes, H4K20me1 was required to transcriptionally repress 
the expression of these genes (Congdon et al., 2010).  
However, another study suggested gene transcription activation by KMT5A mono- 
methylation activity on H4K20, especially in the canonical Wnt signaling pathway (Li et al., 
2011b).  Wnt3a specifically stimulates H4K20 monomethylation at the T cell factor (TCF)-
binding element through KMT5A. KMT5A is crucial for activation of the Wnt reporter gene 
and target genes in both mammalian cells and zebrafish. Additionally, KMT5A interacts with 
lymphoid enhancing factor-1 (LEF1)/TCF4 directly, and this interaction is regulated by 
Wnt3a. KMT5A was suggested to be a Wnt signaling mediator and is recruited by 
LEF1/TCF4 to regulate the transcription of Wnt-activated genes, possibly through H4K20 
monomethylation at the target gene promoters. It also indicate that H4K20me-1 is a marker 
for gene transcription activation, at least in canonical Wnt signaling (Li et al., 2011b) 
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1.6.3.7. Cell proliferation and cell cycle progression 
Cell proliferation includes a number of events that are precisely regulated to ensure that the 
genome and its chromatin are replicated successfully in S phase, followed by condensation 
and segregation of the two sister chromatids in the newly formed daughter cells during 
mitosis. Any defect during this process may lead to DNA damage and may stimulate genomic 
instability as an early step of cancer development (Brustel et al., 2011). 
In addition to the fact that KMT5A expression levels are regulated during the cell cycle 
phases by specific factors, KMT5A presence and histone mono- methylation activity also play 
an essential role in cell cycle progression itself. For example, depleting KMT5A results in 
growth arrest due to increasing DNA damage and defective cell cycle progression in 
embryonic stem cells (Oda et al., 2009). Both the presence of KMT5A and its enzymatic 
activity is important in maintaining cell cycle progression, mitosis, DNA replication, genomic 
stability and transcription (Beck et al., 2012) (Table 1.1).  
Table 1-1 KMT5A function 
Repression Activation 
P53 DNA damage repair 
E-cadherin 
  
 
N-cadherin 
Chromatin compaction 
Gene transcription activation by KMT5A 
mono- methylation activity on H4K20, 
especially in the canonical Wnt signaling 
pathway 
RNA polymerase II  
ERα 
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1.7. KMT5A previous findings in the lab 
Recently, a histone lysine methyl transferase (HMT), KMT5A, was identified as a putative 
AR regulatory protein by siRNA library screening. Upon further investigation it was 
discovered that KMT5A switches from an AR co-repressor to an AR co-activator upon 
acquisition of therapeutics resistance in a prostate cancer cell line model.  Indeed, in LNCaP-
AI cells, a model of androgen independence, it was observed that KMT5A knockdown could 
inhibit proliferation, AR association with the PSA enhancer and inhibit transcription of AR 
regulated genes. In LNCaP cells, a model of androgen dependence, KMT5A knockdown 
resulted in an enhanced level of KLK3 transcription after 48 hours of DHT stimulation. 
However, proliferation was still inhibited, probably due to the effects of KMT5A depletion on 
the cell cycle and DNA repair pathways (Coffey et al, un-published data) (Figure 1.11& 12). . 
Based on these observations KMT5A warrants further investigation as a potential therapeutic 
target in PC and will be the focus of this thesis (Figure 1.13). 
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Figure 1-11 Androgen receptor target genes expression in the presence 
and   absence of KMT5A. LNCaP (A, B) and LNCaP-AI (C, D) cells were reverse 
transfected with siRNA against KMT5A for 72 hours. RNA was collected and KLK3 
and TMPRSS2 mRNA expression was determined by QRT-Error bar represents 
the mean ± SD for triplicate independent experiments. p-values were determined 
by t-test (* p-value <0.05, ** p-value <0.01, *** p-value <0.001 and  **** p- value 
< 0.0001).     
 
A 
B 
C 
D 
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Figure 1-12 Androgen receptor, KMT5A and H4K20me1 enrichment at 
ARIII promoter. LNCaP (A, B, C) cells and LNCaP-AI (D, E, F) cells were starved 
in SDM for 72hours followed by DHT (100 nM) stimulation for 0, 15, 30 and 120 
minutes. Chromatin immunoprecipitation assay was performed. Rabbit IgG was 
used as negative control. Results are expressed relative to the values of untreated 
samples. Error bars represent the mean ± SD for triplicate independent 
experiments. 
A C B 
E F D 
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Figure 1-13 KMT5A activity in LNCaP and LNCaP-AI cell lines. KMT5A 
switches from an AR co-repressor to an AR co-activator upon acquisition of 
therapeutics resistance in a prostate cancer cell line model 
 
 
 
1.8. Project aim  
Due to the increasing interest in KMT5A as an important enzyme in itself and also the 
potentially important role it plays in regulating AR in PC, so this project is put together to: 
 Identify KMT5A regulated genes and AR regulated genes that are modulated by KMT5A. 
 Further investigate the relationship between KMT5A and AR. 
 Validate selected target genes as selectively regulated by KMT5A and/ or AR.   
 Investigate the possibility of using KMT5A target genes as biomarkers to determine the 
activity of KMT5A in aggressive PC, due to the fact that the activity rather than the presence 
is what required to be determined for KMT5A. 
 Investigating the potential of targeting KMT5A therapeutically. 
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2.1. Materials and Reagents 
Chemicals that are regularly used in the lab were either analytical or molecular biology grade, 
unless otherwise stated. These chemicals were purchased from Merck Biosciences 
(Nottingham, UK), VWR International (Leicestershire, UK) and Sigma-Aldrich (Dorset, UK). 
Oligonucleotide primers were designed by National Centre for Biotechnology Information 
NCBI (http://www.ncbi.nlm.nih.gov/) and purchased from Sigma-Aldrich (Dorset, UK), and 
diluted with sterile distilled water to 1 µg/µl as a final stock concentration. Plastic-ware used 
in tissue culture was purchased from Corning (Surrey, UK) and Becton Dickinson (BD, 
Oxford, UK). 
2.2. General Methodology 
2.2.1.  Mammalian Cell Culture 
2.2.1.1. Cell lines 
All cell lines used in this study were purchased from the American Type Culture Collection 
(Manassas, VA, USA). The androgen sensitive LNCaP cell line (Lymph Node Carcinoma of 
the Prostate) is considered as a model of androgen dependent PC which was derived from a 
50 years old patient in 1977 from a left supraclavicular lymph node prostate carcinoma 
metastasis (Horoszewicz et al., 1980). LNCaP-AI, an LNCaP sub-clone, was used as a model 
of androgen independent PC. This was generated by the Solid Tumour Target Discovery 
(STTD) group at Newcastle University by continuous culturing of LNCaP cells in RPMI 1640 
media supplemented with 10% foetal calf serum (FCS) that had been stripped of steroids by 
treatment with dextran-coated charcoal (SDM) (Rigas et al., 2007). All cell lines used in the 
project was authenticated by cell morphology and RNAseq as they have identified the known 
mutations in the parental cell line –T877A in the AR. AR gene was also fully sequenced in all 
the derivatives of the AR which confirmed their origin.   
2.2.1.2. Cell Passaging 
LNCaP cells were maintained in full medium (FM) (RPMI 1640 medium containing HEPES 
buffer (25 mM)), 10% foetal calf serum (FCS) and L-Glutamine (20 mM) at 37 °C in a 
humidified atmosphere of 5% CO2. 
LNCaP-AI cells were grown in steroid depleted medium (SDM) (RPMI 1640 10 % charcoal 
treated FCS at 37 °C in a humidified atmosphere of 5% CO2.  (Thermo Scientific HyClone, 
Logan, USA). Sub- confluent cells were passaged every 3-5 days. Medium was aspirated 
under sterile conditions and then the cells were washed with sterile phosphate buffered saline 
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(PBS). Cells were then trypsinised (1 x trypsin/ EDTA) for 3-5 minutes at 37 °C followed by 
neutralisation by adding the appropriate medium (FM, SDM) according to the cell line. Cells 
were then transferred to a new flask and incubated at 37 °C in a humidified atmosphere of 5% 
CO2. 
2.2.1.3. Cryopreservation of cell lines 
Multiple stocks of all cell lines were cryopreserved for storage. After passaging the cells as 
mentioned above, cells were pelleted by centrifugation at 400 x g for 5 min followed by 
aspiration of all the supernatant and re-suspending the pellet with 1 ml of freezing medium 
(80 % FM, 10 % FCS, 10 % dimethyl sulfoxide (DMSO)) at 2-5 x 106 cells/ml. Cells were 
frozen at 80°C in cryovials. To re-culture the cells from cryopreservation, cells were defrosted 
at 37 °C and gently transferred into 10 ml of FM, followed by centrifuging at 400 x g for 5 
minutes to create a cell pellet. The supernatant was then aspirated to remove any remaining 
DMSO and the pellet re-suspended in 10 ml of the respective medium, transferred to a new 
flask and incubated at 37 °C. 
2.2.1.4. Sulphorhodamine B (SRB) Assay  
Cellular proliferation and growth inhibition were determined by Sulphorhodamine B (SRB) 
assay, based on a protocol by Skehan et al (Skehan et al., 1990). SRB dye binds cellular 
proteins, to reflect the number of cells in each well. 
Cells were seeded out in 96 well plates and incubated at 37 °C for 7 days. Cells were then 
fixed with ice cold Trichloroacetic acid (TCA) at a final concentration of 10 % for 1 hour at 4 
°C. Wells were then washed 4-5 times with tap water to remove any residual TCA and growth 
media. Plates were dried at 37 °C. Cells were then stained with 100 µl of 0.4 % SRB (a 1 % 
solution of SRB in 1 % acetic acid was prepared and then diluted to 0.4 % using 1 % acetic 
acid) and stored  at room temperature for 30 minutes. Following this staining period, cells 
were then washed 5 times with 1 % acetic acid ensuring that all unbound dye is removed and 
left to air dry prior to the solubilisation of the dye in 10 mM Tris (pH 10.5) for 30 minutes 
with agitation. The absorbance was detected using a plate reader (Bio-Rad Model 680 
Microplate Reader(Hercules, CA) at 570 nm (Skehan et al., 1990). 
2.2.1.5. Cell growth 
Cell growth was assessed by cell counting using Incucyte Zoom live cell imager (Essen 
Bioscience). The IncuCyte® live-cell imaging and analysis system permits real-time, 
automated cell proliferation assays within tissue culture incubator. Cell proliferation was 
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observed by analysing the percentage of confluency of cells over time. As cells proliferate, 
the confluence increases. For this assay, cells were grown in 96 well plates (3000 cell/well for 
LNCaP cells and 3500 cell/well for LNCaP-AI cells) with 6 replicate well/plate and incubated 
in the Incucyte for 168 hours with 6 hours interval scan. Data were presented as the average 
fold difference in confluence relative to the control from three independent experiments.  
2.2.2. Gene Expression Analysis 
2.2.2.1. RNA isolation  
All techniques were carried out under RNase free conditions using filter tips (Axygen) and 
Diethylpyrocarbonate (DEPC) treated water for all the required solutions.  
Trizol® reagent (Invitrogen) a monophasic solution of phenol and guanidine isothiocyanate, 
which maintains RNA integrity whilst lysing cells, was used to isolate RNA from cells. 
Adherent cells were washed with 1x PBS then Trizol® (500 µl) was added and incubated at 
room temperature for 5 minutes following the manufacture protocol. Chloroform (200 µl) was 
added followed by centrifugation at 12000 x g for 15 minutes to separate the aqueous phase 
which exclusively contained the RNA. The aqueous phase was collected and Isopropanol 
(500 µl) was added to precipitate the RNA, during a 10 minutes incubation at room 
temperature. The precipitated RNA was then pelleted by centrifugation at 12000 x g for 15 
minutes at 4 °C. Following a washing step with 500 µl of 75 % ethanol, and centrifugation at 
7500 x g for 5 minutes, the RNA pellet was re-suspended in an appropriate volume of DEPC 
treated water. The concentration and purity of RNA was measured using a NanoDrop® ND-
1000 UV-Vis Spectrophotometer (Labtech, East Sussex, UK. The concentration of the sample 
was calculated by the program using Beers law, and the integrity of the sample was assessed 
by the 260/280 ratio (the ratio of absorbance at 260 nm and 280 nm). Optimal 260/280 ratio 
for RNA is 2.0.  
2.2.2.2. Reverse Transcription 
Murine Moloney Leukaemia virus (MMLV) reverse transcriptase system (Promega, Madison, 
USA) was used for cDNA preparation.  Complementary DNA (cDNA) was prepared by 
diluting 1 µg of RNA in the required volume of DEPC water to a final volume of 12.7 µl. 
RNA was incubated at 65 °C for 5 minutes to denature the secondary structure of RNA. A 
master mix of MMLV was prepared, containing 4 μl of 5 x reverse transcriptase (RT) MMLV 
Buffer, 2 μl of 4 mM dNTPs (dGTP, dATP, dCTP and dTTP) (Bioline, London, UK), 1 μl of 
5 μM oligo (dT)16 and 0.3 μl of MMLV reverse transcriptase enzyme. MMLV master mix 
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was added to each sample to make up a final volume of 20 µl and mixed well by vortex. 
Samples were incubated at 37 °C for 1 hour, followed by incubation at 100 °C for 5 minutes 
then transferred immediately to ice to inactivate the MMLV-RT enzymes. The cDNA was 
then stored at -20 °C until required.  
2.2.2.3. Quantitative Real Time Polymerase Chain Reaction (QRT-PCR)  
Following reverse transcription, standard cDNA, known to express the transcript of interest, 
was used to quantify relative amounts of cDNA produced in the PCR reactions. A fluorescent 
reporter (SyBr Green) was used to detect the amount of DNA template in the samples. SyBr 
Green intercalates with the DNA by binding to the minor groove of the double helix. Upon 
binding, SyBr Green fluorescence is enhanced significantly, which make it easier to be 
detected by real time PCR thermocycling. A 5 µl reaction master mix was prepared (2 µl of 
diluted cDNA, 2.5 µl of Platinum® SYBR® Green qPCR SuperMix-UDG plus ROX 
(Invitrogen, New York, USA), 0.2 µl forward and 0.2 µl reverse primer and 0.1 µl sterile 
distilled water), and loaded into a 384 well plate. 
For the standard curve, sample cDNAs were diluted in sterile H2O prior to use. A serial 
dilution of a sample known to express the gene of interest and included 7 dilution data points: 
1, 1/5, 1/10, 1/50, 1/100, 1/500 and 1/1000.  The same sterile H20 used for cDNA dilution was 
loaded first on the plate as non-template control, followed by master mix loading, standard 
curve dilutions and finally the tested samples.  Samples were run in triplicate on each plate. 
The plate was then sealed with a clear plastic cover and ran under the following PCR 
conditions: denaturation step 40 cycles of 95 °C for 15 seconds followed by annealing step 
with 60 °C for 1 minute then dissociation step which consisted of 95 °C for 15 seconds, 60 °C 
for 15 seconds and 95 °C for 15 seconds.  Hypoxanthine phosphoribosyltransferase 1 
(HPRT1) was used as a housekeeping gene to normalise expression levels. The absolute 
quantification method was used on an ABI 7900 sequence detection system (Applied 
Biosystems, UK) according to the manufacturers’ instructions. A single peak in the resultant 
dissociation curve indicates the production of single product. Results were analysed using 
SDS 2.2 software (Applied Biosystems, Warrington), comparing expression with an 
endogenous control (Target/Control = normalised target value) (Normalised target value 
/calibrator normalised target value = relative expression). 
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2.2.3. Protein Expression Analysis 
2.2.3.1. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Cells were lysed in SDS sample buffer (0.125 M Tris-HCl, pH 6.8; 2 % SDS, 10 % glycerol, 
10% β-mercaptoethanol, 0.005 % bromophenol blue) which was added directly to cells in the 
culture plate after washing with PBS to remove all traces of growth media. Cell lysates were 
then incubated at 100 °C for 10 minutes to denature proteins prior to electrophoresis. 
Polyacrylamide gels were prepared by pouring a 12 % resolving gel (0.375 M Tris-HCl, pH 
8.8, 0.1 % SDS, 12 % acrylamide:bisacrylamide mix, 1 % ammonium persulfate (APS) and 
0.1 % N,N,N′,N′-Tetramethylethylenediamine (TEMED)) under a 6 % stacking gel (0.125 M 
Tris-HCL, pH 6.8, 0.1 % SDS, 6% acrylamide:bisacrylamide mix, 1 % APS and 0.1 % 
TEMED). Protein lysates (10-15 μl) were loaded alongside the Spectra™ Multicolor Broad 
Range Protein Ladder (Thermo Fisher Scientific) as a molecular weight reference. Samples 
were then resolved in reservoir buffer (25 mM Tris-HCl, 190 mM glycine, 0.1 % SDS) at 200 
V for 45-60 minutes. 
2.2.3.2. Western blotting 
 Following SDS-PAGE electrophoresis, protein were then transferred onto a Hybond C 
membrane (GE Healthcare, Wisconsin, USA) by electrophoresis in transfer buffer (25 mM 
Tris-HCl, pH 8.3; 0.15 M glycine, 10 % methanol) for 1 hour at 100 volts or overnight at 30 
volts. Membranes were blocked in 5 % non-fat powdered MarvelTM milk in Tris- buffered 
saline (TBS-20 mM Tris-HCl, 500 mM NaCl) to block nonspecific antibody binding for an 
hour, followed by washing with 0.001 % Tween TBS (TTBS) for 10 minutes. The membrane 
was probed with the appropriate primary antibody overnight at 4 °C then washed with TTBS 
twice for 5 minutes then probed with the horseradish peroxidase HRP-conjugated secondary 
antibody at room temperature for 1 hour (Table 2.1). The antibodies were diluted according to 
optimized conditions in 1 % (w/v) Marvel™ diluent, α tubulin was used as a loading control. 
ECL reagents (1:1 from reagent 1 and 2) was then spread over the membrane and incubated 
for 1 minute (GE Healthcare), before being exposed to X-ray film (Fuji Film) for an 
appropriate length of time, before being developed using an automated MediPhot 937 
developer.
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Table 2-1 Western blot secondary antibodies. 
2.2.4. Flow Cytometry 
Flow cytometry can be used to measures multiple features of individual cells that are flowing 
in single file in a stream of fluid through an illumination and light detection system. Light 
scattering at different angles can distinguish differences in size and internal complexity, 
whereas light emitted from fluorescently labelled antibodies can identify a wide array of cell 
surface and cytoplasmic antigens (Brown and Wittwer, 2000). 
2.2.4.1. Cell harvesting for Fluorescence-activated cell sorting (FACS) analysis 
Cells were harvested for DNA staining. Firstly, media from the wells was collected in a 
FACS tube (BD biosciences). Cells were then washed with 500 μl PBS (which was also 
retained for analysis) then detached from the well with 500 μl 1 x trypsin/EDTA. Trypsin was 
neutralised by adding the cells to the collected PBS and media. Cells were then pelleted by 
centrifugation at 2000 x rpm for 5 minutes and resuspended in 100 μl citrate buffer (0.25M 
Antibody Species Catalogue number
HRP-conjugated  
Rabbit anti-mouse 
Mouse polyclonal DakoCytomation 
(P0260) 
HRP- conjugated  
Swine anti-Rabbit 
Rabbit polyclonal DakoCytomation  
(P0217) 
HRP-conjugated 
Light chain Mouse 
Anti-rabbit 
Mouse polyclonal Abcam (ab99697) 
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sucrose, 40 mM sodium citrate, pH 7.6). Cell permeabilization was achieved by using 0.74 % 
TritonX-100, cells were stained with 2.5 mg/ml propidium Iodide, and 100 μg/ml RNase. 
FACScan (BD Biosciences, California, USA) was used to analyse the samples which 
measures 10,000 events per sample.  
2.2.4.2. Data analysis 
Cyflogic software was used for data acquisition and analysis. Cells were gated on Forward 
Scatter versus Side Scatter to exclude cell debris and FL2-Width versus FL2-Area dot-blot 
was used to doublet discriminate to ensure only single cells were examined for cell cycle 
analysis. 
2.2.5.  Immunoprecipitation 
In order to examine protein-protein interactions, immunoprecipitation was used. Cells were 
washed with 1 ml PBS and scraped from the plate using cell scrapper, then pelleted by 
centrifugation at 400 x g for 5 minutes and lysed by adding 1 ml of lysis buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 1 mM phenylmethanesulfonylfluoride (PMSF), 1 mM dithiothreitol 
(DTT), 1 x complete protease inhibitor cocktail tablet per 10 ml, 1 % NP-40 alternative, 0.2 
mM Na3VO4). The lysate was then transferred into Eppendorf tubes and incubated for 2 hours 
at 4 °C with rotation to enhance cell lysis. Meanwhile, the appropriate volume of Protein G 
Sepharose (PGS) (GE Healthcare, UK) was prepared by washing it 3 times with 1 ml of the 
lysis buffer prepared above,  followed by a centrifugation at 14,000 x g for 3 minutes. 
Debris was removed from the cell lysate by centrifugation at 14,000 x g for 3min and the 
supernatant transferred to a new tube. An input sample (100 µl) was taken from each lysate, 
mixed with 50 µl SDS sample buffer and stored at -20 °C until required for Western analysis. 
PGS (30 µl) was added to the supernatant and incubated at 4 °C for 2 hours with rotary 
agitation to preclear the samples. From the pre-cleared supernatant, half (450 µl) was taken 
for the IP reaction to which the appropriate primary antibody was added (2 µg), the remaining 
450 µl was used as a negative control to which 2 µg of rabbit IgG antibody was added. 
Furthermore, 2 µg of the appropriate primary antibody was added to 450 µl of lysis buffer as 
an antibody only control. Following the overnight incubation period, 20 µl PGS was added to 
immunoprecipitate the protein-antibody complexes, and incubated at 4 °C for 1 hour with 
rotation to allow the target antigen to bind to the immobilized antibody. PGS beads were 
collected by centrifugation at 14,000 x g for 3minutes and the supernatant was discarded. 
Beads were then washed using 1 ml IP wash buffer A (PBS, 0.2 % Triton, 350 mM NaCl) 
Chapter 2: Materials and Methods 
 
 
38 
 
followed by two washes with 1 ml IP wash buffer B (PBS, 0.2 % TritonX-100). Beads were 
then resuspended in SDS sample buffer (40-80 μl). Samples were analysed by SDS-PAGE 
and Western analysis as described previously. 
2.2.6. Chromatin Immunoprecipitation (ChIP)  
Cells were seeded in 150 mm dishes to 50 % confluence, followed by 72 hours starvation in 
SDM. This starvation period is essential to diminish AR activity and to remove the AR from 
target gene promoters. Cells were then treated with dihydrotestosterone (DHT) according to 
the specific experiment (see specific materials and methods in each results chapter). 
Formaldehyde (1 % final concentration) was added to the medium for 10 minutes at room 
temperature in order to achieve protein-DNA crosslinks. Excess formaldehyde was 
neutralised by the addition of 125 mM glycine for 5 minutes at room temperature. Cells were 
then washed twice in warmed PBS to remove traces of medium and formaldehyde then 
scraped into ice cold PBS and transferred into pre-chilled tubes. Cell pellets were then 
generated by centrifugation for 10 minutes at 900 x g. Following the removal of the 
supernatant, cell pellets were then re-suspended in 400 μl lysis buffer (1 % SDS, 10 mM 
EDTA, 50 mM Tris-HCl pH 8.1, 1 mM PMSF, 40 μg/ml RNase (Sigma) and 1 x complete 
protease inhibitor cocktail tablet per 10 ml (Roche, Basel, Switzerland)) and incubated on ice 
for 10 minutes. Lysed cells were sonicated using a bioruptor coupled to a water cooler 
(Diagenode Inc. USA) for 3 pulses of 5 minutes ‘30 seconds ON and 30 seconds OFF’ to 
shear the DNA. DNA-protein solutions were then centrifuged to remove cell debris and the 
chromatin was measured using NanoDrop® ND-1000 UV-Vis Spectrophotometer.
Chromatin was diluted by 10 fold using dilution buffer (20 mM Tris-HCl (pH 8.1), 150 mM 
NaCl, 1 % Triton-X 100, 2 mM EDTA, 1 mM PMSF, 1 x complete protease inhibitor cocktail 
tablet per 10 ml) in order to enable antibody-protein binding by reducing the concentration of 
the SDS. From the diluted chromatin, 100 μl was stored as an input sample at -20 °C.  
In order to prevent any non-specific binding, the remaining chromatin solution was pre-
cleared with 40 μl salmon sperm DNA/protein A agarose (Millipore, Massachusetts, USA) for 
30 minutes at 4 °C, on a rotating wheel, to remove potentially reactive components from the 
diluted chromatin. Samples were then centrifuged at 2,500 x g for 5 minutes, and then pre-
cleared chromatin solution supernatant was transferred to a fresh tube. ChIP grade antibodies 
were added to the pre-cleared chromatin (2-4 μg per 100 μg of chromatin) overnight at 4 °C 
on a rotating wheel to immunoprecipitate protein-chromatin complexes.
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Following the incubation, antibody-protein complexes were precipitated by adding 50 μl of 
salmon sperm DNA/protein A agarose for 1 hour at 4 °C. Beads were then collected by 
centrifugation and washed with 1 ml of Buffer I [(0.1 % SDS, 1 % Triton-X 100, 2 mM 
EDTA, 20 mM Tris-HCl (pH 8.1) and 150 mM NaCl), followed by Buffer II (0.1 % SDS, 1 
% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1) and 500 mM NaCl), and then 
Buffer III, (0.25 M LiCl, 1 % NP40, 1 % sodium deoxycholate, 1 mM EDTA and 10 mM 
Tris-HCl (pH 8.1)) ], for 5 minutes at room temperature. Finally the beads were washed twice 
with TE Buffer pH 8.1 (10 mM Tris-HCl (pH 8.1) and 1 mM EDTA). Protein-DNA 
complexes were eluted at room temperature in 250 μl of elution buffer (1 % SDS and 1 mM 
NaHCO3) for 20 minutes on a rotating wheel, and repeated, combining eluates. 
All samples (including inputs) were incubated with NaCl (200 mM) overnight at 65 °C to 
reverse protein-DNA complex crosslinks.  To digest the protein in the samples, proteinase K 
solution (40 μg/ml proteinase K (Qiagen), 10 mM EDTA and 40 mM Tris-HCl pH 6.5) was 
added to the samples for 2 hours at 45 °C. DNA was recovered using GenElute Mammalian 
Genomic DNA miniprep kit (Sigma) following the manufacturer’s protocol and stored at -20 
°C until analysis by QRT-PCR using primers designed against the promoters of interest.
2.2.7. Cytoplasmic and Nuclear extraction 
Nuclear-Cytoplasmic extracts for Western blot analysis were generated using the Thermo 
Scientific™ NE-PER™ Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific). 
Cells were pelleted by centrifugation at 400 g for 5 minutes and then re-suspended in 200 µl 
CER1 by vortexing vigorously for 15 seconds and then incubated on ice for 10 minutes. Ice 
cold CERII (11 µl) was added to the tube, and vortexed for 5 seconds then incubated on ice 
for 1 min followed by another mixing by vortex for 5 seconds. Samples were then centrifuged 
at 16000 g for 10 minutes at 4 °C to separate the cytoplasmic fraction according to the 
manufacture instructions. The supernatant (cytoplasmic extract) was transferred into a new 
pre-chilled tube and stored in -80°C until required. The insoluble pellet fraction was re-
suspended with 100 µl of NER mixed by vortex for 15 seconds and placed on ice for 40 
minutes. Samples were vortexed for 5 sec every 10 min. Samples was centrifuged at 16000 g 
for 4 °C for 10 minutes, and the supernatant (nuclear extract) then transferred into fresh pre-
chilled tube and stored at -80 °C until used or re-suspended in SDS sample buffer and boiled 
at 100 °C for 10 minutes before being subjected to SDS-PAGE.   
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2.2.8. General statistical analysis  
Statistical analysis was performed for the obtained data. To overcome the inter experimental 
variation fold changes of individual, experimental repeats were compared rather than raw 
data, and  for the intra experimental variation, 3 independent experiments were minimally 
done for each data set. Student’s t-test was used for data analysis. Student’s t-test indicates 
whether two sets of data are statistically different. This test deals with the problems associated 
with interference based on small samples by the generation of p-value. When non-randomly 
selected two samples are compared, a paired test should be performed. For examples, 
compare two similar samples with and without treatment. P-value <0.05 is significant. 
For microarray data, Samples were processed by oxford gene technologies (OGT) for 
microarray analysis using a direct hybridization Illumina HT12 v4 BeadChip Array. 
Functional clustering and annotation of genes featuring on lists presented in chapter 7 were 
performed using the online tool: Database for Annotation, Visualisation and Integrated 
Discovery (DAVID), v6.7. The DAVID software was used to analyse large gene lists and 
perform comprehensive clustering to outline genes with a similar function or biological 
theme. KEGG pathway analysis on steroid biosynthesis was included in the DAVID output.  
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Chapter 3 . Determining KMT5A regulated gene expression profiles in a cell 
line model representative of androgen-independent prostate cancer 
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3.1. Introduction 
Histone methylation plays an important role in regulating chromatin compaction, and gene 
transcription. Histone methyltransferase enzymes catalyse the methylation process on the N-
terminal tail of histone proteins in the nucleosome, and several of these enzymes are also 
implicated in the methylation of non-histone proteins (Ma et al., 2014c). Loss of KMT5A 
reduces the level of mono-methylation at H4K20 and also impacts on the di and tri- 
methylation states as indicated by in vivo studies. This suggests that  a methylated template in 
the form of mono-methylated  H4K20 is required for the formation of subsequent di- and tri-
methylation which is mediated by KMT5B and KMT5C, respectively (Balakrishnan and 
Milavetz, 2010). KMT5A has also been suggested to participate in creating a trans-tail histone 
code in cooperation with H3K9 methyltransferases to mark distinct regions in the silent 
chromatin of the mammalian epigenome (Sims et al., 2006). 
KMT5A (SET8, Pre-SET7), was first identified in 2002 (guowei, 2002) and is the sole  
histone lysine methyltransferase responsible for catalysing the mono-methylation of histone 
H4 on lysine 20, to regulate the global levels of H4K20me1. Deposition of H4K20me1 
sustains chromatin silencing and compaction as a requirement for mitotic chromosome 
separation (Couture et al., 2005; Lee and Zhou, 2010; Beck, 2012). KMT5A plays a role in 
numerous cellular processes including cell cycle progression (Abbas et al., 2010b), DNA 
replication (Sims et al., 2006) and DNA damage repair. In particular, recent evidence 
demonstrates the role of KMT5A during DNA damage repair (DDR) at double- strand breaks 
(DSBs), particularly in the non-homologous end joining (NHEJ) pathway, where it is required 
for the accumulation of 53BP1 at  DNA break sites (Dulev et al., 2014). It is also considered 
as an essential developmental gene, as deletion of KMT5A leads to early lethality of mice and 
Drosophila embryos (Lee and Zhou, 2010). Furthermore, KMT5A is over-expressed in a 
number of cancers and its expression positively correlates with metastatic potential (Yang et 
al., 2012a). 
In CRPC, androgen receptor (AR) signalling remains functional via numerous mechanisms 
hence the AR remains a viable therapeutic target (Sung  and Cheung., 2013). The AR 
participates in controlling the expression of genes involved in the development and 
transformation of the prostate thorough association with a number of co-regulatory proteins 
that regulate the activation status of target genes following post-translational modification of 
the AR (Coffey and Robson, 2012). One such modification is lysine methylation of the AR 
(Gaughan et al., 2011; Shang et al., 2012). In order to regulate gene transcription, steroid 
receptors recruit a number of cofactors to form multi-protein complexes that assist in 
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modifying chromatin structure to enhance DNA accessibility for the transcriptional 
machinery. Methylation and demethylation are examples of these modifications that are 
mediated by a number of enzymes, which add or remove histone marks and consequently play 
an essential role in the regulation of gene expression (Stratmann and Haendler, 2012). 
Recently, a study performed in our laboratory investigated the relationship between KMT5A 
and AR highlighting that KMT5A changes from an AR functional co-repressor in androgen-
dependent LNCaP cells to become an AR co-activator in LNCaP-AI cell line that have 
acquired androgen-independent growth. Furthermore, depletion of KMT5A in the LNCaP-AI 
cell line, representative of androgen-independent PC, inhibits AR binding to the PSA 
enhancer. The study also indicated that there was a difference between LNCaP and LNCaP-
AI cells in relation to the presence and activity of KMT5A at androgen regulated promoters. 
In LNCaP cells, KMT5A is present on AR regulated promoters in the absence of androgen 
but dissociates from promoters following DHT stimulation. However, in the LNCaP-AI cell 
line, KMT5A was found to be enriched on androgen responsive promoters in response to 
androgen stimulation (Coffey et al., unpublished data). 
The genes that are regulated directly by KMT5A and the interplay between KMT5A and AR 
to modulate transcriptional output of downstream targets requires further investigation in both 
androgen-sensitive and castrate-resistant models of prostate cancer. 
The aims of this chapter are:  
1. To identify genes that are regulated by KMT5A. 
2. To determine genes that are regulated by both the AR and KMT5A, and genes that are 
regulated by KMT5A independently of the AR. 
3. To validate selected target genes as selectively regulated by KMT5A and/ or AR.
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3.2. Specific Materials and Methods 
3.2.1. Cell lines  
LNCaP and LNCaP-AI cells were used in this study as detailed in Chapter 2.1.1. 
3.2.2.  Antibodies 
A number of primary antibodies were used to detect protein expression by Western blotting 
(Table 3.1). 
Table 3-1 Antibodies used for Western blotting.
Antibody Species Catalogue number 
KMT5A Rabbit  Cell Signalling (2996) 
  PSA  Mouse  BioGenex MU014-UCE 
α-Tubulin Mouse  Sigma  
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3.2.3.  Primers  
To detect the expression of individual genes at the mRNA level, specific primer sets were 
used (Table 3.2).  
Table 3-2 Primers used for QRT-PCR. 
Genes  
 
Forward Primer (5’-3’)  Reverse Primer (5’-3’)  
KMT5A GATCCCAGGCGGTGACAGAG CCCGGTAAATACGTTCTCCCC 
HPRT1 TTGCTTTCCTTGGTCAGGCA 
  
AGCTTGCGACCTTGACCATCT 
KLK3 TCGGCACAGCCTGTTTCAT 
 
TGGCTGACCTGAAATACCTGG  
CDC20 TCGCATCTGGAATGTGTGCT CCGGGATGTGTGACCTTTGA 
HIST1H2BD TAACTTTGCCAAGGGAGAGACA AGCAAACCAGGATGAGT 
YIPF1 GTGGACACCTACCAGGTCTT ACGTCTTCTCTCCCAGATGGA 
CDC42EP3 CGGCGGCCGGTTTGT TTTGCGAAGATCTGAGCCCT 
KIF22 GCCCCTACAGCTAATTCAGGA GAAAAGGCGGAGTGAGGAGAC 
RAB4A GCCGAGAAACCTACAATGCG GGTCCAGCTCACCTGATTCG 
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3.2.4.  Small interference RNAs 
In order to achieve KMT5A depletion, specific siRNAs were used (Table 3.3). 
Table 3-3 Small interference RNAs for KMT5A knockdown in the 
microarray study. 
siRNA Sense sequence Anti-sense sequence 
Non-
silencing 
(NS) 
(1022076) 
(Qiagen 
 
 
UUCUCCGAACGUGUCACGU 
 
 
ACGUGACACGUUCGGAGAA 
 
KMT5A#1 CCAUGAAGUCCGAGGAACA  
 
UGUUCCUCGGACUUCAUGG  
 
KMT5A#2 GATGCAACTAGAGAGACA UGUCUCUCUGUUGCUC 
 
 
3.2.5.  Agilent Bioanalyzer 2100 
Total RNA was extracted from LNCaP-AI cells using Trizol® reagent (Invitrogen) with 
DNase treatment as detailed in Chapter 2.2.1. The integrity and purity of total RNA were 
assessed using Agilent Bioanalyzer 2100.
3.2.6.  Illumina Human HT-12 arrays 
The Human HT-12 v4.0 The HumanHT-12 v4 Expression BeadChip content provides 
genome-wide transcriptional coverage of well-characterized genes, gene candidates, and 
splice variants, delivering high-throughput processing of 12 samples per BeadChip without 
the need for expensive, specialized automation. The BeadChip is designed to support flexible 
usage across a wide-spectrum of experiments. Each array on the HumanHT-12 v4 Expression 
BeadChip targets more than 47,000 probes.The arrays report probe intensity levels which 
represents the level of expression of a gene against which a particular probe is targeted. Array 
processing, normalization, and quality control checks were performed using the R package 
‘Lumi’. Probe intensity values were converted to VSD (variance-stabilized data) using 
variance stabilizing transformation. The robust spline normalization (RSN) was used as the 
array normalization method. Outlier samples, poor quality probes (detection threshold < 
Chapter 3: Determining KMT5A regulated gene expression profile 
 
47 
 
0.01), and probes that were not detected at all were removed prior to downstream analysis. 
The remaining probes (21,111) normalized intensities, VSD were used in the differential 
expression analysis. Differential expression analysis was performed using the R package 
‘Limma’, and p values were adjusted to control the false discovery rate (FDR) using the 
Benjamini–Hochberg method.
 
3.3. Results 
3.3.1.  Identification of an KMT5A regulated gene expression profile 
3.3.1.1. Optimisation of DHT dose  
The microarray experiment in this study was designed to detect the expression profile of 
KMT5A regulated genes and also those genes that are regulated by the AR, as well as genes 
modulated by KMT5A alone. In order to do so, a DHT titration experiment was initially 
performed in LNCaP and LNCaP-AI cell lines over a time period of 24 hours to select the 
dose of DHT to be used for subsequent experiments. Both LNCaP and LNCaP-AI cells were 
grown in SDM for 72 hours prior to DHT treatment in order to diminish AR activity and to 
deplete the AR from target gene promoters. For the androgen treatment, a 10 fold serial 
dilution series of DHT was used ranging from 10 nM to 10-5 nM. Following 24 hours DHT 
treatment, RNA was isolated and the expression of the AR regulated gene, KLK3, was 
assessed by QRT-PCR (Figure 3.1.A-B).  
From the above experiment, 10 nM DHT was observed to cause a statistically significant 
(p≤0.05) increase in KLK3 expression ~30 fold in the LNCaP cell line and ~75 fold in the 
LNCaP-AI cell line. Consequently, 10 nM DHT was selected as the dose to be used for 
stimulation of AR activity in both cell lines for the subsequent experiments as shown in 
Figure 3.1. Secondly, DHT time course experiments (0, 16, 24, 48, 72 hours) were performed 
in both cell lines using 10 nM DHT treatment to determine the optimal duration of AR 
stimulation in both cell lines. KLK3 expression was determined by QRT-PCR in response to 
the experimental conditions (Figure 3.1.C-D).  
The data showed a rapid and significant increase in KLK3 expression in LNCaP cells (p≤0.05) 
that peaked at ~400 fold after 24 hours followed by a gradual reduction over the remaining 
time points of the experiment as the AR ubiquination started and  affecting the enrichmen of 
AR at its target gene promoters such as KLK3, which was agreed with previously mentioned 
data about KLK3 expresssion in LNCaP cells in response to AR stimulation (Figure 3.1.C) 
(Coffey et al, unpublished data). (Figure 3.1.C). In LNCaP-AI cells there was a gradual but 
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significant (p≤0.05) increase in KLK3 expression that peaked at 72 hours, with a ~2000 fold 
increase (Figure 3.1.D). From this experiment, 24 hours of DHT stimulation at a dose of 10 
nM was selected for the subsequent gene profiling experiments in both the LNCaP and 
LNCaP-AI cell lines, to detect genes that are primarily regulated by the AR and also 
modulated by KMT5A depletion in both PC cell lines.
 
 
Figure 3-1  KLK3 expression levels in response to DHT treatment in 
LNCaP and LNCaP-AI cells. (A) (B) Cellular response to increasing doses of 
DHT. Cells were grown in SDM for 72 hours prior to DHT treatment. A 10 fold 
serial dilution of DHT ranging from 10 nM to 10-5 nM was added for 24 hours and 
expression of KLK3 determined by QRT-PCR. (C) (D) Cells were grown in SDM for 
72 hours followed by 10 nM DHT treatment for different periods (0, 16, 24, 48, 72 
hours). RNA was collected and KLK3 expression levels were detected by QRT-PCR. 
Error bars represent the mean ± SD for triplicate independent experiments. p-
values were determined by t-test (* p-value <0.05, ** p-value 0.01, *** p-value 
<0.001 and **** p- value < 0.0001).
A B 
C D 
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3.3.1.2. Depletion of KMT5A in PC cells 
In order to determine the genes that are regulated by KMT5A depletion and those genes 
which are under AR regulation but are also modulated by KMT5A depletion, KMT5A 
knockdown was performed by reverse transfection in SDM for 72 hours using 2 independent 
KMT5A siRNA sequences, to further confirm the data obtained, (Table 3.3) followed by 10 
nM DHT stimulation for 24 hour. Non-Silencing (N/S) siRNA was used as a negative control. 
RNA was isolated and KMT5A knockdown and KLK3 expression were assessed by QRT-PCR 
using primers detailed in Table 3.2. The data was normalised to the N/S control. The data 
showed a significant reduction of ~ 60-80 % in KMT5A expression (p≤ 0.05) in KMT5A 
depleted samples compared to the N/S samples in both DHT treated and untreated arms 
(Figure 3.2.A). KK3 expression was significantly increased in the N/S control in the DHT 
treated arm by ~4 fold compared to N/S control. There was also a significant increase in 
KLK3 expression most notably with KMT5A siRNA#1 by a further ~2 fold following DHT 
treatment compared to N/S control (p≤ 0.05) (Figure 3.2.B). KMT5A knockdown and KLK3 
induction was also confirmed at the protein level by Western blotting in LNCaP cells (Figure 
3.2.C).  
The same experimental conditions were applied in LNCaP-AI cells. The data showed a 
statistically significant reduction of ~80 % in KMT5A expression (p≤0.05) for the KMT5A 
depleted samples by both siRNAs compared to the N/S control (Figure 3.3.A). KLK3 
expression was significantly increased  in response to DHT stimulation ~15 fold in N/S 
control which was further enhanced by KMT5A depletion and was most evident for siRNA#1 
showing a further ~3 fold increase in response to DHT treatment compared to N/S control (p≤ 
0.05) (Figure 3.3.B). The knockdown was also confirmed at the protein level by Western 
blotting in LNCaP-AI cells (Figure 3.3.C) using the same experimental conditions as shown 
in Figure 3.2.C. 
PSA protein expression was also examined by Western blotting. Due to the very low levels of 
PSA expression in the LNCaP-AI cell line, the sensitivity of the Western blotting was 
insufficient to detect the PSA protein.   
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 Figure 3-2 KMT5A knockdown confirmation in LNCaP cells and the effect 
on PSA expression. LNCaP cells were reverse transfected with Non- silencing 
siRNA or the two selected KMT5A siRNAs for 72 hours in SDM followed by either 
stimulation with 10 nM DHT or vehicle control for 24 hours. RNA and protein was 
collected and depletion of KMT5A was confirmed. (A) KMT5A mRNA expression 
and (B) KLK3 mRNA expression were compared to respective expression for the 
N/S 0 hour time point (C) KMT5A and PSA protein expression in LNCaP cells were 
determined.   Error bars represent the mean ± SD for triplicate independent 
experiments. p-values were determined by t-test (* p-value <0.05, ** p-value 
<0.01m,  *** p-value <0.001 and **** p- value < 0.0001).
B A
C
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Figure 3-3 KMT5A knockdown confirmation in LNCaP-AI cells and the 
effect on PSA expression.  LNCaP–AI cells were reverse transfected with N/S 
siRNA or the two selected KMT5A siRNAs for 72 hours in SDM followed by either 
stimulation with 10 nM DHT or vehicle control for 24 hours. RNA and protein was 
collected and knockdown of KMT5A was confirmed. (A) KMT5A mRNA expression 
and  (B) KLK3  mRNA expression were compared to respective expression for the 
N/S 0 hour time point (C) KMT5A and PSA protein expression  in LNCaP-AI cells.  
Error bars represent the mean ± SD for triplicate independent experiments. p-
values were determined by t-test (* p-value <0.05, ** p-value <0.01, *** p-value 
<0.001 and **** p- value < 0.0001).
BA 
C 
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3.3.1.3. Confirmation of KMT5A target gene regulation 
In addition to the functions of KMT5A that have been already  mentioned, KMT5A plays an 
important role in tumour metastasis and progression thorough its effect on the expression of 
TWIST target genes (Yang et al., 2012a). KMT5A acts as a dual epigenetic modifier on the 
promoters of E-cadherin and N-cadherin genes thorough its histone mono-methylation 
activity, thereby regulating their expression and in turn promoting the epithelial- 
mesenchymal transition (EMT). KMT5A is known to positively regulate the expression of 
mesenchymal markers while negatively regulating epithelial markers (Yang et al., 2012b). In 
this study E-cadherin was selected as a representative of  epithelial markers and vimentin as a 
representative of mesenchymal markers (Kalluri and Weinberg, 2009).  
To further validate the specificity of KMT5A knockdown (Figure 3.2.A and Figure 3.3.A) for 
KMT5A regulated genes, known KMT5A regulated genes were investigated. The expression 
levels of CDH1 and VIM were determined as positive controls for KMT5A knockdown in the 
LNCaP and LNCaP-AI cells. As expected, knockdown of KMT5A resulted in an increase in 
CDH1 expression of ~1.5-2 fold in both DHT treated and untreated arms compared to the N/S 
control in the LNCaP cells (Figure 3.4.A). In the LNCaP-AI cells an ~2 fold increase in the 
expression of CDH1 with KMT5A depletion in the presence of DHT was observed, whereas 
no significant changes  in CDH1 expression was observed in the absence of DHT following 
KMT5A depletion (Figure 3.4.B). For VIM, both cell lines showed a statistically significant 
reduction in VIM expression following KMT5A depletion in the DHT treated arm, where an 
~2-3 fold decrease was observed (Figure 3.4.C). In addition, in the untreated arm of the 
LNCaP-AI cells, there was an ~2 fold decrease in VIM expression compared to N/S control 
(Figure 3.4.D).  The overall data indicated that a successful knockdown of KMT5A was 
achieved by the two selected siRNAs with some evidence of an effects on the EMT.
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Figure 3-4 KMT5A positively regulates the expression of epithelial-
mesenchymal transition markers in LNCaP and LNCaP-AI cells. Cells were 
reverse transfected with N/S siRNA or the selected KMT5A#1 siRNA for 72 hours 
followed by either stimulation with 10 nM DHT or vehicle control for 24 hours. 
RNA was collected and the expression levels of CDH1 and VIM were measured by 
QRT-PCR. CDH1 expression was measured in (A) LNCaP and (B) LNCaP-AI cells. 
VIM expression was measured in (C) LNCaP and (D) LNCaP-AI cells. Error bars 
represent the mean ± SD for triplicate independent experiments. p-values were 
determined by t-test (* p-value <0.05,** p-value <0.01 and *** p-value <0.001  ).
A B 
C D 
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3.3.1.4. Microarray experiment in LNCaP-AI cells 
Based on the data obtained from Figure 3.1, the microarray experimental conditions were 
selected and KMT5A knockdown was confirmed in LNCaP and LNCaP-AI cells. The 
LNCaP-AI cell line samples validated in Figure 3.3 were sent for microarray analysis using 
Illumina Human HT-12 arrays. However, subsequent validation of the data obtained was 
more extensive and was performed in both LNCaP and LNCaP-AI cells. In total 24 samples 
were analysed by microarray (4 biological repeats performed for each of the six conditions) as 
shown in Table 3.4. Additional validation of KMT5A knockdown and KLK3 expression was 
confirmed by microarray data. The data showed a statistically significant ~80 % reduction in 
KMT5A expression using  KMT5A siRNA#1 and # 2 compared to the N/S control (p≤0.05) 
in both the DHT treated and untreated arms, which was consistent with the data from Figure 
3.3. For KLK3 expression, treatment with DHT enhanced the expression of KLK3 ~4 fold 
compared to DHT untreated arm. However, there was no significant change in the KMT5A 
depleted samples following DHT treatment compared to the N/S control (Figure 3.5).  
Table 3-1 Microarray experimental conditions 
LNCaP-AI cells 
-DHT + 10nM DHT  
N/S N/S 
siKMT5A#1 siKMT5A#1 
siKMT5A #2 siKMT5A #2 
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Figure 3-5 Confirmation of KMT5A knockdown and the effect on PSA 
expression in LNCaP-AI cells determined by microarray. LNCaP-AI cells 
were reverse transfected with N/S siRNA or the two selected KMT5A siRNAs for 
72 hours in SDM followed by either stimulation with 10 nM DHT or vehicle control 
for 24 hours. RNA was collected and knockdown of KMT5A was confirmed by 
microarray. (A) KMT5A mRNA expression (B) KLK3 mRNA expression compared 
to respective expression for the N/S 0 hour time point. Error bars represent the 
mean ± SD for triplicate independent experiments. p-values were determined by t-
test (* p-value <0.05, ** p-value <0.01, *** p-value <0.001 and  **** p- value < 
0.0001). 
A B 
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3.3.2.   Microarray data analysis 
Differential expression analysis was performed as outlined in Chapter 2.  High quality data 
was obtained overall. Initial data showed 4 of 6 samples belong to the first set of samples 
grouped together but there was two outlier (detection threshold < 0.01). The outlier samples 
were therefore excluded, leaving n=3 for the affected groups. Microarray data analysis 
revealed that subsequent to KMT5A knockdown, 51 genes were regulated by KMT5A, 199 
genes were regulated by KMT5A only in the presence of an active AR and 29 of the genes 
were common between these two groups. 
3.3.2.1. Validation of the selected genes  
A number of genes were selected from the microarray data based on the significance of their 
expression (p≤0.05) and whether they were significantly up or down regulated (p≤0.05) by the 
effect of a particular experimental condition. Microarray data analysis revealed a number of 
androgen- regulated genes ( 199 genes) that were also modulated by KMT5A such as 
CDC42EP3, YIPF1 and KIF22, while some genes were regulated by KMT5A independently 
of the AR (51 genes) such as CDC20, HIST1H2BD and RAB4A.Further investigation of other 
genes included in the microarray data might be done in future experiments.  
CDC42EP3 (up-regulated by DHT stimulation) 
CDC42EP3 (CDC42 Effector Protein 3) encodes a member of the guanosine triphosphate 
(GTP) metabolising proteins, and plays a role in actin cytoskeleton reorganisation during 
changes to cell shape. In solid tumours, cells known as cancer-associated fibroblasts (CAFs) 
have an important role in tumour invasion and angiogenesis, a function supported by 
CDC42EP3 in these cells. Depletion of CDC42EP3 in CAFs  reduces the fibroblast 
stimulation by tumour cells, which suggest the likely importance of CDC42EP3 targeting in 
tumours (Calvo et al., 2015). The mRNA expression level of CDC42EP3 showed a 
statistically significant increase in CDC42EP3 expression in the N/S control following DHT 
stimulation by ~10 fold in LNCaP-AI cell line in the microarray experiment. However, 
KMT5A depletion in the DHT treated arm results in  a significant reduction  in CDC42EP3 
expression by ~4 fold with KMT5A siRNA#1 and ~3 fold with KMT5A siRNA #2 (Figure 
3.6.A). The data was further validated using QRT-PCR in the same LNCaP-AI cells that were 
sent for microarray where similar trends were apparent and an increase in expression in the 
N/S control by ~2 fold was seen following DHT treatment. However, this effect was 
diminished by KMT5A depletion as  reduction in CDC42EP3 expression in response to 
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KMT5A depletion in the DHT treated arm was observed of ~2 fold for siRNA #1 and 
siRNA#2 (Figure 3.6.B).  Both KMT5A siRNAs did reduce the levels of CDC42EP3 mRNA 
in the presence of androgen (Figure 3.6.B). The experiments were further extended to 
evaluate changes in CDC42EP3 mRNA expression in the LNCaP cells line following 
KMT5A depletion.  A statistically significant increase in CDC42EP3 expression in the N/S 
control following DHT treatment was seen of ~3 fold (p≤0.05). However, this effect was 
reduced by ~2 fold in the DHT treated arm most notably with siRNA#2, while no significant 
changes was noticed with siRNA #1 compared to the N/S control (Figure 3.6.C). The data 
therefore confirmed CDC42EP3 as an androgen-regulated gene, and that the androgen-
induced expression of CDC42EP3 was diminished following siRNA-mediated depletion of 
KMT5A (Figure 3.6.B-C). 
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Figure 3-6 KMT5A plays a role in the expression of the androgen 
regulated gene, CDC42EP3. LNCaP and LNCaP-AI cells were reverse 
transfected with N/S siRNA or the two selected KMT5A siRNAs for 72 hours 
followed by either stimulation with 10 nM DHT or vehicle control for 24 hours. 
RNA was collected and CDC42EP3 mRNA expression was determined by 
microarray in (A) LNCaP–AI cells, and by QRT-PCR in (B) LNCaP-AI cells and (C) 
LNCaP cells. Error bars represent the mean ± SD for triplicate independent 
experiments. p-values were determined by t-test (* p-value <0.05, ** p-value <0.01, 
*** p-value <0.001 and  **** p- value < 0.0001). 
  
A 
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YIPF1 (up-regulated by DHT stimulation) 
The expression of YIPF1, a member of Yipf1 domain family, was validated on microarray 
samples in LNCaP-AI cells as being an AR-regulated gene. However, this relationship has not 
been reported previously. The microarray experiment data showed ~2 fold increase in the 
mRNA expression level of YIPF1 in the N/S control in the LNCaP-AI cell line in the DHT 
treated arm compared to N/S untreated control (Figure 3.7.A). Depletion of KMT5A by either 
siRNAs attenuated the DHT-induced increase in YIPF1 to similar levels as for the untreated 
arm.  This was further validated by QRT-PCR in the LNCaP-AI, where YIPF1 expression 
was increased by ~1.5 fold following DHT treatment in the N/S control, whereas depletion of 
KMT5A reduced the DHT-induced increase in YIPF1 expression with both siRNA which was 
consistent with data from the microarray experiment (Figure 3.7.B). The validation was 
extended to include the LNCaP cell line. In this case, no detectable changes in YIPF1 
expression was observed in response to DHT treatment, suggesting YIPF1 is not truely an 
androgen responsive gene (Figure 3.7.C). Additionally, knockdown of KMT5A with either 
siRNA failed to alter the expression of YIPF1. The findings for LNCaP and LNCaP-AI cells 
were contradictory and therefore not conclusive in supporting YIPF1 as an androgen-
regulated gene (Figure 3.7.B-C). 
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Figure 3-7  KMT5A plays a role in the expression of YIPF1. LNCaP and 
LNCaP-AI cells were reverse transfected with N/S siRNA or the two selected 
KMT5A siRNAs for 72 hours followed by either stimulation with 10 nM DHT or 
vehicle control for 24 hours. RNA was collected and YIPF1 mRNA expression was 
determined by microarray in (A) LNCaP–AI cells, and by QRT-PCR in (B) LNCaP-
AI cells and (C) LNCaP cells. Error bars represent the mean ± SD for triplicate 
independent experiments. p-values were determined by t-test (* p-value <0.05, ** 
p-value <0.01, *** p-value <0.001 and  **** p- value < 0.0001).
A 
B 
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KIF22 (up-regulated by DHT stimulation) 
KIF22, kinesin family member 22, is one of the microtubule-dependent molecular motors, 
which plays a role in the transport of organelles and chromosome movement during cell 
division. Furthermore, KIF22  is implicated  in  cellular proliferation and its depletion  results 
in G2/M phase arrest in  tumour cells (Yu et al., 2014). According to the microarray data, 
depletion of KMT5A reduced the level of KIF22 in the absence or presence of DHT. DHT 
treatment enhanced KIF22 expression significantly in the N/S control by ~2 fold (p≤0.05). 
KMT5A depletion in the DHT treated arm resulted in a significant reduction in KIF22 
expression. The most notable statistically significant effect was observed with siRNA#1 in the 
absence of DHT, where KIF22 expression was reduced by ~2 fold compared to N/S control 
(Figure 3.8.A). This data was further validated by QRT-PCR in the LNCaP-AI cell line. A 
small increase in KIF22 expression in the N/S control of ~2 fold following DHT treatment 
was observed.  In keeping with the microarray finding, both KMT5A siRNAs reduced the 
mRNA level of KIF22 in the absence or presence of DHT (Figure 3.8.B).  KIF22 expression 
was reduced significantly by ~2 fold with siRNA# 1 and by ~5 fold with siRNA #2 compared 
to the N/S control in the absence of DHT treatment (p≤0.05). For the DHT treated arm, this 
effect was reduced significantly by both KMT5A siRNAs by ~2 fold (p≤0.05).  The validation 
was extended to include the LNCaP cell line. In this case the androgenic induction of KIF22 
was confirmed as significant and KMT5A depletion was also found to reduce the level of 
KIF22 in the absence and presence of DHT.  The most notable effect was observed with 
siRNA#1 in the absence of DHT where a 2 fold reduction in expression was apparent 
(p≤0.05) (Figure 3.8.C). Overall, the data suggested KIF22 is an androgen-regulated gene in 
both LNCaP and LNCaP-AI cells and that the androgen-induced expression of KIF22 was 
reduced following KMT5A depletion using siRNAs (Figure 3.8.B-C). 
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Figure 3-8 KMT5A plays a role in the expression of the androgen 
regulated gene, KIF22. LNCaP and LNCaP-AI cells were reverse transfected 
with N/S siRNA or the two selected KMT5A siRNAs for 72 hours followed by either 
stimulation with 10 nM DHT or vehicle control for 24 hours. RNA was collected 
and KIF22 mRNA expression was determined by microarray in (A) LNCaP–AI 
cells, and by QRT-PCR in (B) LNCaP-AI cells and (C) LNCaP cells. Error bars 
represent the mean ± SD for triplicate independent experiments. p-values were 
determined by t-test (* p-value <0.05, ** p-value <0.01, *** p-value <0.001 and  
**** p- value < 0.0001). 
A 
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HIST1H2BD (up- regulated by reduced KMT5A expression) 
Histones play a central role in transcriptional regulation, DNA repair, DNA replication and 
chromosome stability. Androgen treatment was found to have little or no effect on 
HIST1H2BD expression (Figure 3.9.A) in the microarray experiment conducted with LNCaP-
AI cell line. The data revealed a statistically significant increase in mRNA expression level of 
HIST1H2BD (p≤0.05) following either KMT5A siRNA#1 or siRNA#2 treatment resulting in 
an ~3 and ~4  fold induction of HIST1H2BD expression in the absence and presence of DHT, 
respectively, compared to the N/S control (Figure 3.9.A). The data was further validated by 
QRT-PCR in the LNCaP-AI cells and also showed a statistically significant increase in 
HIST1H2BD expression (p≤0.05) following KMT5A mRNA depletion (Figure 3.9.B). 
However, the fold-increase in HIST1H2BD expression following KMT5A depletion was 
much greater than that observed for the microarray experiment with an approximately 20 fold 
increase in expression in the absence of DHT with both siRNAs and an ~22 fold and ~11 fold 
with siRNA#2 increase in HIST1H2BD expression for siRNA#1 and siRNA#2, respectively 
in the presence of DHT compared to N/S control (p≤0.05) (Figure 3.9.B). In the LNCaP cells, 
the validation also showed a statistically significant increase of ~6 fold in HIST1H2BD 
expression with siRNA#1 and ~5 fold with siRNA#2 in the absence of DHT. These results 
were mirrored following DHT treatment where an ~5 fold and ~4 fold induction in 
HIST1H2BD expression was observed with KMT5A siRNA#1 and siRNA#2 treatment, 
respectively, relative to  the N/S control (p≤0.05) (Figure 3.9.C). The data strongly indicated 
that HIST1H2BD is an  KMT5A regulated gene in both cell lines and that the androgen 
stimulation following KMT5A depletion using siRNAs had no effect on its expression (Figure 
3.9.B-C).  
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Figure 3-9  KMT5A regulates the expression of HIST1H2BD. LNCaP and 
LNCaP-AI cells were reverse transfected with N/S siRNA or the two selected 
KMT5A siRNAs for 72 hours followed by either stimulation with 10 nM DHT or 
vehicle control for 24 hours. RNA was collected and HIST1H2BD mRNA 
expression was determined by microarray in (A) LNCaP-AI cells and by QRT-PCR 
in (B) LNCaP–AI cells and (C) LNCaP cells. Error bars represent the mean ± SD 
for triplicate independent experiments. p-values were determined by t-test (* p-
value <0.05 and ** p-value <0.01).
B 
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RAB4A (down-regulated following KMT5A depletion) 
The RAB4A gene is a member of the largest group in the Ras superfamily of small GTPases, 
which regulate membrane trafficking. The encoded protein is associated with early 
endosomes and is involved in their sorting and recycling. The RAB4A protein also plays a 
role in regulating the recycling of receptors from endosomes to the plasma membrane 
(Kachhap et al., 2007; Pirngruber et al., 2009).  
The mRNA expression level of RAB4A showed a statistically significant reduction by ~2 fold 
following KMT5A depletion in the microarray experiment for the LNCaP-AI cells in the 
DHT untreated arm (p≤0.05) (Figure 3.11.A). A similar reduction in RAB4A mRNA 
expression was found when DHT was included in the experiment (Figure 3.10.A) particularly 
with siRNA#1. The data was further confirmed by QRT-PCR in the LNCaP-AI cells, where a 
~2 fold reduction in RAB4A expression was found with both KMT5A siRNA#1 and #2 in the  
untreated and DHT treated arms compared to N/S control (p≤0.05)(Figure 3.10.B). In this 
experiment, DHT caused an ~3 fold increase in RAB4A mRNA expression for the N/S control 
arm, suggesting RAB4A as an androgen-regulated gene in the LNCaP-AI cell line.  
However, upon examining RAB4A expression in the LNCaP cell line using QRT-PCR, no 
significant changes in RAB4A expression were observed in response to either DHT 
stimulation and/or KMT5A mRNA depletion (Figure 3.10.C). The data only suggested 
RAB4A as a KMT5A regulated gene in the LNCaP-AI cells (Figure 3.10.B-C). Furthermore, 
RAB4A appears to be under androgen regulation in LNCaP-AI cells but not in the LNCaP 
parental cell line. 
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Figure 3-10 KMT5A regulates the mRNA expression of RAB4A. LNCaP and 
LNCaP-AI cells were reverse transfected with N/S siRNA or the two selected 
KMT5A siRNAs for 72 hours followed by either stimulation with 10 nM DHT or 
vehicle control for 24 hours. RNA was collected and RAB4A mRNA expression was 
determined by microarray in (A) LNCaP-AI cells, and by QRT-PCR in (B) LNCaP-
AI and (C) LNCaP cells. Error bars represent the mean ± SD for triplicate 
independent experiments. p-values were determined by t-test (* p-value <0.05, ** 
p-value <0.01, *** p-value <0.001 and  **** p- value < 0.0001).   
B 
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CDC20 (down-regulated by reduced KMT5A expression) 
CDC20 (cell division cycle homolog 20) plays an important role in cell cycle progression as 
an important subunit of the anaphase promoting complex APC (Izawa and Pines, 2015). The 
microarray experiment indicated that CDC20 was affected by KMT5A but was not regulated 
by DHT treatment. However, CDC20 has previously been reported  as  an AR-dependent 
gene which is up-regulated in response to AR stimulation in an androgen-independent cell 
line derivative of LNCaP, termed LNCaP-Abl cells (Wang et al., 2009). The microarray 
revealed a statistically significant reduction of ~2 fold in the mRNA expression level of 
CDC20 in the LNCaP-AI cell line upon KMT5A knockdown with both siRNAs targeting  in 
the DHT untreated arm (p≤ 0.01) (Figure 3.11.A). Furthermore a similar result was observed 
for the DHT treatment arm for both KMT5A siRNAs. This was further confirmed by QRT-
PCR in LNCaP-AI cells, where a statistically significant reduction in CDC20 expression was 
also found with KMT5A siRNA#1 of ~4 fold and siRNA#2 by ~3 fold in the DHT untreated 
arm compared to N/S control (Figure 3.11.B). The effects of KMT5A depletion on CDC20 
mRNA expression in the DHT treated arm were not as great, but did show a significant 50-60 
% reduction in CDC20 expression (Figure 3.11B). Moreover, in the LNCaP cells, the effects 
of KMT5A depletion on CDC20 mRNA expression were comparable to the effects seen in the 
LNCAP-AI cell line (Figure 3.11.C). In this case, an ~ 3-4 fold reduction in CDC20 in the 
absence of DHT was observed following KMT5A knockdown, when compared to the N/S 
control (Figure 3.11.C). Similarly, when LNCaP cells were stimulated with DHT, the 
depletion of KMT5A resulted in ~2 fold reduction in CDC20 mRNA expression compared to 
the N/S androgen stimulated control (Figure 3.11.C). The data therefore identified CDC20 as 
a KMT5A regulated gene in both cell lines and that the androgen stimulation had no effect on 
CDC20 expression following KMT5A depletion using siRNAs (Figure 3.11.B-C). A 
statistically significant reduction (p≤0.05) in CDC20 expression was apparent for both 
LNCaP and LNCaP-AI cell lines following KMT5A knockdown.
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 Figure 3-11 KMT5A regulates the expression of CDC20. LNCaP and LNCaP-
AI cells were reverse transfected with N/S siRNA or the two selected KMT5A 
siRNAs for 72 hours followed by either stimulation with 10 nM DHT or vehicle 
control for 24 hour. RNA was collected and CDC20 mRNA expression was 
determined by microarray in (A) LNCaP-AI cells, and by QRT-PCR in (B) LNCaP–
AI cells and (C) LNCaP cells. Error bar represents the mean ± SD for triplicate 
independent experiments. p-values were determined by t-test (* p-value <0.05, ** 
p-value <0.01, *** p-value <0.001 and  **** p- value < 0.0001).   
B 
A 
C 
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3.4. Discussion 
Histone modifications are important alterations with critical roles in chromatin regulation and 
cell cycle progression. The histone methyltransferase KMT5A is the sole enzyme responsible 
for catalysing mono-methylation of H4 on lysine 20,whilst  the di- and tri-methylation of this 
particular lysine residue are catalysed by KMT5B and KMT5C respectively (Fang et al., 
2002).  
In PC, the AR remains an important therapeutic target due to the essential role that AR plays 
in the development and progression of the disease. However, targeting the AR in advanced 
PC has started to take a different approach in the experimental pre-clinical studies over the 
last few years, by targeting it indirectly through targeting its co-factors. These include, histone 
methyltransferases that have been found to methylate some non-histone proteins such as p53, 
and AR (Gaughan et al., 2011). The AR transcriptional activity has been shown to be 
influenced thorough the methyl modifications of its lysine residue(s), suggesting it may be 
valuable to investigate the therapeutic targeting of the AR thorough these methyltransferases. 
Of these histone methyltransferases, KMT5A was previously found to be a novel co- 
regulator of the AR (Coffey et al., unpublished data). The ability of KMT5A to regulate AR 
activity was found to switch from being an AR co-repressor in androgen dependent PC cells 
to an AR co-activator for androgen independent PC cells (Coffey et al., unpublished data). 
In order to understand the function of KMT5A and how its enzymatic activity participates in 
cellular functions in PC, a microarray study was designed to identify an expression profile of 
genes that are regulated by KMT5A in an androgen-independent PC cell line model (LNCaP-
AI). This was performed by silencing KMT5A expression using two independent siRNA 
sequences for 72 hours in SDM. Moreover, this was extended to include a subsequent 
stimulation of the AR activity using 10 nM DHT for 24 hours, in order to be able to 
distinguish the genes that are primarily regulated by the AR, but also modulated by KMT5A. 
The comparable experiment was also subsequently conducted in an androgen-dependent PC 
cell line model (LNCaP), and the samples were used for comparison before initiating the 
microarray experiment (Figure 3.2 and 3.3).  
Prior to microarray analysis a number of optimisation experiments were performed to ensure 
that the samples generated for analysis were as consistent and robust as possible in order to 
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ensure that the data generated was of the highest standard. Firstly, the optimum dose of DHT 
which was applied to the cells to stimulate AR activity was determined.  
As a readout of AR activity, KLK3 expression levels are considered as the most  important 
indicator of PC progression in its early stages, treatment outcome and also disease recurrence 
(Catalona et al., 2000; Balk and Knudsen, 2008). As such the expression of KLK3  mRNA 
was used to determine the response to DHT stimulation in LNCaP and LNCaP-AI cells 
(Figure 3.1). The expression levels of AR have  previously been found to be higher in AR-
independent PC compared to AR-dependent PC models, and this is accompanied by higher 
levels of KLK3 expression in such cancers (Shi et al., 2004). The titration experiment 
included serial doses of DHT (5 orders of magnitude) to stimulate AR activity over 24 hours. 
DHT treatment at 10 nM DHT caused a statistically significant (p≤0.05) increase in KLK3 
expression with ~30 fold in LNCaP cells and ~75 fold in LNCaP-AI cells. Consequently, 10 
nM DHT was selected as the dose to be used for stimulation of AR activity in the subsequent 
experiments for both LNCaP and LNCaP-AI cells.  Furthermore, a DHT time course 
experiment was then conducted that extended up to 72 hours. The data showed a rapid and 
statistically significant increase in KLK3 expression in the LNCaP cells (p≤0.05) that peaked 
at 24 hours by ~400 fold followed by a gradual reduction over the remaining time points. In 
the LNCaP-AI cells there was a gradual but statistically significant (p≤0.05) increase in 
KLK3expression that began to plateau at 72 hours with an ~2000 fold increase as shown in 
Figure 3.1. As a result, 24 hours of DHT stimulation at a dose of 10 nM was utilised in the 
subsequent gene profiling of LNCaP and LNCaP-AI cell lines in order to detect genes that 
were regulated primarily by the AR in both cell lines. The data was consistent with previously 
published data revealing that despite the higher levels of the AR protein in the  androgen 
independent PC cells, that the expression levels of KLK3 are substantially lower in the 
absence of AR stimulation (Shi et al., 2004).  
KMT5A depletion (~80 %) was achieved using selected siRNAs against KMT5A (Figure 3.2, 
3.3) in both LNCaP and LNCaP-AI cell lines at both the mRNA and protein levels. In order to 
confirm KMT5A knockdown prior to the microarray, the expression of a set of genes which 
are known to be regulated by KMT5A were examined. Such genes included the TWIST target 
genes CDH1 and VIM which were utilised as a functional readout for KMT5A knockdown. 
TWIST (also known as TWIST1), is a highly conserved basic helix-loop-helix transcriptional 
factor, which has a pivotal role in tumour metastasis by promoting epithelial to mesenchymal 
transition (EMT) (Yang et al., 2012a).  Depletion of KMT5A using small interference RNA 
was shown to result in an increase in the expression of CDH1 and a reduction in the 
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expression of VIM (Hou et al., 2016) which is consistent with the data shown in Figure 3.4. 
and the data obtained by the microarray. The ectopic expression of TWIST results in 
alterations in the expression of some proteins, such as upregulation of mesenchymal markers 
(e.g., N-cadherin, fibronectin, vimentin, and SM-actin) and downregulation of epithelial 
protein markers (e.g., E-cadherin, α-catenin, β-catenin, and Ɣ-catenin).  KMT5A is associated 
with TWIST and acts through its mono-methylation activity on H4K20 as a dual epigenetic 
modifier on twist target gene promoters, namely E-cadherin and N-cadherin. KMT5A and 
TWIST are functionally independent in stimulating EMT (Yang et al., 2012a). This reflect the 
role that KMT5A plays in tumour progression and metastasis and also as a positive reader of 
KMT5A knockdown in the PC cell lines that were used in this study. 
In order to detect KMT5A regulated gene expression profiles, the Illumina Human HT-12 
v4.0 Expression Bead Chip technology was used. Parallel quantification of a large number of 
transcripts is accessible by this high-throughput technology (Schmid et al., 2010). Analysis of 
microarray data revealed a number of genes that were regulated directly by KMT5A 
independently of AR and other genes that were only regulated by KMT5A in the presence of 
active AR. However, there were a low number of genes (29 in total) that appeared to be AR-
regulated but modulated by KMT5A.  Following data analysis using differential expression 
analysis by the R package ‘Limma’, and p values, a number of genes were selected for further 
investigation. 
CDC42EP3  
This gene is one of the CDC42EP family of proteins. In normal cells, alterations to cell shape 
are stimulated by CDC42EP3 which induces the assembly of actin filaments. In human male 
gonads, CDC42EP3 mRNA was suggested to be transcriptionally regulated by PUMILIO2 
binding to a specific nucleotide motif in the CDC42EP3 3'UTR (Calvo et al., 2015). In solid 
tumours, matrix remodelling, invasion of cancerous cells and angiogenesis is facilitated by 
non-cancerous fibroblast cells known as CAFs. This function is enhanced and supported by 
CDC42EP3 in the cancerous cells, and depletion of CDC42EP3 results in a reduction in 
angiogenesis and invasion of these cells. CDC42EP3 plays an important role in coordinating 
the septin and actin filament in the tumour stroma. In normal fibroblast, depletion of 
CDC42EP3 diminishes the fibroblast stimulation by tumour cells (Calvo et al., 2015). The 
expression of CDC42EP3 is also documented to be significantly increased in grade III 
tumours (Gabrovska et al., 2012). The data from the ongoing study identified CDC42EP3 as 
an AR regulated gene that can be modulated by KMT5A depletion in PC cells (Figure 3.6). 
These results might relate to the role that KMT5A plays in regulating cancer invasion and 
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angiogenesis thorough its cooperative effect with the AR in reducing CDC42EP3 expression 
in PC cell lines.  Consequently, CDC42EP3 may reduce the tumour growth promoting ability 
of the cancer associated fibroblasts. Recently, CDC42EP3  has been identified in a study 
using an RNAseq dataset to identify genes that are expressed reciprocally in response to acute 
androgen stimulation using the synthetic androgen (R1881) in culture, and the expression of 
these genes in PC patient under androgen deprivation therapy (ADT) (Munkley et al., 2016). 
CDC42EP3 expression was significantly increased by ~2 fold in response to 10 nM R1881 
treatment for 24 hours. This data is consistent with our data to confirm CDC42EP3 as an AR 
regulated gene. However, further investigation is required to understand this relationship in 
PC. 
 
YIPF1 (YIP domain family member 1) 
Current literature for YIPF1 is extremely limited. A small nucleotide polymorphism in the 
YIPF1 gene  was identified previously as being associated with angiotensin II receptor 
blocker response in a clinical trial for patients with mild-moderate essential hypertension 
(Kamide et al., 2013). The data from the microarray herein showed YIPF1 to be an androgen 
regulated gene in the LNCaP-AI cell line and that the androgen-induced expression of YIPF1 
was reduced to near basal levels following KMT5A depletion (Figure 3.7). Neither androgen-
induction nor KMT5A depletion had any noticeable effect on YIPF1 expression in the LNCaP 
cell line. However, YIPF1 was also included in the study mentioned above (Munkley et al., 
2016) as one of the genes that is significantly upregulated by ~2 fold in response to AR 
stimulation using 10 nM R1881.  
KIF22 (Kinesin family, member 22) 
  KIF22 is a microtubule-dependent molecular motor protein that plays an important role in 
cell mitosis, but also has the ability to bind to DNA (Yu et al., 2014). Depletion of KIF22 has 
been shown to result in cell cycle arrest at the G2/M phase which is accompanied by an 
increase in the activity of CDK1 enzyme and elevated expression of the KIF22 target gene 
CDC25C. Furthermore, KIF22 is overexpressed in cancers where it plays a role in promoting 
cell proliferation (Yu et al., 2014). Consistent with these findings, depletion of KIF22 results 
in a delay in mitotic entry accompanied by a reduction in CDC25C transcription. (Yu et al., 
2014). The microarray data showed significant elevation of KIF22 mRNA expression when 
DHT stimulation was applied to LNCaP-AI cells. The QRT-PCR experiment validated the 
androgen regulation of KIF22 mRNA for both LNCaP and LNCaP-AI cell lines (Figure 3.8).  
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Interestingly, the basal expression and androgen-induced expression of KIF22 was reduced 
following KMT5A depletion using siRNAs. Therefore, it is speculated that KMT5A might 
normally play a role in maintaining PC cell proliferation thorough its cooperative effect with 
the AR in maintaining KIF22 expression to ensure cells progress through the G2/M phase of 
the cell cycle. Consistently, KIF22 expression was recently shown to be  significantly 
increased by ~2 fold in response to 10 nM R1881 treatment for 24 hours (Munkley et al., 
2016), confirming KIF22  as an AR regulated gene. However, further investigation is required 
to understand this relationship in PC. 
HIST1H2BD (Histone cluster 1, H2BD)   
Histone mRNAs generally lack poly-A tails but contain 3’ end, stem loop structures that 
stabilise the mRNA. However, the replication associated histone genes, HIST1H2BD and 
HIST1H2AC can generate alternative transcripts containing poly-adenylated 3’ ends. These 
transcripts change expression during differentiation and tumourigenesis (Kari et al., 2013). 
CDK9 has a regulatory role in the co-transcriptional replication-dependent 3’-end processing 
of these histone mRNAs, a process which involves histones H2B mono-ubiquitination and H3 
lysine 4 tri-methylation. It was found that depletion of CDK9 led to ~15 fold increase in the 
read-through of HIST1H2BD (Pirngruber et al., 2009). With strong cell cycle links, it was 
interesting to observe that KMT5A depletion resulted in a statistically significant increase 
(p≤0.05) in the expression of HIST1H2BD in the presence and absence of DHT in the 
microarray experiment, which was also confirmed using QRT-PCR in both LNCaP and 
LNCaP-AI cells (Figure 3.9).  KMT5A was previously suggested to repress the genes 
required for DNA replication initiation, which would prevent S phase entry (Jørgensen et al., 
2007; Tardat et al., 2007). HIST1H2BD has been shown previously as  one of the DNA repair 
associated genes (Lilach et al., 2013). So the data herein might suggest that depletion of 
KMT5A in PC cells increases the expression of some DNA damage repair genes, such as 
HIST1H2BD in this case, could in turn increase the possibility of DNA damage repair. 
However, further investigation would be required.  
 
RAB4A  
RAB4A is a member of the RAS oncogene family which is known to regulate membrane 
trafficking. It is phosphorylated by CDK1 during mitosis which results in its movement from 
the membrane to the cytoplasm. RAB4A has been described as an effector of NDRG1, and is 
an androgen-regulated gene   that can localise to the recycling/sorting endosomes. NDRG1 is 
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also suggested to play a role in the recycling of E-cadherin, and therefore may play a role in 
the EMT of PC cells (Kachhap et al., 2007; Pirngruber et al., 2009). Interestingly, depletion 
of KMT5A was found to result in a reduction of RAB4A expression in the microarray data. 
The trend was also consistent in the QRT-PCR validation data for both the LNCaP-AI and 
LNCaP cells, although it was not found to be to be significant (Figure 3.10). Based on the 
relationship between RAB4A and KMT5A found here, as well as preceding information, it 
may further imply that KMT5A has an important role in regulating the EMT in PC cells. 
Further investigation of this relationship and its role in EMT is required. 
CDC20 
 CDC20 (Cell cycle division 20 homologue) functions as the substrate recognizing subunit of 
APC/C complex. During early mitosis, CDC20 is responsible for the role of APC/C in 
activating mitotic exit at the metaphase-to-anaphase transition. While during late mitosis and 
G1 phase, Cdh1 can replace CDC20 for this function (Manchado et al., 2010). KMT5A is 
dephosphorylated during early anaphase by the action of Cdc14 phosphatases which enables 
KMT5A to undergo ubiquitination and degradation by APCCdh1 causing a reduction in 
KMT5A levels at the G1 phase of the cell cycle (Wu et al., 2010). This group also suggested 
that as KMT5A is present in early mitosis in its phosphorylated form, there is a high 
possibility that the same mechanisms prevents KMT5A degradation by APCCdc20 complex 
during that phase. Adding to its role as a cell cycle regulator, CDC20 has also been suggested 
to participate strongly in the development and progression of human cancers, and therefore 
could be considered as a novel therapeutic target for cancer treatment (Wang et al., 2013). 
The microarray data showed a statistically significant reduction in CDC20 expression in the 
presence and absence of DHT in LNCaP-AI cells (p≤0.05), which was further confirmed in 
the validation data for both LNCaP and LNCaP-AI cells (Figure 3.11).  The relationship 
between KMT5A and CDC20 will be investigated and discussed further in Chapter 4.  
The established role of KMT5A in different cellular processes identified by previous studies 
was also supported by this study. This further strengthens the existing data for the 
involvement of KMT5A in these cellular processes and identifies specific genes and the 
possible pathways through which KMT5A is involved in order to accomplish these functions. 
KMT5A’s role in EMT was supported by the significant reduction of RAB4A expression 
following KMT5A depletion (Mendiratta et al., 2009; Calvo et al., 2015). Also, the 
upregulation of HIST1H2BD that followed KMT5A knockdown was also a mechanism to 
support the effect of KMT5A in the DNA damage repair process through the up-regulation of 
some DNA damage repair genes. The data also highlights a possible relationship between 
Chapter 3: Determining KMT5A regulated gene expression profile 
 
75 
 
KMT5A and AR in regulating the expression of some genes synergistically in PC cell lines.  
In conclusion, this study has highlighted some of the important and novel functions of 
KMT5A. Therefore, it further  strengthens an argument for therapeutic targeting of KMT5A 
in PC due to its key involvement in cancer-associated processes, including cell cycle, DNA 
repair and EMT that promote progression, invasion and metastasis of PC thorough different 
pathways. 
From the genes regulated by KMT5A, CDC20 expression at the protein level in the presence 
and absence of KMT5A, and the possible mechanism that might role the relationship between 
KMT5A and CDC20 will be investigated further in Chapter 4. 
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Chapter 4 . KMT5A indirectly regulates CDC20 expression via p53 
methylation 
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4.1. Introduction 
CDC20 
 KMT5A was identified in Chapter 3 as a putative novel regulator of CDC20 expression 
(Figure 3.13). CDC20 is an important cell cycle regulatory protein which associates with APC 
to target specifically a 9  amino acid  D-BOX peptide sequence within proteins for 
recognition, such as RxxLxxxN for degradation by the ubiquitination pathway during mitosis 
(Fang et al., 1998). CDC20 consists of 499 amino acids with WD40 repeats at its C-terminus 
for protein binding which is critical for APC substrate recognition. In addition to CDC20, 
CDH1 can also function as a substrate recognition subunit for APC. Proteins which do not 
contain a D-BOX, such as polo-like kinase, are targeted by this complex for destruction 
during G1. Unlike CDC20, whose expression peaks during mitosis and is reduced during G1 
(Figure 4.1), the expression of CDH1 remains persistent during the cell cycle (Fang, 2002). 
Furthermore, many studies have shown that CDC20 also plays an important role in the growth 
and development of human cancers and it is also oncogenic in multiple cancers such as 
ovarian, cervical and gastric cancer (Kidokoro et al., 2008; Smolders and Teodoro, 2011; 
Wang et al., 2013) (Figure 4.1). 
CDC20 is regulated by many factors, including Mad2 and BubR1, which are key components 
of the Mitotic Checkpoint Complex (MCC). Mad2 and BubR1 bind and inhibit CDC20 
activity, which is necessary for the activation of APC (Fang, 2002). Unattached kinetochores 
recruit and activate Mad2, BubR1 and Bub3 during spindle checkpoint arrest, allowing their 
association with Cdc20 that has been phosphorylated by Cdc2 and MAPK. Binding of Mad2, 
BubR1 and Bub3 to Cdc20 prevents Cdc20 from activating the APC (Chung and Chen, 2003). 
Attached kinetochore does not recruit Mad2 and Cdc20, preventing the generation of new 
Mad2–BubR1–Bub3–Cdc20 complex. The existing checkpoint complex may be disassembled 
through dephosphorylation of Cdc20. Inactivation of MAPK by an unknown mechanism may 
result in initial dephosphorylation of Cdc20 and partial activation of the APC. The APC–
Cdc20 then triggers the first phase of cyclin B degradation and inactivation of Cdc2, resulting 
in further dephosphorylation of Cdc20 and rapid accumulation of active APC–Cdc20 to 
trigger the anaphase. Mad3/BubR1 inhibits APC/CCdc20 activity by acting as a 
pseudosubstrate and/or by mediating Cdc20 ubiquitination and degradation(Chung and Chen, 
2003; Elowe, 2011). At physiological concentrations, BubR1 and Mad2 reciprocally promote 
binding of each other to CDC20, to quantitatively inhibit CDC20-APC to prevent premature 
separation of sister chromatids (Fang, 2002). Thus, the cell cycle is arrested at metaphase 
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when the checkpoint detects any defects in microtubule–kinetochore attachment or in the 
tension of the spindles. Only after ensuring proper attachment of the sister chromatids, the 
MCC complex detaches from CDC20 allowing free CDC20 to activate APC to result in cell 
cycle progression (Fang, 2002) (Figure 4.2). 
Emi1 can also regulate APCCDC20 activity by binding to CDC20 as a pseudo-substrate 
resulting in inhibition of Cyclin B degradation (Reimann et al., 2001) . USP44 (Ubiquitin- 
specific protease 44) can deubiquitinate CDC20 and prevent the premature APC activation 
through preventing its inhibitory effect on CDC20-MAD2 complex to regulate mitotic entry 
(Stegmeier et al., 2007). The RASSIF1, tumour suppressor can also regulate APCCDC20 
activity during mitosis by preventing degradation of Cyclin A and Cyclin B at the spindle 
poles, while this activity can be inhibited by Aurora A allowing prometaphase progression of 
the cell cycle (Song et al., 2004; Song et al., 2009). 
 
 
Figure 4-1 CDC20 activity in cell cycle. CDC20 expression peaks during 
mitosis and is reduced during G1.  
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Regulation of CDC20 expression 
Currently, KMT5A has not been reported to modulate the expression of CDC20 directly and 
as such in considering CDC20 as a biomarker for KMT5A activity, it is important to 
determine whether KMT5A can indeed directly affect CDC20 gene expression. As well as 
Smyd2, Set9 andG9a/Glp, KMT5A is also known to methylate p53. Each of these enzymes 
can methylate a different lysine on p53; K370, K372, K373 and K382, respectively. It has 
been found that K382me1 of p53 is reduced in response to DNA damage and that it is the 
preferred site for binding the chromatin compacting factor, L3MBTL1, to result in decreased 
transcription. Furthermore, an increase in the enrichment of p53-K382me1 at DNA repair 
gene promoters and a reduction at promoters of cell cycle arrest and apoptosis genes in 
tumour cells has been observed, which  reflects the changing roles of p53-K382me1 between 
normal and tumour cells (Huang et al., 2010). KMT5A mediated mono-methylation of p53 at 
K382 reduces its ability to bind to the p21 promoter thereby reducing p21 expression.  p53 is 
considered as an important negative regulator of CDC20 that can regulate tumour cell growth 
(Kidokoro et al., 2008).  
p53 is a transcriptional regulator of p21,  and the p53-p21 pathway has been found to regulate 
CDC20 expression through CDE–CHR elements (cell cycle dependent element-cell cycle 
genes homology region). CDE–CHR elements are involved in the regulation of several cell 
cycle regulators including E2F. p53 inhibits tumour cell  growth by indirect regulation of 
CDC20, which  suggests  CDC20 may be a potential therapeutic target for a wide range of 
cancers (Kidokoro et al., 2008). Therefore, due to the impact of p21 on CDC20 expression the 
effect of KMT5A depletion on CDC20 expression may be occurring via p53.  
This chapter is aimed to investigate the possibility of considering CDC20 as a biomarker for 
KMT5A activity in PC and the possible pathways that govern the relationship between 
KMT5A and CDC20. 
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Figure 4-2 Regulation of CDC20. BubR1 and Mad2 reciprocally promote 
binding of each other to CDC20, to quantitatively inhibit CDC20-APC to prevent 
premature separation of sister chromatids.  After ensuring proper attachment of 
the sister chromatids, the MCC complex detaches from CDC20 allowing free 
CDC20 to activate APC to result in cell cycle progression. Adapted from (Chung and 
Chen, 2003; Elowe, 2011) 
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4.2. Specific materials and methods 
4.2.1. Specific materials 
4.2.1.1. Cell lines  
LNCaP and LNCaP-AI cells were used in this study as detailed in Chapter 2.1.1. 
4.2.1.2. Antibodies  
A number of primary antibodies were used to detect protein expression by Western blotting 
(Table 4.1). 
Table 4-1 Western blot antibodies 
 
Antibody Species Catalogue number  
 
KMT5A Rabbit  Cell Signalling (2996) 
CDC20 Mouse Abcam (Ab190711) 
FOXM1 Mouse Santa Cruz (Sc-502) 
PLK1 Mouse Santa Cruz (Sc-55504) 
Cyclin B Mouse BD-Pharm(554176) 
p53 Mouse Calbiochem(pAb-
421#OP03) 
p21 Mouse Calbiochem(Ab-1#OP64) 
Phospho-p53 (Ser15) Rabbit Cell Signalling 
p53 (acetyl K382) Rabbit Abcam (ab75754) 
α-Tubulin Mouse  Sigma  
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4.2.1.3. Primer sequences 
To detect the expression of individual genes at the mRNA level, specific primer sets were 
used (Table 4.2). 
Table 4-2 Primers for QRT-PCR. 
 
  Forward Primer (5’-3’)  Reverse Primer (5’-3’)  
KMT5A GATCCCAGGCGGTGACAGAG CCCGGTAAATACGTTCTCCCC 
HPRT1 TTGCTTTCCTTGGTCAGGCA 
  
AGCTTGCGACCTTGACCATCT 
CDC20 TCGCATCTGGAATGTGTGCT CCGGGATGTGTGACCTTTGA 
FOXM1 CAAGCCAGGCTGGAAGAACTC                 TGCTGCTTAAACACCTGGTCC 
PLK1 CCGCAATTACATGAGCGAGC TGAGCTTGGTGTGATCCTGG 
CCNB TAAGATTGGAGAGGTTGATGTCGA         
    
CCAGGTGCTGCATAACTGGA 
p53 TCAGATAGCGATGGTCTGGC CGCCCATGCAGGAACTGTTA 
CDKN1A TCACCCTCCAGTGGTGTCTC TGTTCAGGCGCCATGTCAG 
CDC20 
promoter 
TCTGAGCACATTCATACAATTCACTC AACACGCCTGGCTTACGCCTCT 
 AREIII  TGGGACAACTTGCAAACCTG                    CCAGAGTAGGTCTGTTTTCAATCCA 
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4.2.1.4. siRNAs sequences  
In order to achieve CDC20 and FOXM1 depletion, specific siRNAs were used (Table 4.3).  
Table 4-3 Small interference RNA sequences. 
4.2.2. Specific Methods 
4.2.2.1. Chromatin Immunoprecipitation (ChIP) 
ChIP technique was used to determine H4K20me1 marker enrichment at the CDC20 promoter 
in response to DHT mediated AR activation over a time period of 0, 30, 60 and 120 minutes 
as described in Chapter 2.2.6 with the following specific modifications. LNCaP cells were 
seeded out in 150 mm dishes in FM. Once cells were 70% confluent, cells were starved in 
SDM for 72 hours, to diminish AR activity and to ensure AR elimination from target gene 
promoters. In LNCaP-AI cells, which are routinely grown in SDM, cells were seeded and 
allowed to adhere for 24 hours prior to stimulation with DHT (100 nM) for 0, 30, 60 and 120 
minutes. ChIP grade antibody H4K20me1 were used in order to identify regions of DNA 
where these proteins are bound.
siRNA Sense sequence Anti-sense sequence 
Non-
silencing 
(NS) 
(1022076) 
(Qiagen 
UUCUCCGAACGUGUCACGU ACGUGACACGUUCGGAGAA 
CDC20 #1 CGGAAGACCUGCCGUUACA UGUAACGGCAGGUCUUCCG 
CDC20 #2 GGGCCGAACUCCUGGCAAA UUUGCCAGGAGUUCGGCCC 
FOXM1#1  GGACCACUUUCCCUACUUUUU AAAAAGUAGGGAAAGUGGUCC
FOXM1#2 GUGGCAGAGUCCAACUCUUUU AAAAGAGUUGGACUCUGCCAC 
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4.3.Results
4.3.1. CDC20 protein expression level is reduced significantly with KMT5A knockdown in 
LNCaP and LNCaP-AI cells 
Data from microarray study showed that KMT5A knockdown by siRNAs results in a 
significant reduction in CDC20 mRNA expression levels in LNCaP-AI cells of ~2 fold  
(p≤0.05). This was further validated by QRT-PCR in both LNCaP and LNCaP-AI cell lines, 
where an ~3-4 fold and ~2-5 fold, respectively (p≤0.05) reduction in expression was observed 
(Figure 3.11). In order to determine whether a reduction at the mRNA levels results in a 
reduction at the protein level, similar experiments were carried out using Western blotting as 
an experimental endpoint.
Depletion of KMT5A was achieved in LNCaP and LNCaP-AI cells by reverse transfection in 
SDM for 72 hours using 2 independent KMT5A siRNA sequences, followed by 10 nM DHT 
stimulation for 24 hours. Non-silencing (N/S) was used as a negative control. In both cell 
lines tested, a robust knockdown of KMT5A was observed both in the presence and absence 
of DHT stimulation. Furthermore, in line with the mRNA data, the levels of KMT5A was 
unaffected by any DHT stimulation. Similarly to the mRNA data, CDC20 levels were 
consistently reduced upon KMT5A knockdown in both cell lines irrespective of DHT 
stimulation, which also had no effect on CDC20 levels in N/S controls (Figure 4.3). The data 
confirm what was observed at the mRNA level, that CDC20 expression was regulated by 
KMT5A in PC cells.
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Figure 4-3 KMT5A knockdown reduces CDC20 expression at the protein 
level. (A) LNCaP and (B) LNCaP-AI cells were reverse transfected with N/S siRNA 
or the two selected KMT5A siRNAs for 72 hours followed by either stimulation 
with 10 nM DHT or vehicle control for 24 hours. Protein was collected and 
knockdown of KMT5A and the effect on CDC20 expression was determined by 
Western blotting (representative blot).
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4.3.2. KMT5A depletion differentially affects the cell cycle profile in LNCaP and LNCaP-AI 
cells 
As KMT5A is a cell cycle regulator, the presence of KMT5A and its histone mono- 
methylation activity play an essential role in cell cycle progression. The cell cycle profile was 
examined in the presence and absence of KMT5A in LNCaP and LNCaP-AI cell lines. 
KMT5A knockdown was achieved using the same protocol as in Figure 4.3. Only one siRNA 
against KMT5A was used for this experiment as both siRNAs gave a significant efficient 
knockdown for KMT5A.  Following the knockdown period, the cells were stained using 
propidium iodide for 40 minutes, then the cell cycle analysis was conducted by flow 
cytometry as described in Chapter 2.2.4.  
The data was averaged over 3 experiments. No significant changes were detected in cell cycle 
progression in LNCaP cells when KMT5A expression was depleted with siRNA#1(Figure 
4.4.A). However, in LNCaP-AI cells there was a significant reduction (p≤0.05) in the 
percentage of cells in G2/M phase of ~50 %, which was accompanied by an increase in the 
percentage of cells in S phase. However, this was not significant. This data reflects a small 
disruption in cell cycle distribution in LNCaP-AI cells in response to KMT5A knockdown 
(Figure 4.4.B). 
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 Figure 4-4 Effect of KMT5A depletion on the cell cycle profile in LNCaP 
and LNCaP-AI cells. (A) LNCaP and (B) LNCaP-AI cells were reverse 
transfected with N/S siRNA or the selected KMT5A siRNA#1 for 72 hours in 6 well 
plates.  Cell cycle analysis was performed using propidium iodide to stain cellular 
DNA for 40 minutes. Error bars represent the mean ± SD for triplicate independent 
experiments. p-values were determined by t-test (* p-value <0.05).
A 
B 
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4.3.3. Reciprocal relationship between CDC20 and KMT5A: CDC20 depletion reduces 
KMT5A mRNA expression 
Phosphorylated KMT5A during early mitosis is protected from being targeted for 
ubiquitination by APCCDC20, similar to the other form of this complex, APCCdh1 during the G1 
phase of the cell cycle  (Wang et al., 2013). Based on this, the relationship between KMT5A 
and CDC20 was further investigated to test whether depletion of CDC20 would result in an 
increase in KMT5A protein levels due to decreased turnover by the ubiquitination pathway. 
CDC20 knockdown was achieved using two independent siRNA sequences for 72 hours in 
LNCaP and LNCaP-AI cells. RNA was then collected and it was observed that an ~80 % 
reduction in CDC20 mRNA level was apparent, when measured by QRT-PCR in LNCaP and 
LNCaP-AI cells (Figure 4.5.A.i- Bi).  Furthermore, KMT5A expression was significantly 
reduced by ~70-80 % (p≤0.05) in LNCaP cells and by ~ 60-70 % (p≤0.05) in LNCaP-AI cells 
in response to CDC20 depletion (Figure 4.5.Aii- Bii). 
In a parallel experiment, protein was collected from LNCaP and LNCaP-AI cells following 72 
hours CDC20 knockdown in their respective medium. CDC20 knockdown was confirmed and 
KMT5A expression was detected at the protein level (Figure 4.5.Aiii-Biii). No robust changes 
were detected in KMT5A expression in response to CDC20 depletion when loading controls 
were taken into account. Hence, the changes observed at the mRNA level (Figure 4.5.Aii-Bii) 
were not reflected at the protein level.  
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Figure 4-5 Effect of CDC20 depletion on KMT5A mRNA and protein 
expression in LNCaP and LNCaP-AI cells. (A) LNCaP cells and (B) LNCaP-AI 
cells were examined for (i) CDC20 mRNA expression (ii) KMT5A mRNA expression 
and (iii) CDC20 protein expression. Cells were reverse transfected with N/S siRNA 
or the two selected siRNAs against CDC20 for 72 hours in 6 well plates. RNA and 
protein were collected and CDC20 knockdown and its effect on KMT5A expression 
levels was determined by QRT-PCR and Western blotting (representative blots). 
Error bars represent the mean ± SD for triplicate independent experiments. p-
values were determined by t-test (* p-value <0.05, ** p-value <0.01, *** p-value 
<0.001 and **** p- value < 0.0001).
A (i) B (i)
(ii) 
(iii)
(ii) 
 (iii) 
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4.3.4. The effect of CDC20 depletion on cell cycle profile in LNCaP and LNCaP-AI cells 
As KMT5A depletion showed some disruption in cell cycle progression in LNCaP-AI cells 
(Figure 4.4) the subsequent effect of a reduction in CDC20 levels, which is also a cell cycle 
regulator, may be playing a role in this disruption. To test this, the cell cycle profile was 
examined in the presence and absence of CDC20 in LNCaP and LNCaP-AI cell lines.  
CDC20 knockdown was achieved using CDC20 siRNA#1 (Table 4.3) for 72 hours for each 
cell line in its respective medium. Only one siRNA against CDC20 was used for this 
experiment as both siRNAs gave a significant efficient knockdown for CDC20. Following the 
knockdown period, cells were stained using propidium iodide for 40 minutes, then the cell 
cycle analysis was conducted by flow cytometry as detailed in Chapter 2.2.4.  
The data was averaged over 3 experimental repeats. CDC20 depletion was previously 
reported to prevent the progression of the cell cycle in mitosis. In agreement with this report, 
in the LNCaP cells there was a statistically significant ~90 % increase (p≤0.05) in the 
percentage of cells in  G2/M phase compared to the N/S control, suggesting a cell cycle arrest 
at this phase in response to CDC20 knockdown (Figure 4.6.A). However, in contrast no 
significant changes were detected in LNCaP-AI cells (Figure 4.6.B).  
Chapter 4: KMT5A indirectly regulates CDC20 expression  
 
 
91 
 
 
 
Figure 4-6 Effect of CDC20 depletion on cell cycle profile in LNCaP and 
LNCaP-AI cells. (A) LNCaP and (B) LNCaP-AI cells  were reverse transfected 
with N/S siRNA or the selected CDCC20 siRNA#1 for 72 hours in 6 well plates. 
Cell cycle analysis was performed using propidium iodide to stain cellular DNA for 
40 minutes. Error bars represent the mean ± SD for triplicate independent 
experiments. p-values were determined by t-test (* p-value <0.05).
A 
B 
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4.3.5. KMT5A and CDC20 depletion reduce LNCaP and LNCaP-AI cellular proliferation 
rate 
In order to address the findings from Figure 4.3 and Figure 4.5 which were inconsistent with 
previously published data regarding cell cycle progression following knockdown of KMT5A 
or CDC20, an experiment was designed to look at cellular proliferation over a longer time 
period. In previous experiments, cells were only subjected to 72 hours knockdown prior to the 
assessment of cell cycle profile. Previously, it has been found that in order for some of these 
cell cycle enzymes to have a phenotypic effect, cells must undergo a minimum of 2 cell cycles 
in their absence (Abbas et al., 2010a). 
Knockdown of KMT5A or CDC20 was performed in LNCaP and LNCaP-AI cells for 72 
hours in their respective medium. Cells were then counted and seeded out in 96 wells plates 
for a further 96 hours. Cellular proliferation was then determined by SRB assay as described 
in Chapter 2.2.1.4.  
Approximately 50 % reduction in the proliferation was observed following either KMT5A or 
CDC20 knockdown in LNCaP cells (p≤0.05) (Figure 4.7. A-B), whilst an ~75 % reduction in 
cellular proliferation was observed in LNCaP-AI cells with both KMT5A and CDC20 
knockdown (Figure 4.7.C-D). The data  was consistent with previously reported data which 
showed a rapid reduction in U2OS cell line proliferation in response to KMT5A depletion 
(Oda et al., 2009), and also with data published regarding CDC20 as one of the genes 
required for human cancer cell proliferation (Huang et al., 2009).
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Figure 4-7 Effect of KMT5A and CDC20 depletion on LNCaP and LNCaP-
AI cell proliferation. LNCaP cells (A) with KMT5A depletion and (B) CDC20 
depletion. LNCaP-AI cells(C) with KMT5A depletion and (D) CDC20 depletion. 
Cells were reverse transfected with N/S siRNA or the siRNAs against KMT5A and 
CDC20 for 72 hours in 6 well plates. Cells were then counted and re-seeded in 96 
well plates. Cell growth was determined after a period of 4 days using SRB assays. 
Error bars represent the mean ± SD for triplicate independent experiments. p-
values were determined by t-test (* p-value <0.05, ** p-value 0.01 and *** p-value 
<0.001).
A B
C D 
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4.3.6. CDC20 expression in PC cell lines  
CDC20 basal expression was previously reported to be less in LNCaP compared to LNCaP-
ABL cells (an androgen independent derivative of LNCaP cells) (Wang et al., 2009). To 
further expand this observation, CDC20 expression levels were detected in a panel of PC cell 
lines, which are representative of different stages of the disease.   
No robust major changes in CDC20 expression were observed between the different cell lines 
tested when the loading controls were taken into account A double band was apparent for 
CDC20 in the DU145 cell line, which may be an indicator of the presence of two isoforms for 
CDC20 in this cell line, although this has not been investigated further in this study (Figure 
4.8.A). CDC20  has previously been reported to have five isoforms in Arabidopsis thaliana, 
where  CDC20.1 and CDC20.2 were detailed as the two active and redundant isoforms, which 
both played a role in the regulation of APC/C activity by binding to the APC10 subunit 
(Kevei et al., 2011). However, no other isoforms for CDC20 have been reported to date in any 
other species.  
Prior to investigating the relationship between KMTA and CDC20, and in order to clearly 
understand the localization pattern of KMT5A and CDC20 in PC cells, cellular distribution of 
both KMT5A and CDC20 was investigated in the LNCaP-AI cell line using methods outlined 
in Chapter 2.2.7. Fractionation efficiency was confirmed by immunoblot with an α-tubulin 
antibody that specifically localises its antigen in the cytoplasm, and a PARP antibody that 
detects its antigen specifically in the nucleus. CDC20 was found to be predominantly 
localized in the cytoplasm, while KMT5A was detected in both cytoplasmic and nuclear 
compartment, which is consistent with previously reported data about their cellular 
localisation in different cancers (Figure 4.8.B). KMTA was previously reported to be 
localised either in the nucleus or the cytoplasm mainly depending on cell cycle (Yin et al., 
2008b) which is consistent with the data in this figure. Whereas for CDC20, it has been 
reported as being a part of the APC/C complex, its  activity toward securin started  in the 
cytoplasm and then on the chromosomes,  to stimulate the final and rapid activation of 
separase on chromosomes  before  the onset of anaphase (Sivakumar et al., 2014).  From the 
data above, it would be most likely that KMT5A and CDC20 would form any possible 
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interaction in the cytoplasm as both are localised there at some part of the cell cycle. Further 
investigation is required to determine the possible interaction. 
 
 
 
 
 
Figure 4-8 CDC20 expression and cellular distribution (A) CDC20 
expression in a panel of PC cell lines. Protein lysate were collected from 500000 
cells from each cell line and the expression of CDC20 was detected by Western 
blotting. (B) Cellular localisation of KMT5A and CDC20 in LNCaP-AI cells. 
LNCaP-AI cells were grown to 70 % confluency in SDM and nuclear cytoplasmic 
extracts generated using the NE-PER™ Nuclear and Cytoplasmic Extraction Kit 
were evaluated in Western blot analysis (representative blot).
A B 
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4.3.7.KMT5A and CDC20 protein interaction: endogenous and exogenous interaction 
KMT5A has been reported previously to interact with a large number of proteins including 
PCNA, DDX21 (Qin et al., 2013) and  also with p53 where KMT5A binds to K382  to 
catalyse the methyltransferase function (Scoumanne and Chen, 2008). To investigate if 
KMT5A can also regulate CDC20 expression via its methylation activity through direct 
contact, the interaction between KMT5A and CDC20 was investigated.  
Firstly, LNCaP and LNCaP-AI cells were grown in their respective medium for 48 hours.  
Native immunoprecipitation was then performed, as outlined in Chapter 2.2.5. KMT5A was 
found to be immunoprecipitated from both cell lines as demonstrated by Western blotting and 
its interaction with CDC20 was confirmed endogenously in both cell lines (Figure 4.9.A).  
Secondly, KMT5A-CDC20 interaction was investigated exogenously in 293T cells, when 
both KMT5A and CDC20 were overexpressed.  Cells were grown to 70 % confluency before 
forward transfection of 1 μg of pFlag-KMT5A WT and / or pHA-CDC20 into 293T cells 
using Lipofectamine TM LTX (Invitrogen, New York, USA) according to the manufacturer’s 
recommendations. KMT5A was successfully immunoprecipitated from LNCaP and LNCaP-
AI cell lines demonstrated by Western blotting, and its interaction with CDC20 was 
confirmed in both cell lines (Figure 4.9.B). KMT5A interaction was only observed when both 
constructs were present as a band of 52 kD which represent a full length CDC20 protein. The 
data indicated that KMT5A and CDC20 do indeed interact which raises the possibility that the 
two proteins are resident in the same complex. 
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Figure 4-9 KMT5A interacts with CDC20 (A) Endogenous interaction between 
KMT5A and CDC20 in LNCaP and LNCaP-AI cells. Cells were grown to 70% 
confluency and a cell pellet was generated by centrifugation and native IP was 
applied to pull down KMT5A. (B) Exogenous interaction between KMT5A and 
CDC20 in 293T cells. Cells were grown for 48 hours followed by forward 
transfection with pFlag-KMT5A WT and / or pHA-CDC20 for 48 hours. Cell lysates 
were collected, immunoprecipitation performed and subjected to Western blotting 
using anti-KMT5A to confirm the pull down and anti-CDC20 to confirm the 
interaction (representative blots). 
Chapter 4: KMT5A indirectly regulates CDC20 expression  
 
 
98 
 
4.3.8. H4K20me1 mark is enriched at the CDC20 promoter  
From (Figure 4.7), KMT5A and CDC20 interaction was confirmed. It was next decided to 
determine whether KMT5A directly controls CDC20 expression through KMT5A enzymatic 
activity acting via mono-methylation of H4K20 at the CDC20 promoter. 
In this experiment, the effect of DHT stimulation on KMT5A activity was also examined to 
explore whether the differential effect of DHT stimulation on KMT5A expression in LNCaP 
and LNCaP-AI cells (Coffey et al, unpublished data) was due to differences at the promoter 
level. LNCaP cells were starved in SDM for 72 hours, followed by DHT (100 nM) 
stimulation for 0, 15, 30 and 120 minutes. The same treatment was also performed in LNCaP-
AI cells following 72 hours growth in its respective medium (SDM).  
Following DHT treatment, the enrichment of H4K20me1 on the CDC20 promoter was found 
to vary between the two cell lines tested. In the LNCaP cells, there was a reduction in the 
level of H4K20me1 at the CDC20 promoter region in response to DHT treatment. However in 
LNCaP-AI cells, DHT treatment clearly enhanced H4K20me1 which peaked at ~5 fold after 
30 minutes stimulation (Figure 4.10).  This data is consistent with the data previously 
obtained  in our group (Coffey et al, unpublished data), which indicated the difference in 
KMT5A expression  in response to DHT stimulation where KMT5A expression was 
decreased and increased respectively in LNCaP and LNCaP-AI cells, which would impinge 
on its mono-methylation activity at the target genes promoters. 
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Figure 4-10 Assessment of the H4K20me1 mark at the CDC20 promoter in 
response to DHT treatment in LNCaP and LNCaP-AI cells. (A) LNCaP cells 
and (B) LNCaP-AI cells were starved in SDM for 72hours followed by DHT (100 
nM) stimulation for 0, 15, 30 and 120 minutes. Chromatin immunoprecipitation 
assay was performed as previously described. Rabbit IgG was used as negative 
control under identical conditions and at the same concentration as H4K20me1 
antibody. Results are expressed relative to the values of untreated samples. Error 
bars represent the mean ± SD for triplicate independent experiments. 
A
B
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4.3.9. KMT5A depletion reduces FOXM1 expression, a potential regulator of CDC20 
KMT5A was confirmed to be able to control CDC20 expression through the mono-
methylation activity in response to DHT stimulation (Figure 4.10). To understand if KMT5A 
can affect CDC20 expression indirectly through other pathways that might be affected by 
KMT5A depletion, FOXM1 was selected to be investigated as it  has been reported as a 
transcriptional regulator of CDC20 (Xie et al., 2015). KMT5A depletion resulted in a 
significant reduction in FOXM1 expression of ~1.5-2 fold in the absence of DHT most 
notably with siRNA#2 (p≤0.05) in the microarray data (Figure 4.11.A). The data was also 
confirmed by QRT-PCR in LNCaP-AI cells as ~2 fold reduction was also observed in the 
absence of DHT when compared to the N/S control (Figure 4.11.B). The validation was 
extended to include the LNCaP cells were a significant reduction in FOXM1 expression of ~2 
fold was observed particularly with siRNA#1 in the DHT untreated arm (Figure 4.11.C).  
To further investigate the effect of KMT5A depletion on FOXM1 expression, the protein 
expression of FOXM1 was measured in response to KMT5A knockdown in LNCaP and 
LNCaP-AI cells. A robust reduction in FOXM1 expression  in response to KMT5A depletion 
was observed, which was enhanced with DHT treatment in LNCaP cells (Figure 4.11.D) and 
also in LNCaP-AI cells (Figure 4.11.E). From the data above, FOXM1 expression in the 
LNCaP-AI cells was found to be down-regulated by DHT treatment at the mRNA and protein 
level, while in the LNCaP cells a slight up-regulation at both the mRNA and protein level was 
observed in response to DHT treatment. 
Prior to investigating the effect of KMT5A and FOXM1 on CDC20 expression, the activity of 
FOXM1 in response to KMT5A knockdown was also investigated by looking at the 
expression level of selected FOXM1 downstream targets (Cyclin B and PLK1). The 
microarray data showed a statistically significant reduction in PLK1 (Figure 4.12.A) and 
Cyclin B (Figure 4.12.B) expression of ~3 fold and 2 fold, respectively.  Most notable effects 
were observed with siRNA#2 in the absence of DHT for Cyclin B and also for PLK1 in the 
presence of DHT (p≤0.05) where a significant ~2-3 fold reduction was observed. Both Cyclin 
B and PLK1 expression levels were correlated with FOXM1 reduction in response to KMT5A 
depletion. Interestingly, the same trend was also detected for these FOXM1 substrates in the 
initial microarray data set and subsequent Western blotting experiments (Figure 4.11). A 
robust reduction in Cyclin B and PLK1 expression at the protein level was detected in LNCaP 
and LNCaP-AI cell lines (Figure 4.12. C-D). This data supported the possible effect of 
KMT5A depletion on CDC20 via FOXM1 as one of its substrates.
Chapter 4: KMT5A indirectly regulates CDC20 expression  
101 
Figure 4-11 Effect of KMT5A knockdown on FOXM1 expression in LNCaP 
and LNCaP-AI cells. LNCaP-AI ( A,B,E) and LNCaP( C,D) cells  were reverse 
transfected with N/S siRNA or the two selected KMT5A siRNAs for 72 hours 
followed by either stimulation with 10 nM DHT or vehicle control for 24 hours. 
RNA and protein were collected and KMT5A knockdown and its effect on FOXM1 
expression levels were determined by QRT-PCR and Western blotting 
(representative blots). Error bars represent the mean ± SD for triplicate 
independent experiments. p-values were determined by t-test (* p-value <0.05, ** 
p-value <0.01, *** p-value <0.001 and **** p- value < 0.0001). 
A B
C
D E
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Figure 4-12  KMT5A knockdown reduces FOXM1 and downstream targets 
in LNCaP and LNCaP-AI cells. LNCaP-AI (A, B, D) and LNCaP(C) cells were 
reverse transfected with N/S siRNA or  the two selected KMT5A siRNAs for 72 
hours followed by either stimulation with 10 nM DHT or vehicle control for 24 
hours. RNA and protein were collected and KMT5A knockdown and its effect on 
FOXM1, PLK1 and Cyclin B expression levels was determined by QRT-PCR and 
Western blotting (representative blots). Error bars represent the mean ± SD for 
triplicate independent experiments. p-values were determined by t-test (* p-value 
<0.05, ** p-value <0.01 and *** p-value <0.001)
A B 
C D 
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4.3.10. The effect of AR stimulation on the regulation of FOXM1 and expression of its 
downstream substrates  
The differences in FOXM1 expression in response to DHT stimulation between LNCaP and 
LNCaP-AI cells with KMT5A depletion (Figure 4.11, Figure 4.12) was the driving factor to 
investigate FOXM1 expression at the protein level in response to DHT treatment over a 
number of time points. It has been reported previously that FOXM1 indirectly elevated AR 
dependent transcription and AR protein levels,  and that FOXM1 and AR proteins physically 
interact in PC cells (Liu et al., 2014). Therefore, trying to investigate this reciprocal effect of 
AR on FOXM1 expression was required. 
In order to do so, both LNCaP and LNCaP-AI cells were starved for 72 hours in SDM to 
down-regulate AR signalling, then stimulated with 10 nM DHT for 0, 8 and 24 hours. Protein 
was then collected and the expression of FOXM1 and some of its substrates (PLK1, SKP2, c-
Myc) were detected by Western blotting. An increase in the expression level of FOXM1 in 
LNCaP cells was observed in response to DHT treatment. The same trend was also observed 
for the FOXM1 substrates investigated. In contrast for the LNCaP-AI cells a reduction in 
FOXM1 and its substrates expression was observed in response to AR stimulation (Figure 
4.13). The data suggested that FOXM1 is regulated by AR in PC cells. However, further 
investigation is required to further understand the underlying mechanism.
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Figure 4-13 Androgenic effect on FOXM1 and its target proteins in LNCaP 
and LNCaP-AI cell lines. LNCaP and LNCaP-AI cells were grown in SDM for 
72 hours followed by treatment with 10 nM DHT for 0, 8 and 24 hours. Protein 
lysates were collected and FOXM1, PLK1, c-Myc, SKP2 and Alpha-tubulin 
expression were detected by Western blotting (representative blot).
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4.3.11. The effect of FOXM1 knockdown on CDC20 expression level in LNCaP and LNCaP-
AI cells 
As knockdown of KMT5A causes a reduction in FOXM1 expression, which can drive the 
reduction in CDC20 expression, it is important to directly assess the effect of FOXM1 in 
these cell lines as a regulator of CDC20. To further investigate CDC20 regulation by FOXM1 
in PC cells, FOXM1 itself was depleted using two independent siRNA sequences. The 
knockdown was performed in LNCaP and LNCaP-AI cell lines each in its own respective 
medium for 72 hours. RNA and protein was then collected, and the knockdown of FOXM1 
was confirmed by QRT-PCR and by Western blotting. Significant knockdown in FOXM1 
expression of ~ 70-80 % was achieved at the mRNA level in both cell lines (p≤0.05) (Figure 
4.14.Ai-Bi). However, no significant change in CDC20 mRNA expression was apparent with 
one of the targeting siRNAs, but there was a very small but significant effect on CDC20 
expression with the second siRNA in response to FOXM1 knockdown (Figure 4.14.Aii-Bii) 
in both LNCaP and LNCaP-AI cell lines. The data was mirrored at the protein level, as a 
robust reduction in FOXM1 expression at the protein level was seen with no robust changes 
in CDC20 expression (Figure 4.14.Aiii- Biii). This is a likely indicator that the changes in 
CDC20 expression in response to KMT5A knockdown are not driven by FOXM1, but 
probably act through a different pathway independent of FOXM1.
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Figure 4-14 FOXM1 depletion does not affect CDC20 expression. (A) LNCaP 
cells and (B) LNCaP-AI cells (i) FOXM1 depletion and (ii) CDC20 expression, (iii) 
FOXM1 depletion at protein level. Cells were reverse transfected with N/S siRNA 
or the two selected siRNAs against FOXM1 for 72 hours in 6 well plates. RNA and 
protein were collected and FOXM1 knockdown and its effect on CDC20 expression 
levels was determined by QRT-PCR and Western blotting (representative blots). 
Error bars represent the mean ± SD for triplicate independent experiments. p-
values were determined by t-test (* p-value <0.05, ** p-value <0.01, *** p-value 
<0.001 and **** p- value < 0.0001).
A 
A 
B 
B 
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4.3.12. p53 regulates CDC20 expression in response to KMT5A mono-methylation at K382: a 
proposed model 
CDC20 expression is clearly regulated by the expression of KMT5A (Figure 4.3). The 
transcriptional regulation of CDC20 by FOXM1 in response to KMT5A knockdown was 
tested revealing that indeed KMT5A can modulate the levels of FOXM1, but, FOXM1 does 
not play a role in CDC20 expression in the PC cell lines tested.  
 Interestingly, CDC20 has been reported to be regulated by p53, to exert its anti-tumour 
activity, which in turn has been reported to be modulated by KMT5A under certain cellular 
conditions (Kidokoro et al., 2008). p53 can down-regulate CDC20 expression in response to 
DNA damage by direct binding to a p53 consensus sequence within the CDC20 promoter in a 
response element (RE) located 689-bp upstream of the transcription start site (TSS). p53 can 
also regulate CDC20 expression through a CDE-CHR element, but acting independently of 
p21 and only under conditions of  p53 overexpression  and not in response to DNA damage 
(Banerjee et al., 2009; Nath et al., 2015; Wang et al., 2015). 
p53 mono-methylation at K382 by KMT5A can reduce p53 activation by reducing the 
acetylation of p53 at the same lysine residue. Down-regulation of KMT5A upon DNA 
damage, can reverse the mono-methylation process on K382 to result in increased p53 
stability by converting the mono-methylated p53-K382  into p53-K832me2/3 by histone 
methyltransferase (Shi et al., 2007; Williams et al., 2014).  
As a combination of what has been explained above, a model is suggested to be further 
investigated in this thesis. This model suggests that in the presence of KMT5A, KMT5A can 
mono-methylate p53 at K382 resulting in inhibition of its transcriptional activity, therefore 
diminishing its negative regulation of CDC20 and increasing CDC20 expression. However, 
when KMT5A is depleted as in silencing of KMT5A by siRNAs, the mono-methylation 
activity of KMT5A on p53-K382 will be reduced. This results in an increase in p53 activity to 
transcriptionally down-regulate CDC20 expression, or through binding to CDE-CHR element 
independently of p21 (Figure 4.15). 
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Figure 4-15 p53 regulates CDC20 expression in response to KMT5A mono-
methylation at K382: a proposed model. KMT5A can mono-methylate p53 at 
K382 resulting in inhibition of its transcriptional activity therefore reducing its 
negative regulation of CDC20. KMT5A depletion enables p53 activity resulting in 
transcriptional down-regulation of CDC20 expression directly by binding to its 
promoter or indirectly through binding to CDE-CHR independently of p21 
resulting in down-regulation of CDC20 expression.
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4.3.13. CDKN1A expression increases in response to KMT5A knockdown in LNCaP and 
LNCaP-AI cells 
In order to test the model of how KMT5A can regulate CDC20 through p53, the expression 
levels of CDKN1A were examined in the microarray data. A significant increase in CDKN1A 
expression was observed in the microarray data, particularly with siRNA#2 of ~3 fold in 
LNCaP-AI cells (p≤0.05) (Figure 4.16.A). A similar trend was seen overall in subsequent 
validation experiments for both LNCaP cells where an ~2 fold increase in expression with 
siRNA# 1 and in LNCaP-AI cells where an ~6 fold increase in expression  with siRNA# 2 
was observed (p≤0.05) (Figure 4.16.B-C).  
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Figure 4-16 KMT5A knockdown increases CDKN1A expression. LNCaP 
cells (C, F) and LNCaP-AI cells (A, B, D, E) were reverse transfected with N/S 
siRNA or the two selected KMT5A siRNAs for 72 hours. RNA was collected and 
knockdown of KMT5A and the effect on CDKN1A expression at mRNA level was 
determined by QRT-PCR. Error bars represent the mean ± SD for triplicate 
independent experiments. p-values were determined by t-test (* p-value <0.05, ** 
p-value <0.01, *** p-value <0.001 and **** p- value < 0.0001).
A 
B 
C 
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4.3.14.The expression of p53 and p21 in response to KMT5A depletion at the protein level 
The expression levels of p53 and p21 were then examined at the protein level using the same 
experimental conditions as Figure 4.14. KMT5A knockdown was performed using two 
selected siRNA in both LNCaP and LNCaP-AI cells grown in SDM for 72 hours. Protein was 
collected and KMT5A knockdown was confirmed by Western blotting. In LNCaP cells, there 
was a slight increase in p53 expression in response to KMT5A knockdown. However, p21 
showed a reproducible increase in expression with one of the siRNA sequences, while a 
reduced expression was observed with the second siRNA. This was consistent with the 
mRNA expression (Figure 4.17. A). In LNCaP-AI cells, p53 showed a small reduction in 
expression and this was associated with a substantial increase in p21 protein in response to 
KMT5A knockdown supporting the proposed model (Figure 4.17.B). 
 
 
 
Figure 4-17 KMT5A knockdown increases p21 protein expression. (A) 
LNCaP and (B) LNCaP-AI cells were reverse transfected with N/S siRNA or the 
two selected KMT5A siRNAs for 72 hours. Protein was collected and knockdown of 
KMT5A and the effect on p53 and p21 expression at protein level was determined 
by Western blotting (representative blot).
A B 
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4.3.15. The effect of KMT5A knockdown on MDM2 protein expression level in LNCaP and 
LNCaP-AI cells 
p53 protein levels are usually very low in the cells, and rapidly increase following DNA 
damage to promote cell cycle arrest to allow the DNA damage to be repaired. The function 
and  protein levels of p53 are tightly regulated by MDM2, as its binding results in reduced 
p53 activity and also reduced  protein levels through ubiquitin-mediated proteasomal 
degradation (Kubbutat et al., 1997). To rule out MDM2 involvement in p53 mediated 
regulation of CDC20, MDM2 expression levels were evaluated in response to KMT5A 
knockdown under identical experimental conditions as those used in Figure 4.17. A small 
reduction in MDM2 protein expression was observed in both cell lines. It has not been 
reported that KMT5A can affect MDM2 expression, which is consistent with these 
observations (Figure 4.18).  
Figure 4-18 KMT5A knockdown has a small effect on MDM2 protein 
expression. (A) LNCaP and (B) LNCaP-AI cells were reverse transfected with N/S 
siRNA or the two selected KMT5A siRNAs for 72 hours. Protein was collected and 
expression of KMT5A and the effect on MDM2, p53, and p21 protein expression 
was determined by Western blotting (representative blot).
A B 
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4.3.16. KMT5A knockdown affects phosphorylation of p53 at Serine 15 
p53 phosphorylation facilitates the binding of the  p53 co-activator acetyltransferase 
KAT3A/B which catalyses p53 acetylation at lysine residues (K373 and K382) to initiate 
transcription which further stabilizes p53 and promotes p53-DNA interaction (Scoumanne 
and Chen, 2008). Phosphorylation of p53 at S15/S20 promotes the recruitment of  these 
transcriptional coactivators through reducing the affinity of p53 for its primary negative 
regulator Hdm2 (Dai and Gu, 2010). 
As p53 is mono-methylated by KMT5A at K382, the effect of p53 phosphorylation at S15 
was tested in this experiment to examine the effect of KMT5A depletion on levels of 
phosphorylated p53. KMT5A was depleted in both cell lines for 72 hours in SDM. Protein 
was then collected and the knockdown was confirmed by Western blotting (Figure 4.19). 
Depletion of KMT5A in LNCaP-AI cells resulted in an increase in p53 phosphorylation at 
S15. However, the opposite effect was seen with LNCaP cells as both siRNAs resulted in a 
reduction in p53 phosphorylation at S15 (Figure 4.19). 
Figure 4-19 Effect of KMT5A knockdown on p53-S15-P expression in 
LNCaP and LNCaP-AI cells. (A) LNCaP and (B) LNCaP-AI cells were reverse 
transfected with N/S siRNA or the two selected KMT5A siRNAs for 72 hours. 
Protein was collected and knockdown of KMT5A and the effect on p53-S15-P 
expression was determined by Western blotting (representative blot). 
A B 
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4.3.17. Acetylation of p53 at K382 following KMT5A knockdown 
KMT5A has the ability to mono-methylate p53 at K382 which prevents the acetylation of p53 
at the same lysine residue to  prevent the activation process of p53 (Scoumanne and Chen, 
2008). To test if p53-K382 acetylation is affected by KMT5A depletion, the expression of p53 
–K382 acetylation in the presence and absence of KMT5A was investigated in LNCaP and 
LNCaP-AI cells growing in SDM. The data was inconsistent between the two cell lines. In the 
LNCaP cells, there was a reduction in p53–K382 acetylation with KMT5A knockdown. In the 
LNCaP-AI cells there was an increase in acetylation with only one of the siRNAs used in the 
experiment (Figure 4.20). This data was consistent with the expression levels of p53-S15-P 
(Figure 4.19), which has been mentioned to be considered as a preceding step to the 
acetylation of p53 at the same lysine residues K382 used by KMT5A for the methylation of 
p53. This data part supports the effect of KMT5A in the regulation of p53 in PC cells. 
 
 
 
Figure 4-20 Effect of KMT5A knockdown on the expression of p53-K382-
AC in LNCaP and LNCaP-AI cells. LNCaP and LNCaP-AI cells were reverse 
transfected with N/S siRNA or the two selected KMT5A siRNAs for 72 hours. 
Protein was collected and knockdown of KMT5A and the effect on p53-K382-AC 
expression was determined by Western blotting (representative blot).
A B 
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KMT5A knockdown was also performed in LNCaP cells grown in FM for 72 hours, to test if 
AR has any effect on KMT5A in the proposed model. The data showed a slight reduction in 
total p53 expression and a substantial reduction in p21 expression, which is consistent with 
their expression in response to KMT5A knockdown in LNCaP cells grown in SDM. This 
indicated independent function of KMT5A from AR in the proposed model (Figure 4.21). 
However, p53-S15-P and p53-K382-AC expression in LNCaP cells in FM were inconsistent. 
here was an increase in p53-S15-P and p53-K382-AC expression with the siRNA#2, while no 
changes were seen using  siRNA#1, which demonstrated lower efficiency in  depleting 
KMT5A compared to the siRNA#2 (Figure 4.21). The differences observed for the two 
KMT5A-depleting siRNAs might be due to the residual levels of KMT5A present in the cells, 
as near 100 % depletion of KMT5A protein was achieved with siRNA #2, whilst siRNA# 1 
was estimated to cause 80-90 % KMT5A depletion. It would appear that near total removal of 
KMT5A is required to induce both phosphorylation at S15 and acetylation at K382 of p53 
(Figure 4.21). The absence of KMT5A suggests its methylase activity directed against K382 
of p53 is important in regulating alternative post-translational modifications of p53.The 
generation of a commercial antibody targeted at p53 K382–me1 would greatly aid progress 
into mechanisms controlling p53 transcriptional activity.   
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Figure 4-21 Efficient KMT5A knockdown increase p53-S15-P and  p53-
K382-AC expression  in LNCaP cells grown in FM. LNCaP cells were reverse 
transfected in FM with N/S siRNA or the two selected KMT5A siRNAs for 72 hours. 
Protein was collected and knockdown of KMT5A and the effect on p53-S15-P and 
p53-K382-AC expression was determined by Western blotting (representative 
blot).
Chapter 4: KMT5A indirectly regulates CDC20 expression  
117 
4.3.18. The MDM2-p53 inhibitor, Nutlin3 (MDM2 inhibitor) affects the expression of p53, 
p21 and CDC20 proteins in LNCaP and LNCaP-AI cells 
To further confirm the role of p53 and p21 in the regulation of CDC20 expression in PC cells, 
an experiment was designed using Nutlin3, small molecule MDM2 antagonist that interacts 
with the p53 binding domain of MDM2, preventing negative regulation of p53 by MDM2, 
therefore allowing the persistence of p53-mediated signalling (Valentine et al., 2011) . Cells 
were grown in their own respective medium for 24 hours then Nutlin3 was applied for 0, 6 
and 16 hours. Protein lysates were collected and p53, p21 and CDC20 expression levels were 
assessed by Western blotting.   
An increase in p53 expression was observed alongside an increase in MDM2 expression 
confirming successful Nutlin3 treatment. As the levels of p53 increased an increase in p21 
expression was observed. This increase in p53 and p21 expression was accompanied by a 
decrease in CDC20 expression, confirming the role of p53 in CDC20 regulation in PC cells 
(Figure 4.22).
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Figure 4-22 CDC20 expression is reduced in response to Nutlin3 
treatment. (A) LNCaP and (B) LNCaP-AI cells were grown in their respective 
medium for 24 hours followed by treatment with 5 µM Nutlin3 for 0, 6 and 16 
hours. Protein was then collected and the expression levels of p53, p21, MDM2 and 
CDC20 were detected by Western blotting (representative blot). 
A B
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The same basic experiment was repeated but with additional time points to determine Nutlin3 
effects on CDC20 and CDKN1A mRNA expression. In LNCaP cells, there was a statistically 
significant ~62 fold increase in CDKN1A expression ( p≤0.05) at 16 hours of Nutlin3 treatment, 
which was expected as p53 transcriptional activity should be increased with the inhibition of 
MDM2 (Figure 4.23.A). A statistically significant increase of ~3 fold in CDC20 expression 
(p≤0.05) was apparent at 3 hours of Nutlin3 treatment which was followed by a steady reduction 
in CDC20 over the remaining time course of the experiment (Figure 4.23.B) which was 
consistent with what was observed at the protein level (Figure 4.22). In LNCaP-AI cells, 
CDKN1A expression increased gradually to reach ~21 fold at 16 hours of Nutlin3 treatment 
(Figure 4.23.C), while CDC20 expression decreased by ~2 fold by 3 hours and continued to 
decrease to ~5 fold at 16 hours, which was consistent with previous reports (Kidokoro et al., 
2008), and with the model under investigation (Figure 4.23.D).
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Figure 4-23 Effects of Nutlin3 treatment on CDKN1A and CDC20 mRNA 
expression in LNCaP and LNCaP-AI cells. LNCaP cells (A) CDKN1A 
expression (B) CDC20 expression and LNCaP-AI cells (C) CDKN1A expression (D) 
CDC20 expression, were grown in their respective medium for 24 hours  followed 
by treatment with 5 µM Nutlin3 for 0, 3, 6 and 16 hours.  RNA was then collected 
and the expression of CDKN1A and CDC20 was determined by QRT-PCR. Error 
bars represents the mean ± SD for triplicate independent experiments. p-values 
were determined by t-test (* p-value <0.05, ** p-value <0.01, *** p-value <0.001 
and **** p- value < 0.0001).  
A
B
C
D
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4.3.19. p53 regulates FOXM1 expression in response to KMT5A mono-methylation at K382: 
a proposed model  
FOXM1 expression is reduced by KMT5A depletion both at the protein and mRNA levels 
(Figure 4.10), but was found to have no effect on CDC20 expression in the tested PC cells in 
this study (Figure 4.13).  However, FOXM1 was previously reported to be down-regulated by 
p53 particularly after DNA damage both at the mRNA and the protein levels (Barsotti and 
Prives, 2009). In turn, to further investigate how KMT5A can regulate FOXM1 in PC cells, a 
model was suggested to be tested in PC cell lines that included p53. Specifically, it was 
questioned, can the impact of KMT5A knockdown on p53 transcriptional activity affect 
FOXM1 levels and downstream target genes both at the protein and mRNA levels (Figure 
4.24). 
Figure 4-24 p53 regulates FOXM1 expression in response to KMT5A mono-
methylation at K382: a proposed model.  KMT5A can mono-methylate p53 at 
K382 resulting in inhibition of its transcriptional activity therefore reducing its 
negative regulation on FOXM1. KMT5A depletion enables p53 to remain active 
and retain transcriptional downregulation of FOXM1 expression. 
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4.3.20. FOXM1 expression level are altered in response to Nutlin3 treatment in LNCaP and 
LNCaP-AI cells. 
To start to investigate the proposed model (Figure 4. 24), the regulatory effect of p53 on 
FOXM1 expression was first investigated using samples that were generated in Figure 4.20, 
where  MDM2 inhibitor, Nutlin3, was used to inhibit MDM2 expression to stimulate p53 
activation in LNCaP and LNCaP cells. Protein was collected and p53, p21and FOXM1 
expression were detected by Western blotting.   
The data was consistent with the model being proposed and FOXM1 protein expression was 
robustly reduced with Nutlin3 treatment (Figure 4.25). This could also explain the effect that 
KMT5A might have on FOXM1 through the mono-methylation of p53 at K382 and 
subsequently prevent acetylation at the same lysine site which would reduce p53 activity on 
its downstream targets including FOXM1.
Figure 4-25 FOXM1 protein expression is reduced in response to Nutlin3 
treatment in LNCaP and LNCaP-AI cells. Cells were grown in their respective 
medium for 24 hours followed by treatment with 5 µM Nutlin3 for 0, 6 and 16 
hours. Protein was then collected and the expression levels of p53, FOXM1 and α-
Tubulin was detected by western blotting (representative blot).
A B 
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The same experimental conditions were repeated to check FOXM1 expression at the mRNA 
level in response to Nutlin3 treatment at 0, 3, 6, and 16 hours in LNCaP and LNCaP-AI cells. 
FOXM1 mRNA was found to be reduced in response to Nutlin3 treatment as a result of p53 
activation. Specifically, in LNCaP cells a 2 fold reduction in FOXM1 was observed after 3 
hours of treatment and continued a gradual decrease to ~6 fold (Figure 4.26) at 6 and 16 hours 
of treatment. In LNCaP-AI cells there was a similar ~2 fold reduction in FOXM1 expression 
after 3 hours of treatment which continued to decrease to ~5 fold reduction in FOXM1 at 16 
hours (Figure 4.26).  
Figure 4-26 FOXM1 mRNA expression is reduced in response to Nutlin3 
treatment in LNCaP and LNCaP-AI cells. Cells were grown in their respective 
medium for 24 hours followed by treatment with 5 µM Nutlin3 for 0, 3, 6 and 16 
hours RNA was then collected and the expression of FOXM1 was determined by 
QRT-PCR. Error bars represent the mean ± SD for triplicate independent 
experiments. p-values were determined by t-test (* p-value <0.05, ** p-value <0.01 
and *** p-value <0.001). 
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4.4. Discussion  
Accumulating evidence has shown the important roles that KMT5A plays in regulating 
critical cellular  functions, including cell cycle progression, DNA damage repair gene 
transcription, chromosome condensation and tumourigenesis (Schotta et al., 2008; Oda et al., 
2010). 
 In this study, KMT5A was found to regulate CDC20 expression at both the mRNA and 
protein levels (Figure 3.11 and Figure 4.3). Based on these observations, CDC20 was 
investigated in this chapter as a possible biomarker for KMT5A to determine the activity of 
KMT5A in aggressive PC. Interestingly, KMT5A was found to interact with CDC20 both 
endogenously and exogenously (Figure 4.9). It has been reported that KMT5A can exert its 
functional effect such as involvement in cell cycle progression and DNA damage repair 
through interaction with a number of factors, such as TWIST, RNA polymerase II and ERα. 
KMT5A through the mono-methylation activity can affect TWIST target genes promoters. 
The mono-methylation activity of KMT5A also regulates both H4K16Ac and H4K20me3 
marks, and in turn regulates RNA polymerase II pausing dynamics, and it was found to be 
essential to facilitate the recruitment of the MSL complex subsequent to H4K16Ac to release 
RNA polymerase II for active elongation. H4K20me1 activity was also reported to be  
required for ERα regulated transcription (Kapoor-Vazirani and Vertino, 2014) (Li et al., 
2011a; Wang et al., 2015). Additionally, KMT5A can also bind to PCNA through the PIP 
domains to be recruited at the DNA replication foci (Beck, 2012). 
Hence, there is potential that KMT5A may be able to affect the function of CDC20 in a 
similar way through the mono-methylation of H4K20 at the CDC20 promoter to regulate its 
transcription. The enrichment of H4K20me1 at the CDC20 promoter was investigated herein, 
and the data showed a variation in the enrichment of H4K20me1 at the CDC20 promoter 
between the LNCaP and LNCaP-AI cell lines tested, as it was reduced in LNCaP cells in 
response to DHT treatment.  However, in LNCaP-AI cells, DHT treatment clearly enhanced 
H4K20me1 enrichment at the CDC20 promoter which peaked at ~5 fold after 30 minutes 
stimulation (Figure 4.10). Further experiments would be recommended to support the role of 
KMT5A activity in regulating CDC20 expression by knockdown of KMT5A and looking at 
H4K20me1 enrichment at the CDC20 promoter in LNCaP and LNCaP-AI cells. However, the 
required KMT5A antibody is unavailable commercially.  
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KMT5A is known to be targeted for degradation by APCcdh1 during the transition from 
metaphase to anaphase (Wu and Rice, 2011). In addition, APCCDC20 can target KMT5A for 
degradation. The possibility of CDC20 regulating KMT5A by targeting it for degradation as a 
part of the APCCDC20   complex was initially investigated in this study. However, knockdown 
of CDC20 by two selected siRNA sequences did not affect KMT5A protein levels (Figure 
4.5). Further experiments such as immunoprecipitation are required to see if KMT5A and 
CDC20 interact as part of the APC complex or whether they can interact independent of this. 
The effect of KMT5A and CDC20 on the cell cycle profile was also determined in this thesis, 
as both KMT5A and CDC20 are known cell cycle regulators. The data was partly inconsistent 
with previous reports about KMT5A and CDC20 depletion.  It was found that KMT5A 
depletion causes a significant reduction by ~50 % in G2/M phase in LNCaP-AI cells. 
However, no significant change was noticed in the LNCaP cell cycle profile (Figure 4.4). 
Furthermore, the effect of CDC20 knockdown on cell cycle profile was also inconsistent 
between LNCaP and LNCaP-AI cells. Whilst, there was a significant increase by ~90 % in the 
G2/M phase in LNCaP cells, while no significant changes was observed in the LNCaP-AI cell 
cycle profile (Figure 4.6). These inconsistencies may be due to inefficient knockdown of 
KMT5A levels or differences in susceptibility to the absence of KMT5A between LNCaP and 
LNCaP-AI cells. It would be important to repeat this experiment with a shorter KMT5A 
depletion period as KMT5A knockdown may require less than 72 hours to exert an impact on 
the cell cycle profile. Therefore, cells might have already started to recover at the time 
samples were collected for staining following 72 hours of KMT5A knockdown. Moreover, it 
is also important to include longer durations of KMT5A knockdown  as cells may require 
prolonged KMT5A depletion to cause cell cycle changes as previously reported for some cell 
cycle enzymes (Abbas et al., 2010a). To address the possibility that KMT5A and CDC20 
depletion might require a prolonged knockdown period to exert their phenotypic effects, the 
proliferation of LNCaP and LNCaP-AI cells was determined in the presence and absence of 
KMT5A and CDC20 over a 72 hours period of KMT5A and CDC20 knockdown followed by 
96 hours of incubation at 37 °C in 96 well plates. Depletion of either KMT5A or CDC20 
significantly reduced the proliferation by ~50 % and ~75 % in the  LNCaP and LNCaP-AI 
cells, respectively (Figure 4.7), consistent with previously published data about the effect of 
KMT5A and CDC20 depletion on cellular proliferation (Huang et al., 2009; Oda et al., 2009). 
To understand the relationship and the role of KMT5A in the regulation of CDC20 
expression, FOXM1 was tested as a well-known CDC20 transcriptional regulator (Xie et al., 
2015). The data from this study showed that with KMT5A knockdown, FOXM1 expression 
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was robustly reduced at the protein level and significantly at the mRNA level (p≤0.05) 
(Figure 4.11). Despite this, CDC20 expression level in this study was found not to be 
regulated by FOXM1 expression level neither at the protein, nor at the mRNA level, as 
depletion of FOXM1 by siRNAs had no significant effect on CDC20 expression both 
transcriptionally and post-translationally (Figure 4.14), which contradicts what has been 
reported previously (Xie et al., 2015). This might be due to some difference in the 
experimental conditions or due to effect of the tested cell line. The data also showed that 
stimulation of AR expression with DHT can stimulate FOXM1 expression in LNCaP cells, 
but not LNCaP-AI cells which was further confirmed by the DHT time course experiment that 
showed an increase in FOXM1 expression with treatment time in LNCaP, but not LNCaP-AI 
cells (Figure 4.13). This data contradict with the previously reported data which presented  
FOXM1 as an AR transcriptional regulator (Liu et al., 2014).  
Previous studies also reported a number of factors whose expression can be regulated by 
KMT5A presence and activity such as Numb and p53, by the methylation of Numb in the 
PTB domain, which would lead to the inhibition of p53 dependent apoptosis, or by direct 
methylation of p53 at K382 (Shi et al., 2007; Dhami et al., 2013; Jørgensen et al., 2013).  
CDC20 has been previously reported to be negatively regulated by p53 (Kidokoro et al., 
2008; Banerjee et al., 2009), either by binding directly to the CDC20 promoter and inhibiting 
its transcription, or indirectly through binding at the CDE-CHR element and regulating its 
transcription independently of p21. KMT5A is also  known to mono-methylate p53 at lysine 
382 (Shi et al., 2007) which  results in inhibition of the p53 transcriptional activity. This study 
suggested a model for CDC20 being transcriptionally regulated by KMT5A indirectly through 
KMT5A mono-methylation activity at p53-K382. This model suggested that with KMT5A 
depletion, p53 would fail to be efficiently mono-methylated making the K382 residue 
available for acetylation and activation. This should increase p21 and in turn reduce CDC20 
expression. A significant increase in p21 expression at the mRNA level was seen in LNCaP 
and LNCaP-AI cells, which was also mirrored at the protein level, most notably in LNCaP-AI 
cells (Figure 4.16,17). Further experiments would be required to look at the enrichment of 
p53 and p21 at the CDC20 promoter in PC cells. 
To confirm the effect of p53 on CDC20 in PC cells, treatment with Nutlin3 (an MDM2 
inhibitor) which can inhibit the MDM2-p53 interaction was conducted. Nutlin3 is also 
demonstrated to inhibit MDM2 dependent transcription of p53 (Barsotti and Prives, 2009). 
The data showed a significant (p≤0.05) increase in p53 and p21, whilst a decrease in CDC20 
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mRNA and protein expression was observed, which was expected as being directly regulated 
by p53 (Figure 4.22). The data was consistent with the previously reported data about the 
regulation of CDC20 by p53 (Banerjee et al., 2009). Further investigation to look at p53-
K382 -me1 expression levels in the presence and absence of KMT5A is required to further 
support the suggested possible pathway.  
p53 was also suggested as a negative regulator of FOXM1 expression (Barsotti and Prives, 
2009) in a p21 and Rb dependent fashion or in some cases in an independent manner. To test 
the possible effect of p53-K382-me1 catalysed by KMT5A, on FOXM1 expression in PC 
cells, a model was suggested. In this model, with KMT5A depletion, p53 will be released 
from the mono-methylation effect and possibly facilitate K382 acetylation and subsequent 
p53 activation, which enables its transcriptional activity on its substrates, including the 
negative regulation of FOXM1 and in turn its substrates (Figure 4.24). Two FOXM1 
substrates were selected to test this model (Cyclin B and PLK1). KMT5A knockdown was 
found to reduce FOXM1 and its two targets substrates expression both at the mRNA and 
protein level. Also, treatment of LNCaP and LNCaP-AI cells with 5 µM Nutlin3 resulted in a 
significant reduction in FOXM1 expression both at the protein and mRNA level (Figure 4.25, 
Figure 4.26). This highlights that p53 does regulate FOXM1 expression in PC cells and that 
the tested model remains viable. Further experiments looking at the effect of KMT5A 
depletion on the expression of p53-K382-me1 at the protein level is essential to correlate 
FOXM1 expression changes to KMT5A through p53-K382-me1. 
The relationship between p53 and KMT5A was previously reported and also the relationship 
between p53 and CDC20. This study has managed to correlate these two relationships through 
looking at KMT5A as the driver of p53 effect on CDC20 through mono-methylation of p53- 
K382 and through that on CDC20. The suggestion of CDC20 as a biomarker for KMT5A 
expression in PC would require further experimentation, particularly to confirm that KMT5A 
does regulate CDC20 directly at the promoter level. However, the regulation of CDC20 by 
p53 would impact the possibility of considering CDC20 as a biomarker for KMT5A, as any 
defect in p53 would affect CDC20 expression even independently of KMT5A. To cover this 
possibility, an experiment using mutated versus wild type p53 cells or p53 null cell lines to 
look at the effect of KMT5A depletion on CDC20 expression would help to either confirm or 
refute the possibility of having CDC20 as a biomarker for KMT5A. 
The effect of KMT5A depletion using siRNAs on CDC20, FOXM1, PLK1 will be 
investigated further using KMT5A inhibitors in chapter 5.
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Chapter 5 . The effect of KMT5A inhibitors UNC0379 and Ryuvidine on 
KMT5A activity in PC cells 
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5.1. Introduction  
To compare the data obtained by depleting KMT5A using siRNA sequences, KMT5A 
inhibitors were used to study their effect on the same tested factors on the previous chapters. 
Methyltransferases, such as KMT5A, play important roles in many different cellular processes 
such as proliferation, DNA damage repair, chromatin condensation, cell cycle progression, 
cancer development and progression, highlighting their importance as potential therapeutic 
targets (Hui and Ye, 2015). Indeed, inhibition of their enzymatic activity with small molecule 
inhibitors is an area of research for many groups. Developing KMT5A inhibitors with cellular 
activity is a key step toward illuminating the diverse roles of KMT5A via convenient 
pharmacological perturbation. 
The first selective KMT5A inhibitor (Marine natural product, nahuoic acid A) was selected as 
the most effective against KMT5A from a library of marine organisms extract and pure 
marine natural products. As mentioned in Chapter 1, KMT5A catalyzes the methylation of 
histone and non-histone proteins by binding the sulfonium methyl group of the cofactor S-
adenosyl-methionine (SAM) on various histone and non-histone protein targets (Kouzarides, 
2007). Nahuoic acid is a competitive inhibitor of SAM binding but a non-competitive 
inhibitor with respect to the binding of the peptide substrate. Nahuoic acid A inhibited 
KMT5A activity with an IC50 value of 6.5 ± 0.5 μM (Williams et al., 2012) (Figure 5.1.A). 
The first synthetic inhibitor of KMT5A was UNC0379, which has been shown to be active in 
multiple biochemical assays. Different biophysical assays have been used to confirm its 
specificity and affinity for KMT5A, including isothermal titration calorimetry (ITC), surface 
plasmon resonance (SPR) studies, and biochemical assays such as microfluidic capillary 
electrophoresis and radioactive methyl transfer. UNC0379 inhibited KMT5A activity with an 
IC50 value of 7.3 ± 1.0 μM in a radioactive biochemical assay.  However, the effect of this 
inhibitor has not been tested as yet for cell lines  (Ma et al., 2014a) (Figure 5.1.B).  
Three other inhibitors SPS8I 1, 2 and 3 also known as NSC663284, Ryuvidine and BVT948 
respectively, were identified with a radioactivity-based scintillation proximity imaging assay 
(SPA) in a high throughput screening (HTS) format aimed to identify novel KMT5A 
inhibitors (Blum et al., 2014). SPS8I1 and 3 were selected from the screen as substrate 
dependent inhibitors, while SPS8I2 is a substrate independent inhibitor of KMT5A.  These 
three compounds are structurally able to inhibit KMT5A through specific structural motifs 
and modes of action. They are also able to target KMT5A enzymatic activity as demonstrated 
by H4K20me1 level reduction and having the ability to cause S phase cellular arrest, similar 
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to the effect obtained by KMT5A depletion using siRNAs (Blum et al., 2014). Ryuvidine 
(SPS8I2) inhibited KMT5A activity with an IC50 value of 0.5 ± 0.2 μM  which is much more 
potent than nahouic acid and UNC0379 (Figure 5.1.C). 
The aim of this chapter is to test two of these KMT5A inhibitors UNC0379 and Ryuvidine, 
for their effect on KMT5A activity and the downstream effects on AR, CDC20, p53 and 
FOXM1. Phenotypic effects will also be compared to those observed in Chapter 3, 4 where 
siRNA against KMT5A was utilized. 
                                                    
 
 
 
Figure 5-1 Chemical structure of KMT5A inhibitors. (A) Nahuoic acid A 
(Marine natural product) (B) UNC0379 (synthetic inhibitor) measured by a 
radioactive biochemical assay and (C) Ryuvidine in HEK293T cells (Hui and Ye, 
2015). 
 
A B C 
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5.2. Specific materials and methods 
5.2.1. Cell lines  
LNCaP and LNCaP-AI cells were used in this study as detailed in Chapter 2.1.1.
5.2.2. Antibodies  
A number of primary antibodies were used to detect protein expression by Western blotting 
(Table 5.1). 
Table 5-1 Western blot antibodies. 
 
 
 
 
Antibody Species Catalogue number  
 
KMT5A Rabbit  Cell Signalling (2996) 
CDC20 Mouse Abcam (1b190711) 
FOXM1 Mouse Santa Cruz (Sc-502) 
PLK1 Mouse Santa Cruz (Sc-55504) 
α-Tubulin Mouse  Sigma  
H4K20me1  Rabbit Millipore (07-1570) 
H4 Rabbit  Millipore (07-108) 
HRP-conjugated  
Rabbit anti-mouse 
Mouse  DakoCytomation 
(P0260) 
HRP- conjugated  
Swine anti-Rabbit 
Rabbit  
 
DakoCytomation  
(P0217) 
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5.2.3. QRT-PCR primers 
To detect the expression of individual genes at the mRNA level, specific primer sets were 
used (Table 5.2). 
Table 5-2 QRT-PCR primers. 
 
 
 
 
 
 
 
 
Genes  
 
Forward Primer (5’-3’)  Reverse Primer (5’-3’)  
KLK3 TCGGCACAGCCTGTTTCAT TGGCTGACCTGAAATACCTGG  
KLK2 AGCATCGAACCAGAGGAGTTCT        TGGAGGCTCACACACTGAAGA 
HPRT1 TTGCTTTCCTTGGTCAGGCA 
  
AGCTTGCGACCTTGACCATCT 
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5.2.4. KMT5A inhibitors  
Two KMT5A inhibitors were used to test their effect on KMT5A activity in PC cells (Table 
5.3). Chemical structure of the inhibitors are shown in Figure 5.1.B- C. 
 
Table 5-3 KMT5A inhibitors 
.  
 
 
 
 
5.2.5. Determination of GI50 for UNC0379 and Ryuvidine 
 
LNCaP and LNCaP-AI cells were grown in their respective medium in 96 well plates (3000 
cells/well for LNCaP and 3500 cells/well for LNCaP-AI cells) for 24 hours at 37 °C. 
UNC0379 was then added to the wells (6 wells/ concentration) in the following 
concentrations: 0, 0.25, 0.5, 1, 2, 4, 6.25, 12.5, 25 and 50 µM.  Ryuvidine was added to the 
wells (6 wells/ concentration) in the following concentrations: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 
and 5 µM. Cells were left to grow for 7 days at 37 °C. Cells growth was determined using 
SRB assays in the last day of the experiment as described in Chapter 2.2.1.4. 
Absorbance was measured at 570 nm using a 96-well plate reader (BioRad). Three repeats of 
the experiment were done for each cell line. Data were plotted using Graph Pad prism 6.0 and 
GI50 values were determined using the point-to-point curve fit analysis package (Figure 5.2 
and Figure 5.3).
Inhibitor            Manufacture 
UNC0379 Selleckchem(S7570) 
SPS8I2 (Ryuvidine)  
 
R&D (2609) 
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Figure 5-2 Growth inhibition in LNCaP and LNCaP-AI cells using 
UNC0379.  Cells were seeded out in 96 well plates for 24 hours followed by 
treatment with a serial dilution of UNC0379. Cell growth over 7 days was 
measured using SRB assay in the last day of the experiment. Error bars represent 
the mean ± SD for triplicate independent experiments. Absorbance was measured 
at 570nm using a 96-well plate reader (BioRad). 
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Figure 5-3 Growth inhibition in LNCaP and LNCaP-AI cells using 
Ryuvidine. Cells were seeded out in 96 well plates for 24 hours and followed by 
treatment with a serial dilution of Ryuvidine. Cell growth over 7 days was 
measured using SRB assay. Error bars represent the mean ± SD for triplicate 
independent experiments. Absorbance was measured at 570nm using a 96-well 
plate reader (BioRad). 
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5.3. Results  
5.3.1. Effect of UNC0379 on KMT5A activity 
Whilst UNC0379 has been shown to inhibit KMT5A methylase activity (Ma et al., 2014a), it 
has not been tested for PC cells. Furthermore, the effect of UNC0379 on the levels of 
KMT5A is unknown in these systems. Hence, the effect of increasing doses of UNC0379 on 
KMT5A expression was assessed prior to determining any effect on the enzymatic activity of 
KMT5A. No robust changes in KMT5A expression were observed in LNCaP and LNCaP-AI 
cells when compared to α-tubulin loading control (Figure 5.4.A- B). There was a robust 
reduction observed in the expression of H4K20me1 in both cell lines in response to the 
treatment with UNC0379 (Figure 5.4.C). However, similar to tubulin levels, the level of total 
histone H4 was also found to decrease in these cell lines at higher doses. At lower doses, the 
levels of H4 are relatively constant, while a clear reduction in H4K20me1 levels can be seen. 
Therefore, the data supported the inhibitory effect of UNC0379 on the enzymatic activity of 
KMT5A in PC cells. 
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Figure 5-4 UNC0379 inhibits KMT5A methylase activity in PC cells. LNCaP 
and LNCaP-AI cells were seeded out at appropriate densities and allowed to 
adhere for 24 hours. UNC0379 was then applied at (0, 2, 4, 6, 7, 8 µM) for a further 
48 hours. Protein lysates were collected and the levels of KMT5A in (A) LNCaP 
and (B) LNCaP-AI cells and (C) H4K20me1 in both cell lines were determined by 
Western blotting. Alpha-tubulin and total Histone H4 were used as loading 
controls, respectively (representative blot).
A B 
C 
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5.3.2.The effect of UNC0379 on AR target genes expression in LNCaP and LNCaP-AI cells 
KMT5A has been found to act as an AR suppressor in LNCaP cells and an AR activator in 
LNCaP-AI cells. Specifically, knockdown of KMT5A in LNCaP-AI cells was found to inhibit 
AR binding to the PSA enhancer, thereby affecting AR function (Coffey et al, unpublished 
data). Furthermore, data shown in Figure 5.4, demonstrates that the activity of KMT5A was 
robustly affected by UNC0379 in both PC cell lines. Hence, inhibition of KMT5A activity 
with UNC0379 may affect AR target genes expression in LNCaP and LNCaP-AI cells.  
To test this theory, LNCaP and LNCaP-AI cells were treated with UNC0379 using a single 
concentration for each cell line compared to a vehicle control. In both cases, the GI50 value (7 
µM LNCaP and 4 µM LNCaP-AI) in their respective medium for 48 hours at 37 °C was 
applied. RNA was subsequently isolated and AR target gene expression (KLK3 and KLK2) 
was assessed by QRT-PCR using primers detailed in Table 5.2. Surprisingly, no significant 
changes in KLK3 and KLK2 expression were detected in LNCaP cells (Figure 5.5.A- B) or in 
LNCaP-AI cells (Figure 5.5.C- D). The data indicated that despite affecting the activity of 
KMT5A, UNC0379 had no effect on AR target gene expression in both PC cell lines.
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Figure 5-5 UNC0379 does not affect AR target gene expression in PC cell 
lines. LNCaP cells (A) KLK3 and (B) KLK2 and LNCaP-AI cells (C) KLK3 and (D) 
KLK2. Cells were seeded out for 24 hours and then treated with UNC0379 for 48 
hr. RNA was collected, then KLK3 and KLK2 expression levels were detected by 
QRT-PCR. Error bars represent the mean ± SD for triplicate independent 
experiments. p-values were determined by t-test (* p-value <0.05). 
A 
B 
C 
D 
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5.3.3. UNC0379 has no effect on cell cycle distribution in LNCaP and LNCaP-AI cells 
Silencing of KMT5A using siRNA has been reported to cause cellular arrest at G2/M phase  
of the cell cycle (Lee and Zhou, 2010). The effect of UNC0379 on cell cycle distribution has 
not been previously investigated although it may be predicted to result in similar effects to 
KMT5A knockdown. To test this theory in LNCaP and LNCaP-AI cells,  cells were treated 
with the GI50 doses of UNC0379 (7µM LNCaP and 4 µM LNCaP-AI) for 48 hours at 37 °C, 
followed by cell cycle profile determination  using flow cytometry protocol detailed in 
Chapter 2.2.4. Surprisingly, in both LNCaP (Figure 5.6.Ai) and LNCaP-AI cells (Figure 
5.6.Bi), no significant changes in cell cycle profile were detected.  
To further investigate the cell cycle distribution upon treatment with UNC0379, Western 
blotting was carried out against cyclin B, a G2/M phase marker, in response to UNC0379 
treatment in LNCaP and LNCaP-AI cells. Increasing doses of UNC0379 (0, 2, 6, 7 and 8 µM) 
was added to each cell line for 48 hours at 37 °C. Significant changes were detected in cyclin 
B levels at the protein level was noticed by measuring with densitometry in LNCaP cells 
(Figure 5.6.Aii, iii) and  LNCaP-AI cells (Figure 5.6. Bii, iii). The overall data suggested that 
UNC0379 appears to have an effect on cell cycle distribution in LNCaP and LNCaP-AI cells 
confirmed by looking at cyclin B expression in response to UNC0379 treatment (Figure 5.6).  
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Figure 5-6 UNC0379 has no impact on cell cycle distribution in PC cells. 
LNCaP (A) and LNCaP-AI cells (B) cells were treated with increasing doses of 
UNC0379 (0, 2, 4, 6, 7 and 8 µM) for 48 hours in 6 well plates. Cell cycle analysis 
was performed using propidium iodide to stain cellular DNA for 40 minutes.  
Protein was also collected from samples treated with increasing doses of UNC0379 
(0, 2, 6, 7 and 8 µM) and cyclin B expression was detected by Western blotting (ii).  
and measured by densitometry using Epson scanner and labWork 4.0 software(iii), 
p-values were determined by t-test (* p-value <0.05, ** p-value <0.01, *** p-value 
<0.001 and **** p- value < 0.0001).  
 
B(i) 
(ii) (ii) 
A(i) 
(iii) (iii) 
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5.3.4. The effect of UNC0379 on FOXM1, PLK1 and CDC20 expression in LNCaP and 
LNCaP-AI cells 
In Chapter 4, KMT5A was shown to have an effect on the expression level of CDC20, 
FOXM1, and PLK1. Depletion of KMT5A by siRNAs for 72 hours, resulted in a robust 
reduction in their expression at the protein level and statistically significant reduction at the 
mRNA level (p≤0.05). In both LNCaP and LNCaP-AI cells, an ~3-4 fold reduction in CDC20 
expression was observed (Figure 3.11). Similarly an ~2, and 3-4 fold reduction in FOXM1 
expression was observed in LNCaP and LNCaP-AI cells, respectively (Figure 4.9). PLK1 
expression was also confirmed to be reduced by ~3-4 fold in LNCaP-AI cells as detected by 
the microarray data (Figure 4.10).  
UNC0379 effects on CDC20, FOXM1 and PLK1 was tested to compare it with the effect 
obtained by KMT5A depletion using siRNAs. LNCaP and LNCaP-AI cells were treated with 
UNC0379 (7 µM LNCaP and 4 µM LNCaP-AI) for 48 hours at 37 °C. Protein was collected, 
and the expression levels of CDC20, FOXM1and PLK1 was measured by Western blotting 
(Figure 5.7). In LNCaP cells, the effect of UNC0379 remained unclear due to problems with 
protein loading caused by the effect of the drug on cell proliferation (Figure 5.7.A). However, 
in LNCaP-AI cells, there was a clear reduction in FOXM1, PLK1 and CDC20 expression 
upon UNC0379 treatment compared to the DMSO control (Figure 5.7.B). The data obtained 
from this experiment for LNCaP-AI cells was consistent with that obtained by depleting 
KMT5A using siRNAs in Chapter 4, which would support the role of KMT5A in regulating 
CDC20 expression in LNCaP-AI cells.   
Chaper5: The effect of KMT5A inhibitors on its activity 
 
 
143 
 
 
 
 
 
 
 
 
 
Figure 5-7 UNC0379 inhibits FOXM1, PLK1 and CDC20 expression in 
LNCaP-AI cells. (A) LNCaP and (B) LNCaP-AI cells. Cells were seeded out at 
appropriate densities and allowed to adhere for 24 hours. UNC0379 was then 
applied at 7 µM in LNCaP and 4 µM in LNCaP-AI cells for 48 hours. Protein 
lysates were then collected and the levels of FOXM1, CDC20 and PLK1 were 
determined by Western blotting. Alpha-tubulin was used as a loading control 
(representative blot).
A B 
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5.3.5. Effect of Ryuvidine on KMT5A activity 
Due to the non-specific effects on KMT5A that UNC0379 might have (Ma et al., 2014a), 
another  KMT5A inhibitor  was selected for inclusion in this study. According to (Blum et al., 
2014), Ryuvidine can target KMT5A enzymatic activity demonstrated by a reduction in 
H4K20me1 levels in HEK293T cells. To test if this also applied to PC cells, the effect of 
increasing doses of Ryuvidine ( 0, 1, 1.5, 2, 2.5 and 3 µM) on KMT5A expression was tested 
in LNCaP cells (Figure 5.8.A) and LNCaP-AI cells (Figure 5.8.B) followed by looking at its 
effect on H4K20me1 levels in both cell lines (Figure 5.8.C). 
 There were no noticed changes either in KMT5A or in H4K20me1 expression in LNCaP-AI 
cells. A slight reduction in KMT5A and H4K20me1 expression in LNCaP cells was detected 
when α-tubulin and H4 control levels were taken into account (Figure 5.8). However,  the 
level of total histone H4 was found to be reduced in these cell lines with increasing dose of 
Ryuvidine, which was consistent with what was reported on Ryuvidine effect on the cell cycle 
progression at higher doses (Blum et al., 2014). The data indicated that Ryuvidine might 
affect KMT5A activity in LNCaP cells, but not in LNCaP-AI cells. While UNC0379 showed 
a robust reduction in H4K20me1 levels in both cell lines (Figure 5.4).
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Figure 5-8 Ryuvidine inhibits KMT5A methylase activity in LNCaP cells. 
LNCaP and LNCaP-AI cells were seeded out at appropriate densities and allowed 
to adhere for 24 hours. Ryuvidine was then applied at (0, 1, 1.5, 2, 2.5 and 3 µM) 
for a further 48 hours. Protein lysates were then collected and the levels of KMT5A 
at (A) LNCaP and (B) LNCaP-AI cells and (C) H4K20me1 level in both cell lines 
were determined by Western blotting. Alpha-tubulin and total Histone H4 were 
used as loading controls (representative blot).
A B
C
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5.3.6. The effect of Ryuvidine on AR target genes expression 
The effect of the first studied KMT5A inhibitor, UNC0379, on AR target gene expression, 
was determined (Figure 5.5). No significant changes were observed. To determine the effect 
of Ryuvidine on AR target gene expression, Ryuvidine GI50 values that were established for 
each cell line (0.77 µM for LNCaP cells and 2.76 µM for LNCaP-AI cells) were applied for 
48 hours at 37 °C. RNA was collected and the expression level of AR target genes (KLK3 and 
KLK2) was determined by QRT-PCR using primers detailed in Table 5.2. KLK3 and KLK2 
expression was found to be significantly reduced by ~2 fold in response to Ryuvidine 
treatment compared to untreated control in LNCaP cells (p≤0.05) (Figure 5.9.A-B). The 
results also showed the same trend for the LNCaP-AI cell line where a  significant reduction 
by ~2 fold in both KLK3 and KLK2  mRNA expression compared to untreated control in 
LNCaP-AI cells was also noted (p≤0.05) (Figure 5.9.C-D). 
From the data above, Ryuvidine does significantly reduce the expression of AR target gene in 
both LNCaP and LNCaP-AI cells (p≤0.05). However, Ryuvidine had no effect on KMT5A 
levels or H4K20me1 levels in LNCaP-AI cells, so any effects on AR-regulated genes may be 
the result of Ryuvidine having off target effects in this cell line rather than solely inhibiting 
KMT5A.
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Figure 5-9 Ryuvidine reduces AR target gene expression in PC cell lines. 
LNCaP cells (A) KLK3 and (B) KLK2 and LNCaP-AI cells (C) KLK3 and (D) KLK2. 
Cells were seeded out for 24 hours and then treated with the Ryuvidine as 
indicated for 48 hours. RNA was collected and KLK3 and KLK2 expression levels 
were assessed by QRT-PCR. Error bars represent the mean ± SD for triplicate 
independent experiments. p-values were determined by t-test (* p-value <0.05, ** 
p-value 0.01, *** p-value <0.001 and **** p- value < 0.0001).  
 
 
A  C 
B  D 
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5.3.7. The effect of Ryuvidine on cell cycle profile in LNCaP and LNCaP-AI cells 
KMT5A depletion has been reported to cause cellular arrest at G2/M of the cell cycle (Rice et 
al., 2002; Lee and Zhou, 2010). Similarly, Ryuvidine treatment also causes a S-phase arrest in 
HEK293T cells (Blum et al., 2014). To determine whether the same effects are seen in 
LNCaP and LNCaP-AI cells, flow cytometry as detailed in Chapter 2.2.4, was used. In both 
cell lines, there were no significant changes in cell cycle profile, as in both cases ~60 % of the 
cells were in G1, ~15-20 % in S phase and  ~20 % of the cells were in G2/M both in the 
control and Ryuvidine treated arms (Figure 5.10). 
To further investigate  the  cell cycle distribution upon treatment with Ryuvidine, cyclin B 
levels were assessed by Western blotting in a similar experiment to that performed for 
UNC0379 (Figure 5.6). Significant changes were detected in cyclin B levels at the protein 
level was noticed by measuring with densitometry (Figure 5.10). Therefore, it may be 
concluded from the experimental conditions herein that Ryuvidine does affect cell cycle 
distribution of LNCaP and LNCaP-AI cells confirmed by looking at cyclin B expression level 
, particularly with the high doses of Ryuvidine.
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Figure 5-10 Ryuvidine has no impact on cell cycle distribution in PC cells. 
(A) LNCaP and (B) LNCaP-AI cells were treated with Ryuvidine for 48 hours in 6 
well plates. Cell cycle analysis was performed using propidium iodide to stain 
cellular DNA for 40 minutes. Protein was also collected from samples treated with 
increasing doses of Ryuvidine (0, 1, 1.5, 2, 2.5, 3 µM) and cyclin B expression was 
detected by Western blotting and measured by densitometry using Epson scanner 
and labWork 4.0 software. p-values were determined by t-test (* p-value <0.05, ** 
p-value <0.01, *** p-value <0.001 and **** p- value < 0.0001).  
A (i) 
(ii) (ii) 
B(i) 
(iii) (iii) 
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5.3.8. The effect of Ryuvidine on FOXM1, PLK1, CDC20 expression in LNCaP and LNCaP-
AI cells 
Depletion of KMT5A was shown to cause a statistically significant  reduction (p≤0.05) in 
CDC20, FOXM1, and PLK1 expression at both the protein and mRNA levels when siRNA 
against KMT5A was used in LNCaP and LNCaP-AI cells (Figure 4. 1, Figure 4. 9 and Figure 
4. 10). In order to determine the effect of Ryuvidine as a KMT5A inhibitor on the expression 
levels of these proteins, LNCaP and LNCaP-AI cells were treated with Ryuvidine (0.77 µM 
LNCaP and 2.76 µM LNCaP-AI) for 48 hours at 37 °C. Protein lysates were collected and the 
expression levels of CDC20, FOXM1and PLK1 were measured by Western blotting (Figure 
5.11). In LNCaP cells, there was a significant reduction in CDC20 and a modest reduction in 
FOXM1 expression. However, no changes were detected in PLK1 expression (Figure 
5.11.A). Interestingly, in LNCaP-AI cells, a robust reduction in FOXM1, CDC20, and PLK1 
expression was clearly detected (Figure 5.11.B).  
From the data above, Ryuvidine showed consistency with the effect of KMT5A knockdown 
on CDC20, FOXM1 and PLK1 expression in LNCaP-AI cells. Furthermore, the depletion of 
CDC20 in LNCaP and LNCaP-AI cells in response to Ryuvidine supports the role of KMT5A 
in regulating CDC20 expression of PC cells. 
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Figure 5-11 Effects of Ryuvidine on FOXM1, PLK1 and CDC20 expression 
in LNCaP and LNCaP-AI. (A) LNCaP and (B) LNCaP-AI cells were seeded out 
at appropriate densities and allowed to adhere for 24 hours. Ryuvidine was then 
applied 0.77 µM in LNCaP and 2.76 µM in LNCaP-AI cells for 48 hours. Protein 
lysates were then collected and the expression of FOXM1, PLK1 and CDC20 were 
determined by Western blotting. Alpha-tubulin was used as loading control 
(representative blot).  
A B 
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5.4. Discussion 
 
KMT5A is being considered as an important new therapeutic target, due to its effect on a wide 
range of cellular biological processes and role in carcinogenesis (Shi et al., 2007; Takawa et 
al., 2012). UNC0379 was the first KMT5A selective inhibitor to be discovered (Ma et al., 
2014a). UNC0379 was initially designed to target L3MBTL1, but, the required activity was 
not found. However, it was found to be active against KMT5A using a radioactive 
biochemical assay looking at the ability to transfer the tritiated methyl group from 3H-SAM to 
a peptide substrate (Ma et al., 2014a; Milite et al., 2016).  
In this study, the effect of UNC0379 on KMT5A enzymatic activity was evaluated for LNCaP 
and LNCaP-AI cells, by investigating the changes in the levels of H4K20me1. In vivo studies 
suggest that the loss of KMT5A has the effect of decreasing the creation of H4K20me1 mark 
(Balakrishnan and Milavetz, 2010)  therefore by targeting KMT5A with a selective inhibitor a 
similar effect on H4K20me1 formation would be expected. Indeed, a robust reduction in 
H4K20me1 expression was detected in both cell lines (Figure 5.4). 
Previously, it has been shown that KMT5A can function as a coactivator of the AR, a key 
therapeutic target for PC (Coffey et al, unpublished). The inhibition of KMT5A may result in 
a reduction in AR activity in PC cell line models. Therefore, the effect of UNC0379 on AR 
target gene expression (KLK3, KLK2) was the next aspect that was investigated. The results 
showed that targeting LNCaP and LNCaP-AI cells with UNC0379 had no significant effect 
on AR target genes expression (Figure 5.5.) in both cell lines. This is contradictory to the 
study by Coffey et al., and the data obtained by KMT5A depletion by siRNA, which showed 
a significant increase in KLK3 expression in response to KMT5A knockdown accompanied 
by DHT treatment in LNCaP and LNCaP-AI cells (Figure 3.2, 3.3). However, in the study by 
Coffey et al., and the experiment performed in Figure 3.2 and 3.3, DHT was used to stimulate 
the activity of the AR. Hence, another repeat of this experiment in the presence of DHT is 
recommended for future studies to determine whether AR-regulated genes are truly affected 
by UNC0379. 
As another method to validate the inhibition of KMT5A with UNC0379, cell cycle profiles 
were determined (Figure 5.6) and compared to the data generated in Chapter 4 (Figure 4.2) 
where cell cycle profile was detected following KMT5A depletion using siRNA. Treatment 
with UNC0379 showed a significant reduction in cyclin B expression was noticed at the 
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protein level, which indicate an effect on cell cycle progression. The effect of UNC0379 on 
cultured cells has not been studied before, therefore, the effect on cell cycle profile was 
unknown. However, trying to repeat this experiment by looking at cell proliferation in the 
presence of UNC0379 will be essential to directly compare with the data obtained in Chapter 
4 (Figure 4.4) which showed a significant reduction in LNCaP and LNCaP-AI cell 
proliferation in response to KMT5A depletion using siRNAs. 
In Chapter 4, KMT5A depletion using siRNAs was found to affect the expression of CDC20, 
FOXM1, and PLK1 (Figure 4.1, Figure 4.9 and Figure 4.10). As another method to determine 
whether KMT5A is truly inhibited by UNC0379, the expression of these proteins was 
assessed in the presence and absence of this drug. Interestingly, a clear reduction was 
observed in the expression of all these proteins in LNCaP and LNCaP-AI cell lines upon 
application of UNC0379 for 48 hours (Figure 5.7) suggesting that UNC0379 may well be able 
to inhibit the activity of KMT5A. The relationship between KMT5A and these proteins has 
not been previously reported and it is still unknown whether it is the presence or the activity 
of KMT5A that is required for the regulation of these proteins. In addition, since UNC0379 
showed an effect on both the expression (although non-robust) and the activity of KMT5A, 
this data does go some way to support a role for KMT5A in the regulation of CDC20, 
FOXM1 and PLK1. The data also support the role of UNC0379 as an inhibitor for KMT5A in 
PC cells. 
Ryuvidine, also known as SPSI82 was one of three compounds (SPSI81, 2 and 3) with 
cellular activity against KMT5A that was discovered as a part of a high throughput screen 
(Blum et al., 2014). This study showed a significant reduction in H4K20me1 levels following 
24-48 hours treatment with increasing doses range of Ryuvidine (0-3 µM). This data could 
not be reproduced in LNCaP and LNCaP-AI cells when the same dose of Ryuvidine (0-3 µM) 
was used for the same period of time. This might be a result of using PC cells, while in their 
study the effect was tested in HEK293T cells. The Blum group also demonstrated a 
significant accumulation of cells in S-phase following treatment with 1 µM Ryuvidine for a 
period of 24-48 hours. This experiment was repeated in Figure 5.10, and also showed a 
significant reduction in cyclin B expression a the protein level, which suggest an effect on cell 
cycle progression in response to Ryuvidine treatment. 
Similar to experiment done for UNC0379, the effect of Ryuvidine on AR target genes 
expression was also investigated (Figure 5.9). A significant reduction was detected in 
KLK3and KLK2 expression in LNCaP and LNCaP-AI cells in response to Ryuvidine, 
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applying GI50 dose treatment for 48 hours (p≤0.05). Another repeat of this experiment 
including the DHT stimulation is recommended, so it can be directly compared to KLK3 
expression data obtained by KMT5A depletion accompanied by DHT stimulation in LNCaP 
and LNCaP-AI cells (Figure 3.2, 3.3). 
The effect of Ryuvidine on the protein expression levels of FOXM1, CDC20 and PLK1 was 
also tested similarly to UNC0379. A robust reduction in the expression of CDC20 in both cell 
lines and FOXM1 and PLK1 in LNCaP-AI cells was detected in response to Ryuvidine 
treatment (Figures 5. 11) further supporting the model that KMT5A can regulate the 
expression of these proteins and that they may serve to function as biomarkers for the 
KMT5A activity. 
Both UNC0379 and Ryuvidine showed an effect on the loading controls in western blotting, 
both tubulin and H4 loading controls showed the same effect with the higher doses of the 
drugs, as the bands started to faint with dose increase. This might be due to the effect of the 
higher doses of the drugs on the proliferation of the cells, as was noticed by looking to the 
cells treated with these two drugs under the microscope, which was consistent with what was 
reported on Ryuvidine effect on the cell cycle progression at higher doses (Blum et al., 2014). 
Further investigation of the effect of increasing doses of these two drugs on the tested cell 
lines proliferation might be required. 
To conclude, UNC0379 was more effective when directly examining KMT5A enzymatic 
activity represented by fluctuation in H4K20me1 expression, while Ryuvidine did not show 
such an effect. On the other hand, UNC0379 showed less effect on AR target genes 
expression, while Ryuvidine did significantly reduce their expression at the mRNA level. 
Both UNC0379 and Ryuvidine robustly reduced CDC20 expression at the protein level. 
Further experiments are required to determine the specificity of UNC0379 and Ryuvidine 
towards KMT5A to determine if the data obtained is a direct result of the inhibited KMT5A 
activity or whether the effects are through other pathways in the cell that could be affected by 
these two inhibitors, as for example Ryuvidine is documented as an in vitro inhibitor of 
cyclin-dependent kinase 4 and 2 (CDK4/2) with a GI50 > 5 µM (Blum et al., 2014).The effect 
of  UNC0379, on H4K20me1 activity of KMT5A might also has an extended effect to the 
different substrates being methylated by KMT5A such as TWIST, RNA polymerase II and 
ERα (Kapoor-Vazirani and Vertino, 2014; Li et al., 2011a; Wang et al., 2015). This possible 
effect might be further examined to confirm the specicifty of UNC0379 as KMT5A inhibitor. 
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6.1. Expression profile of KMT5A regulated genes 
KMT5A has been subjected to intense study since its discovery in 2002, a consequence of the 
major role that this histone lysine methyltransferase enzyme plays in regulating various 
aspects of cellular functions (guowei, 2002).  However, KMT5A regulated gene profiles have 
not been conducted to date. Previous study by Coffey et al, has shown the important role that 
KMT5A plays in regulating the AR in PC, and how this role changes from being an AR 
suppressor in an androgen-dependent PC cell line model to be become an AR activator in an 
androgen-independent model (Coffey et al, unpublished data). To understand the relationship 
between KMT5A and the AR, and the genes that might be regulated by this relationship, 
KMT5A regulated gene expression profiles were studied in this thesis. 
Using Illumina Human HT-12 arrays, genes that are regulated by KMT5A in the presence of 
activated AR and genes that are independently regulated by KMT5A in PC cells were 
identified. Specifically, 51 genes were regulated by KMT5A independently of AR, from 
which CDC20, HIST1H2BD and RAB4A were further validated; 199 genes were androgen- 
regulated genes that are modulated by KMT5A, from which CDC42EP3, YIPF1 and KIF22 
were validated. Originally the microarray experiment was carried out in the LNCaP-AI cell 
line, which is a model of androgen independence. In this cell line, KMT5A had been found to 
be a coactivator of the AR. However, validation experiments included both LNCaP-AI and 
the parental, androgen dependent, LNCaP cell line. Interestingly, although KMT5A has been 
found to have differing effects on AR activity in these cell lines (Coffey et al., unpublished 
data), there was no significant difference in the expression of the selected AR regulated/ 
KMT5A modulated genes from the microarray experiment for both cell lines. One possible 
explanation for this is the length of DHT stimulation used in this experiment. As shown in 
Figures 3.1.C and D., KLK3 expression peaked at 24 hours in LNCaP cells and then begins to 
fall slightly, while it continues to increase over the full 72 hours in the LNCaP-AI cells. 
However, the time point of 24 hours that was selected for the microarray experiment was 
designed to detect genes that are directly regulated by AR rather than genes which are 
regulated by secondary effects of alternative signaling pathways that KMT5A depletion might 
affect. A longer DHT treatment should be considered to give a better indication of any 
temporal differences and fold changes in expression of these genes between the LNCaP and 
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LNCaP-AI cell line models, as differential effects were clearly observed between 48 and 72 
hours DHT stimulation in the initial study which identified KMT5A as an AR regulator 
protein (Coffey et al, unpublished data). Genes that were identified and selected as AR 
regulated/ KMT5A modulated genes (CDC42EP3, YIPF1 and KIF22) have previously been 
identified as androgen responsive in PC cells treated with R1881 and PC patients under ADT 
(Munkley et al., 2016). A number of genes that have been described as KMT5A regulated 
such as p53, CDH1 and VIM (Yang et al., 2012b; Marouco et al., 2013) were shown to 
respond in the same way in the microarray and the subsequent validation data. Specifically for 
CDH1 and VIM, an increase in the expression of CDH1 and a reduction in the expression of 
VIM following KMT5A depletion confirmed CDH1  and VIM as being negatively and 
positively regulated, respectively by KMT5A, likely through its mono-methylation activity on 
promoters of these genes (Figure 3.4). In addition, KMT5A depletion promoted p53 
transcriptional activity, which was reflected by evaluating p53 target gene expression, where 
CDKN1A expression was found to increase significantly in response to KMT5A depletion 
according to the microarray results (Figure 4.16). 
6.2. CDC20 as a potential biomarker for KMT5A activity in CRPC 
CDC20 was identified as a novel KMT5A regulated gene independent of the AR according to 
the microarray data (Figure 3.11 and Figure 4.3). CDC20, an APC substrate recognizing 
subunit,  plays an important role in cell cycle progression during early mitosis from 
metaphase to anaphase (Manchado et al., 2010). CDC20 expression was reduced significantly 
in response to KMT5A depletion in both LNCaP and LNCaP-AI cells both at the protein and 
the mRNA levels independently of AR (Figure 3.11 and Figure 4.3). As both, CDC20 and 
KMT5A, are cell cycle regulators (guowei, 2002; Rice et al., 2002), it was not surprising to 
find a significant reduction in cellular proliferation in response to either CDC20 or KMT5A 
knockdown, which is an important indicator of the potential role that these two proteins play 
in the progression of PC. A physical interaction was also detected between KMT5A and 
CDC20, which reflects the possible role that KMT5A enzymatic activity has in regulating 
CDC20 expression. This was further confirmed by looking at H4K20me1 enrichment at the 
CDC20 promoter in both LNCaP and LNCaP-AI cells. However, the enrichment of 
H4K20me1 at the CDC20 promoter following AR activation using 100 nM DHT was varied 
between LNCaP and LNCaP-AI cells. However, the data is consistent with our group 
previous work demonstrating DHT-induced, reduction in KMT5A expression in LNCaP cell 
line but oppositely DHT-induced, increased KMT5A expression, in LNCaP-AI cells (Coffey 
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et al, unpublished data). The altered levels of KMT5A would therefore impact on the level of 
H4K20me1 at the CDC20 promoter as was demonstrated (Figure 4.10).  
KMT5A was found to be a regulator of CDC20 expression in this thesis, hence, CDC20 may 
be a potential biomarker for KMT5A activity in PC cells. The same effect was also observed 
in response to the KMT5A inhibitors UNC0379 and Ryuvidine, as both robustly reduced the 
expression of CDC20. However, more experiments are required, mainly to confirm that 
KMT5A does indeed regulate CDC20 directly at the promoter. These experiments could 
include knockdown of KMT5A and monitoring H4K20me1 enrichment at the CDC20 
promoter in both LNCaP and LNCaP-AI cell lines. However, the lack of a suitable KMT5A 
commercial antibody for application in ChIP experiments is currently hampering these 
experiments.  
6.3. KMT5A can regulate CDC20 expression indirectly through p53 K382me1 
FOXM1 which plays an important role in regulating G2/M phase progression (Dai et al., 
2013) has been reported as a CDC20 transcriptional activator in tumour initiating cells (TICs) 
(Xie et al., 2015). As such, FOXM1 was investigated as a factor that may function as an 
intermediate in the regulation of CDC20 by KMT5A. Interestingly, a significant reduction 
was noticed in FOXM1 expression in response to KMT5A knockdown both at the mRNA and 
the protein level (Figure 4.11), which was also reflected in downstream FOXM1 substrate 
expression (PLK1 and Cyclin B). Expression of both genes was significantly reduced in 
response to KMT5A depletion as noticed from the microarray data and also the subsequent 
validation at the protein level in LNCaP and LNCaP-AI cell lines (Figure 4.12). However, 
this experiment does not conclusively show that this is a direct effect of KMT5A on FOXM1 
expression, further experimentation would be required including ChIP assays to look at 
KMT5A recruitment to the FOXM1 promoter. Nevertheless, this preliminary data does 
suggest that FOXM1 may be an important intermediary. To investigate further, depletion of 
FOXM1 was performed, looking at CDC20 expression in PC cells. No significant effect on 
CDC20 expression was apparent with one of the targeting siRNAs but there was a very small 
but significant effect on CDC20 expression with the second siRNA (Figure 4.14). This 
observation was not wholly consistent  with  previous reports which demonstrated a 
significant reduction in CDC20 expression with FOXM1 depletion in TICs (Xie et al., 2015), 
suggesting that cellular background may be important. Hence, it was concluded that FOXM1, 
whilst clearly regulated by KMT5A in PC cell line models, does not participate in the 
subsequent regulation of CDC20.     
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A second line of investigation was pursued based on the fact that p53 can regulate CDC20 
expression either directly through binding to the CDC20 promoter or indirectly through p53 
binding to the CDE-CHR element independently of p21. KMT5A has been shown to 
methylate p53 at K382 in order to regulate its activity (Kidokoro et al., 2007; Banerjee et al., 
2009). A model was therefore proposed to explain the possible relationship between KMT5A, 
p53 and CDC20 in PC cells (Figure 4.15). This hypothesis was investigated by mining the 
microarray data which revealed an increase in CDKN1A and a reduction in CDC20 expression 
in response to KMT5A depletion in LNCaP-AI and LNCaP cells. To determine whether the 
post-translational modification of p53 was indeed responsible for this observation, p53 
acetylation and phosphorylation markers were assessed (Figure 4.19, 4.20) as methylation of 
p53 at K382 by KMT5A results in an inability of acetylation and phosphorylation to occur 
(Shi et al., 2007). Interestingly, knockdown of KMT5A in LNCaP-AI cells resulted in an 
increase in the acetylation of p53 at K382 and the phosphorylation at S15 as predicted, which 
was also reflected in the knockdown of KMT5A in LNCaP cells grown in FM (Figure 4.20).  
 As a second method to investigate these findings, Nutlin3 was used to activate p53 as a more 
specific way to affect p53 activity, as knockdown of KMT5A will affect many pathways in 
the cell which could be interfering with p53 activity. A significant increase in p53 and p21 
expression was seen in both cell lines in response to Nutlin3, which was accompanied by a 
reduction in CDC20 expression both at the protein and the mRNA level (Figure 4.22, 4.23). 
The data showed that CDC20 is affected by p53 activity in PC cells and that it is possible that 
KMT5A can regulate CDC20 expression through its methylation activity on p53-K382. 
p53 has also been reported to be a negative regulator of  FOXM1 expression in  either a p21 
and Rb dependent or in an independent manner (Barsotti and Prives, 2009). A possible model 
was suggested in Chapter 4 (Figure 4.24) to explain how that might be happening. With 
KMT5A depletion, p53 is less likely to be subject to mono-methylation. Consequently, the 
K382 residue will be available for acetylation, which enables p53 transcriptional activation 
and subsequent activity to be exerted on its substrates, including FOXM1. Activated p53   
would results in reducing FOXM1 expression and in turn its activity on its substrates. 
Treatment of LNCaP and LNCaP-AI cells with 5 µM Nutlin3 resulted in significantly reduced 
FOXM1 expression both at the protein and the mRNA level, which confirmed that p53 does 
regulate FOXM1 expression in PC cells and that the model tested is still feasible (Figure 4.25, 
4.26). No further work has been done on this aspect. However, the preliminary data is 
encouraging. A critical experiment that should be performed is the detection of p53-K382-
me1 at the protein level in response to KMT5A depletion in order to determine the effect of 
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KMT5A methylation activity on p53 in androgen dependent and independent PC cells. 
However, a specific p53-K382-me1 antibody is unavailable commercially. 
6.4. KMT5A inhibition in LNCaP and LNCaP-AI cells  
As KMT5A is an important regulator of many cellular functions, a number of attempts have 
been made to develop inhibitors against KMT5A activity. From the limited inhibitors 
available that are claimed to target KMT5A activity, UNC0379 and Ryuvidine (Blum et al., 
2014; Ma et al., 2014b) were selected to be tested in this thesis. The effect of these inhibitors 
was studied on KMT5A activity in PC cells, and a robust reduction in H4K20me1 was 
detected using UNC0379, while a lesser effect was seen with Ryuvidine. However, both of 
the inhibitors robustly reduced the expression of CDC20 and FOXM1 at the protein level in 
both cell lines (Figure 5.7, 5.11). Hence, using these inhibitors supported the suggested model 
for the regulation of CDC20 by KMT5A as described in Chapter 4. 
A previous study found that Ryuvidine causes an accumulation of cells in the S phase of the 
cell cycle (Ma et al., 2014a), an effect which was noticed in this thesis  using the same dose 
range of  Ryuvidine for the same duration looking at cyclin B expression at the protein level 
as a marker for G2/M phase of the cell cycle(Figure 5.10). The same effect on cyclin B was 
also noticed with UNC0379 treatment (Figure 5.6). Further experiments are required to 
confirm the specificity of these inhibitors towards KMT5A in a cellular context, in order to 
confirm that the cellular changes observed are not due to off target effects rather than the 
inhibition of KMT5A activity itself. For example, Ryuvidine has been documented as an in 
vitro inhibitor of cyclin-dependent kinase 2 and 4 (CDK2/4) with GI50 > 5 µM (Blum et al., 
2014). 
6.5. Conclusion  
Determination of KMT5A regulated gene expression profiles revealed that CDC20 is 
regulated by KMT5A indirectly via p53 methylation, and that more experiments are required 
to cover the possibility of considering CDC20 as a putative biomarker for KMT5A activity in 
PC cells through a direct regulation at the CDC20 promoter level. The independent effect of 
KMT5A from AR in the regulation of CDC20 in both androgen dependent and independent 
PC models used in this study might give another possible explanation for the continuity of PC 
cells growth and proliferation despite antiandrogen treatment, and that targeting CDC20 via 
using KMT5A inhibitors might play a role in the regulation of PC cells proliferation.  The 
data also showed that for the models of PC used in this study, AR was found not to be integral 
to KMT5A activity in models of androgen independence used.
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Future directions 
Further experiments might be required in order to confirm or investigate in depth some of the 
study findings including: 
1. Looking at the effect of KMT5A depletion on the expression of p53-K382-me1 at the 
protein level is essential to correlate FOXM1 expression changes to KMT5A through 
p53-K382-me1. 
2. Looking at p53-K382 -me1 expression levels in the presence and absence of KMT5A 
is required to further support the suggested possible pathway.  
3. Investigating the enrichment of p53 and p21 at the CDC20 promoter in PC cells. 
4. Immunoprecipitation are required to see if KMT5A and CDC20 interact as part of the 
APC complex or whether they can interact independent of this. 
5. To support the role of KMT5A activity in regulating CDC20 expression by 
knockdown of KMT5A and looking at H4K20me1 enrichment at the CDC20 promoter 
in LNCaP and LNCaP-AI cells. However, the required KMT5A antibody is 
unavailable commercially.  
6.  FOXM1 seems to be regulated by AR in PC cells. However, further investigation is 
required to further understand the underlying mechanism 
7. Confirm the specificity of these inhibitors towards KMT5A in a cellular context. 
8. Another repeat of the experiment of the effect of Ryuvidine and UNC0379 on AR 
target genes including the DHT stimulation is recommended, so it can be directly 
compared to PSA expression data obtained by KMT5A depletion accompanied by 
DHT stimulation in LNCaP and LNCaP-AI cells (Figure 3.2, 3.3). 
9. This possible effect of UNC0379 and Ryuvidine on cell proliferations on the tested 
cell lines. 
10. Further examination of the effect of treatment of the tested PC cell lines on the 
H4K20me1 activity of KMT5A on some of its substrates as TWIST, ERα and RNA 
polymerase II, to confirm the specicifty of UNC0379 as KMT5A inhibitor.  
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7.1. Microarray  
Table 7-1 microarray samples  
Condition Sample ID description KMT5A 
knockdown 
DHT
AI.NS.0hr‐DHT 1A, 1B, 1C, 1D Non‐silencing under steroid 
depleted conditions 
no no
AI.NS.24hr+DHT 4A, 4B, 4C, 4D Non‐silencing with 10 nM DHT 
for 24 hours
no yes
AI.#1.0hr‐DHT  2A, 2B, 2C, 2D KMT5A knockdown with siRNA 
#1 under steroid depleted 
conditions 
yes no
AI.#124hr+DHT  5A, 5B, 5C, 5D KMT5A knockdown with siRNA 
#1 with 10 nM DHT for 24 hours 
yes yes
AI.#2.0hr‐DHT  3A, 3B, 3C, 3D KMT5A knockdown with siRNA 
#2 under steroid depleted 
conditions
yes no
AI#2.24hr+DHT  6A, 6B, 6C, 6D KMT5A knockdown with siRNA 
#2 with 10 nM DHT for 24 hours 
yes yes
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7.2   Microarray data analysis: Heat map 
 
 
 
  
Figure 7-1: Microarray data analysis: Heat map of expression intensities of : (A) genes that 
are regulated by KMT5A in the presence and absence of DHT stimulation, (B) genes that are 
regulated by KMT5A only in the presence of androgen stimulation in LNCaP-AI cells and (C) genes 
that are regulated by KMT5A independent of DHT stimulation. Y axis represents the genes in each 
group. X axis represents experiments samples, each group (B, C) includes a non-silencing sample 
+/- DHT (10 nM) and KMT5A siRNA samples +/- DHT (10 nM). 
 
 
A B C 
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Figure 7-2 Hierarchical clustering analysis of the microarray samples 
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Figure 7-3 PCA blot of : (A) microarray samples, (B) microarray groups 
A 
B 
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Table 7-2 microarray data analysis: 57 genes regulated by KMT5A independent 
of DHT 
ID  symbol  logFC  AveExpr  P.Value  adj.P.Val 
ILMN_1757467  H1F0  ‐1.08835 11.22026 6.27E‐09 2.66E‐05 
ILMN_1805271  ZNF721  ‐1.04533 9.007149 2.31E‐05 0.012968 
ILMN_2347068  MKNK2  ‐1.03495 12.16529 2.46E‐05 0.013318 
ILMN_3238680  C7orf55  ‐0.96964 12.23243 6.20E‐06 0.005196 
ILMN_2405592  EMC6  ‐0.96195 10.50941 5.79E‐07 0.00108 
ILMN_1758674  EMC6  ‐0.94091 12.17065 4.20E‐08 0.00014 
ILMN_2055165  MRFAP1  ‐0.91885 13.008 7.60E‐05 0.022612 
ILMN_2359789  RAC1  ‐0.91883 11.77133 1.92E‐05 0.011812 
ILMN_2104106  XPR1  ‐0.88566 10.13699 0.000101 0.026185 
ILMN_2110532  RPL26L1  ‐0.87964 11.24658 4.63E‐08 0.00014 
ILMN_1744912  CTTN  ‐0.86911 9.7198 2.06E‐06 0.002511 
ILMN_1779751  C7orf55  ‐0.86137 10.88068 0.000184 0.034831 
ILMN_2128741  RDH11  ‐0.84181 10.34657 1.36E‐05 0.009594 
ILMN_2393712  CTTN  ‐0.81809 9.834393 1.61E‐05 0.010625 
ILMN_2388507  AKT1  ‐0.78835 10.20818 7.06E‐05 0.021931 
ILMN_1652512  C2CD2  ‐0.7623 10.31097 7.48E‐05 0.022559 
ILMN_2307032  OSBPL5  ‐0.76054 9.07594 0.000241 0.040124 
ILMN_1720438  RPL26P30  ‐0.75084 11.63348 5.36E‐06 0.00492 
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ILMN_1772981  EPN1  ‐0.74729 12.14168 0.000117 0.029838 
ILMN_1804735  CBS  ‐0.73195 11.33409 4.82E‐05 0.019954 
ILMN_1712556  ZW10  ‐0.7167 9.735771 0.000255 0.041436 
ILMN_1705876  NAP1L1  ‐0.67497 9.201547 3.09E‐05 0.014819 
ILMN_1703891  TBC1D9  ‐0.67318 8.760676 4.91E‐05 0.019954 
ILMN_1773567  LAMA5  ‐0.65483 11.29597 0.000174 0.033454 
ILMN_2373763  CASP7  ‐0.64758 8.305084 5.32E‐05 0.020061 
ILMN_1776586  RPL26L1  ‐0.62479 10.32787 0.000122 0.029886 
ILMN_1751346  ERBB3  ‐0.60254 11.02226 7.79E‐06 0.005873 
ILMN_1678087  MAP3K4  ‐0.54956 8.699426 7.90E‐05 0.023168 
ILMN_1802799  AKIRIN1  ‐0.54647 9.307711 6.87E‐05 0.021931 
ILMN_1660341  LRPAP1  ‐0.53766 10.04378 0.000141 0.032068 
ILMN_1714756  YIPF5  ‐0.5343 8.20526 2.26E‐06 0.002511 
ILMN_1785356  DENND5A  ‐0.46799 8.83668 0.000316 0.048047 
ILMN_1775939  SF3B2  ‐0.3539 10.99705 4.78E‐05 0.019954 
ILMN_2112599  C16orf80  0.391709 10.34499 0.000313 0.048047 
ILMN_1770035  NCOA5  0.430095 8.74122 0.000145 0.032411 
ILMN_1753286  MYO19  0.461585 8.148915 5.71E‐05 0.020791 
ILMN_3239181  ITPRIP  0.507681 8.901604 5.04E‐05 0.019959 
ILMN_2077886  C1orf109  0.52436 9.305174 0.000122 0.029886 
ILMN_1680091  POP7  0.526673 9.896519 0.000326 0.04874 
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ILMN_1805192  ITPRIP  0.58975 9.188232 9.37E‐07 0.001319 
ILMN_1711450  NELFCD  0.591567 10.81805 9.75E‐05 0.026185 
ILMN_1678678  SLC37A4  0.640783 12.01151 0.000163 0.03305 
ILMN_1684205  CIB1  0.646404 12.89573 6.40E‐06 0.005196 
ILMN_1756355  NDUFS3  0.678602 12.39527 6.36E‐05 0.021644 
ILMN_1676296  PPAP2A  0.71265 10.28284 0.00015 0.032528 
ILMN_1750711  MYO19  0.716666 8.399239 0.000171 0.033454 
ILMN_1681008  CGRRF1  0.80424 9.566361 3.72E‐06 0.003743 
ILMN_3306742  SIGMAR1  0.869332 9.722861 0.000205 0.036906 
ILMN_2398489  SIGMAR1  0.877311 10.24105 0.000102 0.026185 
ILMN_2340721  TMEM134  1.00009 10.83618 0.00015 0.032528 
ILMN_1698243  C1orf85  1.012752 11.25785 6.98E‐07 0.001134 
ILMN_3231944  NA  1.078141 11.94226 0.000229 0.038471 
ILMN_1651936  SETD8 1.088865 8.542859 1.37E‐09 9.63E‐06 
ILMN_1802205  RHOB  1.208194 10.46835 6.30E‐06 0.005196 
ILMN_1808196  GSTO1  1.257747 11.02817 2.20E‐05 0.012895 
ILMN_1669210  SNORD16  1.362918 9.861519 1.34E‐07 0.000349 
ILMN_1796923  LOC81691  1.650372 9.536422 1.49E‐07 0.000349 
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Table 7-3 microarray data analysis: 226 genes regulated by KMT5A in the 
presence and absence of DHT 
ID  symbol  logFC  AveExpr  P.Value  adj.P.Val 
ILMN_1784602  CDKN1A  ‐1.46704 13.70571 2.36E‐06  0.001918 
ILMN_1676984  DDIT3  ‐1.43733 9.723055 5.96E‐06  0.004061 
ILMN_1651496  HIST1H2BD  ‐1.246 8.939616 1.39E‐05  0.006028 
ILMN_1792689  HIST1H2AC  ‐1.21968 9.385179 1.01E‐05  0.005207 
ILMN_1659047  HIST2H2AA3 ‐1.18965 11.81669 0.000406  0.032553 
ILMN_2377900  MAP1B  ‐1.12583 9.067097 0.000612  0.039518 
ILMN_1801205  GPNMB  ‐1.124 10.09419 0.000659  0.041302 
ILMN_2407389  GPNMB  ‐1.09216 9.462667 0.000852  0.048333 
ILMN_1667561  IFRD1  ‐1.05601 9.260324 2.24E‐06  0.001918 
ILMN_2089875  TNFSF4  ‐1.05425 8.736964 0.000158  0.019549 
ILMN_1768719  RDH11  ‐1.02956 12.75064 2.60E‐07  0.000687 
ILMN_1702933  ADM2  ‐1.0242 9.830516 2.70E‐05  0.007648 
ILMN_1718982  BEST1  ‐1.00953 8.351679 8.14E‐06  0.004523 
ILMN_1811264  C15orf57  ‐1.00543 9.756403 2.94E‐07  0.00069 
ILMN_1712556  ZW10  ‐0.95387 9.735771 3.98E‐07  0.000773 
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ILMN_1680154  MAP1B  ‐0.94359 8.581749 0.000168  0.019835 
ILMN_2390310  MIR22HG  ‐0.93089 8.548372 5.53E‐05  0.010616 
ILMN_1746948  MYL5 ‐0.89413 9.769292 0.000493  0.035654 
ILMN_2347068  MKNK2  ‐0.89159 12.16529 6.87E‐06  0.004144 
ILMN_3243253  LPAR3  ‐0.88855 9.760098 6.90E‐05  0.012255 
ILMN_1702683  SLC33A1  ‐0.87329 9.129753 1.85E‐06  0.001699 
ILMN_2404688  NUPR1  ‐0.86939 10.42869 0.00014  0.018235 
ILMN_1709719  LPAR3  ‐0.85529 9.112139 0.000169  0.019835 
ILMN_1758674  EMC6 ‐0.84881 12.17065 4.33E‐09  1.83E‐05 
ILMN_1745620  KRCC1  ‐0.84664 9.861956 1.51E‐05  0.006028 
ILMN_2405592  EMC6 ‐0.84012 10.50941 1.09E‐07  0.000382 
ILMN_1748281  MAPK10  ‐0.80493 9.03555 0.000817  0.047106 
ILMN_2128741  RDH11  ‐0.79625 10.34657 1.08E‐06  0.001357 
ILMN_3246900  LOC92249  ‐0.79481 10.1246 1.43E‐06  0.001631 
ILMN_1712678  RPS27L  ‐0.78939 12.5714 0.000193  0.021736 
ILMN_1796179  HIST1H2BK  ‐0.77855 12.42091 0.000109  0.015604 
ILMN_1758623  HIST1H2BD  ‐0.7751 8.815392 0.000135  0.017849 
ILMN_1654629  TMEM175  ‐0.75967 9.620888 1.47E‐06  0.001631 
ILMN_1777591  HOGA1  ‐0.74383 8.950932 9.78E‐07  0.001357 
ILMN_2316236  HOPX ‐0.73901 8.399782 1.65E‐05  0.006028 
ILMN_1658469  TP53TG1  ‐0.73656 9.725012 1.90E‐05  0.006367 
ILMN_1672128  ATF4 ‐0.72538 13.17621 1.58E‐05  0.006028 
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ILMN_2220739  TMCO3  ‐0.71689 9.039204 1.51E‐05  0.006028 
ILMN_1677843  RAB24  ‐0.71241 10.83457 0.000131  0.017667 
ILMN_1700915  BMI1  ‐0.70521 10.10946 2.90E‐05  0.007897 
ILMN_2359789  RAC1  ‐0.70284 11.77133 2.22E‐05  0.007113 
ILMN_2358457  ATF4  ‐0.70137 9.514065 0.000733  0.044326 
ILMN_1698019  LGMN  ‐0.69317 10.22165 0.000812  0.047106 
ILMN_1675406  PPAPDC1B  ‐0.67944 9.999557 0.000269  0.0269 
ILMN_1724897  C14orf93  ‐0.67593 9.053742 0.000338  0.029317 
ILMN_1694106  GPD1L  ‐0.66788 10.68853 2.72E‐05  0.007648 
ILMN_2379718  RAB24  ‐0.66231 9.774575 2.86E‐05  0.007897 
ILMN_1902658  LOC92249  ‐0.66103 9.60327 3.50E‐06  0.002638 
ILMN_2198878  INPP4B  ‐0.63836 8.665254 0.000264  0.026743 
ILMN_1805271  ZNF721  ‐0.63201 9.007149 0.000326  0.028902 
ILMN_1667564  ALDH3A2  ‐0.62977 8.774448 0.000838  0.047817 
ILMN_2110532  RPL26L1  ‐0.6275 11.24658 1.51E‐07  0.000455 
ILMN_1804735  CBS  ‐0.62708 11.33409 1.51E‐05  0.006028 
ILMN_1690703  LINC00478  ‐0.62486 10.2114 2.70E‐05  0.007648 
ILMN_1807662  IGF2R  ‐0.61068 11.35487 6.10E‐05  0.011498 
ILMN_1763568  ZDHHC16  ‐0.59618 11.34801 0.000619  0.039618 
ILMN_1704793  MYPOP  ‐0.59111 9.502472 8.18E‐05  0.012985 
ILMN_1802799  AKIRIN1  ‐0.57679 9.307711 1.65E‐06  0.001631 
ILMN_1779751  C7orf55  ‐0.57379 10.88068 0.000776  0.045708 
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ILMN_1779530  COG6 ‐0.56948 9.08974 5.07E‐05  0.010186 
ILMN_1803744  VIMP ‐0.56079 9.92619 4.31E‐05  0.009389 
ILMN_2346997  RAB23  ‐0.55719 9.612534 0.000277  0.027111 
ILMN_1791306  IDNK ‐0.55235 9.079785 0.00027  0.0269 
ILMN_1756572  COQ2 ‐0.54914 10.46523 0.00061  0.03948 
ILMN_1739441  GANAB  ‐0.54856 9.905494 0.000855  0.048405 
ILMN_3251501  SERF2 ‐0.54677 9.788033 0.000403  0.032553 
ILMN_3245458  SNORA61  ‐0.54393 9.807032 1.60E‐05  0.006028 
ILMN_1652512  C2CD2  ‐0.54349 10.31097 0.000179  0.020738 
ILMN_1804652  PLEKHH3  ‐0.54205 10.46956 1.33E‐05  0.006028 
ILMN_2158705  ACYP2  ‐0.53185 9.315826 0.000707  0.043259 
ILMN_2091375  KRCC1  ‐0.52971 8.190943 0.000135  0.017849 
ILMN_1787680  VIMP ‐0.52704 11.71035 8.41E‐05  0.013253 
ILMN_1680937  HIST1H2BC  ‐0.52221 7.979589 3.66E‐05  0.008777 
ILMN_1714599  CAMLG ‐0.5214 12.16864 0.000167  0.019835 
ILMN_1689908  ANKRD13A  ‐0.51925 10.11783 0.0003  0.027677 
ILMN_1773567  LAMA5  ‐0.51692 11.29597 0.000144  0.018252 
ILMN_1785356  DENND5A  ‐0.51039 8.83668 7.17E‐06  0.004206 
ILMN_2089073  ATP9A ‐0.5101 10.77621 0.000122  0.016877 
ILMN_1693227  ZC3H7A  ‐0.50468 8.850819 8.68E‐05  0.013375 
ILMN_1660341  LRPAP1  ‐0.50455 10.04378 1.67E‐05  0.006028 
ILMN_2413318  C15orf57  ‐0.50423 8.579085 3.76E‐05  0.008824 
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ILMN_1746492  IFT27  ‐0.50411 8.757326 0.000711  0.043388 
ILMN_1767422  POLR1D  ‐0.50334 14.25387 6.81E‐06  0.004144 
ILMN_2291619  RAB3IP  ‐0.49752 9.588614 3.49E‐06  0.002638 
ILMN_1732923  SIPA1L2  ‐0.49643 8.134009 1.56E‐05  0.006028 
ILMN_2056815  LINGO4  ‐0.49634 8.217291 0.000602  0.03948 
ILMN_1802631  AGA  ‐0.49332 8.923947 5.16E‐05  0.010273 
ILMN_2107991  HABP4  ‐0.49163 8.109203 5.63E‐07  0.00085 
ILMN_1735014  KLF6  ‐0.48673 8.511669 0.000758  0.045357 
ILMN_1728224  OGFR  ‐0.4824 8.254581 0.000103  0.015111 
ILMN_1654861  ACO2  ‐0.4816 10.00446 0.000162  0.019835 
ILMN_1760593  CRY1  ‐0.47997 8.780637 7.03E‐05  0.012266 
ILMN_1760174  MCCC1  ‐0.46752 10.39325 0.000576  0.038953 
ILMN_1720438  RPL26P30  ‐0.46394 11.63348 7.54E‐05  0.012673 
ILMN_1757467  H1F0  ‐0.4574 11.22026 2.50E‐05  0.007529 
ILMN_2393712  CTTN  ‐0.45467 9.834393 0.00054  0.037623 
ILMN_1794560  EMC6  ‐0.45358 8.73559 0.000445  0.03406 
ILMN_1727553  C5orf54  ‐0.44685 8.614251 3.93E‐05  0.009021 
ILMN_1706873  RPL34  ‐0.44619 10.43693 0.000579  0.038981 
ILMN_3247645  LOC550643  ‐0.44439 11.65188 0.00029  0.027501 
ILMN_1656335  RIT1  ‐0.44365 8.549628 0.000117  0.016378 
ILMN_1797342  FNBP1  ‐0.43751 9.807298 7.62E‐05  0.012673 
ILMN_1654060  MKNK2  ‐0.43737 8.224322 0.000132  0.017779 
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ILMN_1744912  CTTN  ‐0.43024 9.7198 0.000339  0.029317 
ILMN_1745152  UQCC1  ‐0.42924 9.245704 0.000361  0.030202 
ILMN_3245413  DENND5A  ‐0.42606 8.49004 8.17E‐05  0.012985 
ILMN_1776993  COG2  ‐0.41949 10.02662 4.50E‐05  0.009413 
ILMN_1681670  SLC25A4  ‐0.41725 10.53003 0.000167  0.019835 
ILMN_2202637  CRY1  ‐0.41301 8.967114 0.000346  0.029583 
ILMN_1777660  RNF144A  ‐0.41143 9.052313 0.000128  0.017511 
ILMN_1764500  BRK1  ‐0.40557 10.79488 0.000424  0.033237 
ILMN_1728426  INPPL1  ‐0.37618 9.159725 2.93E‐05  0.007897 
ILMN_1675038  PRMT2  ‐0.37284 8.635139 0.000636  0.040222 
ILMN_1794157  CATSPER2P1 ‐0.37145 8.517667 0.000463  0.034923 
ILMN_1754727  GPRASP2  ‐0.36956 9.158124 6.23E‐05  0.011643 
ILMN_1777106  LRRC57  ‐0.36385 8.302459 0.000475  0.035138 
ILMN_1719219  ZNF616  ‐0.36151 8.004969 1.62E‐05  0.006028 
ILMN_2115696  USP42  ‐0.35644 9.451247 0.000463  0.034923 
ILMN_2396956  AKAP13  ‐0.3554 8.28927 0.000417  0.033036 
ILMN_2340131  MAPK10  ‐0.35233 7.908372 0.00028  0.027229 
ILMN_1722726  ARHGAP32  ‐0.34896 9.164974 0.000295  0.027668 
ILMN_1751692  ZNF17  ‐0.34785 8.191574 0.000197  0.021975 
ILMN_1671777  FGF13  ‐0.33825 8.425269 0.000169  0.019835 
ILMN_2355225  LSP1  ‐0.33425 8.52703 0.000141  0.018235 
ILMN_2415911  ENOX2  ‐0.32187 8.346536 0.000898  0.049765 
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ILMN_1751346  ERBB3  ‐0.32023 11.02226 0.000468  0.035057 
ILMN_1774949  PIGP ‐0.31649 9.605158 0.000618  0.039618 
ILMN_1771800  PRKCA  ‐0.31567 8.185216 0.000587  0.039103 
ILMN_1746561  BCL2L2  ‐0.30828 9.463855 0.000606  0.03948 
ILMN_2246510  TSC1 ‐0.29434 9.416984 0.000803  0.047002 
ILMN_1677885  FMO4 ‐0.29282 8.013498 0.000553  0.038136 
ILMN_1699496  PHF21A  ‐0.28735 9.493864 0.00035  0.029583 
ILMN_1779841  PPP2R1B  ‐0.2867 8.022399 0.000622  0.039652 
ILMN_1788149  NEK11  ‐0.28363 8.193447 0.000595  0.039339 
ILMN_1792672  POLR2D  ‐0.28307 8.68112 0.000887  0.04952 
ILMN_1692413  NMNAT1  ‐0.28199 8.412449 9.85E‐05  0.014751 
ILMN_1714756  YIPF5 ‐0.27423 8.20526 0.000256  0.026446 
ILMN_2299843  ATP5S  ‐0.27065 9.064271 0.000149  0.018856 
ILMN_2388484  MAP2 ‐0.27045 7.907366 0.000478  0.035138 
ILMN_1764201  MAP2 ‐0.25969 7.834426 0.000394  0.032142 
ILMN_2333865  DNAJB12  ‐0.24794 9.123363 0.000705  0.043259 
ILMN_1682818  TTLL3 ‐0.22563 7.884228 0.000666  0.041615 
ILMN_3251155  PCBP2  0.261776 8.120238 0.000286  0.027322 
ILMN_1768226  ARMCX6  0.282263 8.029951 0.000151  0.018936 
ILMN_1733703  TRMU  0.288393 8.240659 0.000348  0.029583 
ILMN_1744959  NFX1  0.292108 9.024486 0.000307  0.027845 
ILMN_1691458  SYPL1  0.296264 9.097584 0.000269  0.0269 
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ILMN_1708369  EPS15L1  0.298147 8.16339 0.000433  0.033486 
ILMN_1701244  ITFG2  0.302417 8.143035 4.44E‐05  0.009413 
ILMN_1694274  NDUFC2  0.315259 8.19186 0.000672  0.041845 
ILMN_1725071  CCDC12  0.318827 9.988297 0.000342  0.029462 
ILMN_3272378  EZR  0.351794 12.14009 0.000806  0.047002 
ILMN_1672094  DLX1  0.355073 8.125494 0.000166  0.019835 
ILMN_1764851  TP53RK  0.359074 9.352697 0.000274  0.026999 
ILMN_1805192  ITPRIP  0.360311 9.188232 1.87E‐05  0.006367 
ILMN_1692429  PQBP1  0.381165 8.014851 6.35E‐06  0.004064 
ILMN_1795383  RPUSD3  0.388348 10.33861 0.000317  0.028223 
ILMN_1664761  TMEM138  0.388706 9.317954 0.000178  0.020714 
ILMN_3239181  ITPRIP  0.408294 8.901604 3.30E‐05  0.008201 
ILMN_1703894  BOLA2  0.42558 8.154848 0.000154  0.019295 
ILMN_1763875  ABCF1  0.428048 11.21989 0.000229  0.024035 
ILMN_1663954  NELFCD  0.4343 11.10966 6.91E‐05  0.012255 
ILMN_1673363  CD97  0.435428 10.1343 0.000221  0.023725 
ILMN_1753353  SLBP  0.443764 9.983898 0.000378  0.03093 
ILMN_1690125  PDLIM7  0.444988 8.451727 0.000568  0.03855 
ILMN_2077886  C1orf109  0.453575 9.305174 3.65E‐05  0.008777 
ILMN_1657898  MTFP1  0.453718 8.090228 7.51E‐05  0.012673 
ILMN_1695868  PRICKLE4  0.471815 12.40211 4.49E‐05  0.009413 
ILMN_2375418  DPH2  0.477601 10.23343 5.04E‐05  0.010186 
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ILMN_1810488  NFYC  0.488292 9.253861 5.51E‐05  0.010616 
ILMN_1681340  HSPB11  0.490309 10.01032 6.92E‐05  0.012255 
ILMN_2367191  PSMF1  0.49063 10.93973 0.000552  0.038136 
ILMN_1656254  NOTCH2NL  0.498286 8.583788 4.96E‐07  0.000805 
ILMN_1672080  NR2F6  0.501647 10.28405 5.49E‐05  0.010616 
ILMN_1687430  EIF2B4  0.503658 11.47999 9.96E‐05  0.014812 
ILMN_2402674  DPM3  0.507683 11.46211 0.000609  0.03948 
ILMN_1780924  SLC43A1  0.512675 8.297344 1.48E‐05  0.006028 
ILMN_1698243  C1orf85  0.51743 11.25785 0.000108  0.015604 
ILMN_1774432  DTD1  0.532781 9.45361 0.00019  0.021638 
ILMN_1718832  SPHAR  0.538741 8.607833 0.000565  0.038496 
ILMN_1812856  ZSWIM1  0.556158 10.06701 5.33E‐05  0.010513 
ILMN_2055477  EXOSC7  0.556828 10.55544 0.000258  0.026464 
ILMN_2356672  EIF2B4  0.557596 11.54201 0.000271  0.0269 
ILMN_1677877  UBE2L3  0.559589 9.132145 0.000332  0.02909 
ILMN_1711450  NELFCD  0.561718 10.81805 9.50E‐06  0.005011 
ILMN_1775677  TYSND1  0.571773 11.45695 0.000496  0.035714 
ILMN_1652777  CDC42EP2  0.572491 8.324909 7.16E‐05  0.012398 
ILMN_1803564  YIPF1  0.592997 10.02486 0.000208  0.022832 
ILMN_1704024  TMEM160  0.594535 9.593687 0.000283  0.027229 
ILMN_1775304  DNAJB1  0.594935 10.01511 7.77E‐06  0.004435 
ILMN_2052163  YIPF1  0.605483 10.77574 0.000375  0.03093 
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ILMN_1771376  PEA15  0.615298 11.79585 0.000247  0.025667 
ILMN_1679482  TUBA3C  0.629282 8.295667 0.000776  0.045708 
ILMN_1657796  STMN1  0.629924 9.43299 0.000213  0.023273 
ILMN_1738093  RNFT2  0.629982 9.933434 7.61E‐05  0.012673 
ILMN_1782633  BOLA2  0.649301 10.82018 0.000474  0.035138 
ILMN_2162253  NMU  0.654307 9.590243 0.000483  0.035225 
ILMN_1731640  TMSB15B  0.691827 9.753279 0.000596  0.039339 
ILMN_2042771  PTTG1  0.693154 12.26927 0.000419  0.033036 
ILMN_1796923  LOC81691  0.701897 9.536422 0.000226  0.024011 
ILMN_1676296  PPAP2A  0.706752 10.28284 9.21E‐06  0.004983 
ILMN_1737283  TMSB15B  0.707993 9.826054 0.000225  0.024009 
ILMN_1813260  TIMM17B  0.708093 9.772335 0.000473  0.035138 
ILMN_2330243  NUDT1  0.715069 9.700859 7.62E‐05  0.012673 
ILMN_1695491  WDYHV1  0.716721 9.115042 0.00013  0.017642 
ILMN_1681737  TMSB15A  0.733159 10.14198 0.000312  0.028063 
ILMN_1802205  RHOB  0.752864 10.46835 7.92E‐05  0.012768 
ILMN_1704873  TCEB1  0.758011 10.48937 6.30E‐06  0.004064 
ILMN_2227573  GSTO1  0.767017 11.68359 0.000401  0.032536 
ILMN_2157510  BLOC1S1  0.77094 10.05744 4.75E‐05  0.009772 
ILMN_1729179  SPATA5L1  0.775786 9.491515 0.000486  0.035247 
ILMN_1721868  KPNA2  0.778836 10.21664 1.62E‐06  0.001631 
ILMN_1811921  CSRP1  0.805965 10.52105 0.000501  0.035832 
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ILMN_2355665  MTFP1  0.820035 10.4277 0.000316  0.028223 
ILMN_1691237  CAP2  0.821721 11.41357 1.48E‐05  0.006028 
ILMN_1808196  GSTO1  0.862994 11.02817 8.57E‐05  0.013299 
ILMN_1708041  PLEKHF1  1.005253 10.33165 6.29E‐05  0.011649 
ILMN_1792681  CCDC86  1.009792 10.89798 2.34E‐05  0.007263 
ILMN_1803408  KRT18  1.018243 9.365723 1.70E‐06  0.001631 
ILMN_1651936  SETD8  1.052161 8.542859 4.13E‐11  8.73E‐07 
ILMN_1660793  PAQR4  1.086005 9.42754 2.41E‐05  0.007374 
ILMN_1663390  CDC20  1.102881 12.87905 0.000811  0.047106 
ILMN_2041222  KRT18P55  1.221556 11.56213 7.86E‐05  0.012768 
ILMN_1753584  KRT8  1.274144 10.65308 1.04E‐05  0.005252 
ILMN_1669210  SNORD16  1.519279 9.861519 5.70E‐10  4.01E‐06 
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7.3. Pathways analysis of the microarray data using Database for Annotation, Visualisation 
and Integrated Discovery (DAVID), v6.7   
Figure 7-4  Agrin in postsynaptic differentiation pathway. Genes included in 
the microarray data labelled by stars. Database for Annotation, Visualisation and 
Integrated Discovery (DAVID), v6.7 was used to analyse large gene lists and perform 
comprehensive clustering to outline genes with a similar function or biological theme. 
KEGG pathway analysis on steroid biosynthesis was included in the DAVID output.
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Figure 7-5 B cell survival pathway. Genes included in the microarray data 
labelled by stars. Database for Annotation, Visualisation and Integrated Discovery 
(DAVID), v6.7 was used to analyse large gene lists and perform comprehensive 
clustering to outline genes with a similar function or biological theme. KEGG 
pathway analysis on steroid biosynthesis was included in the DAVID output.  
Chapter 7: Appendix 
184 
Figure 7-6 MAPKinase signalling pathway. Genes included in the microarray 
data labelled by stars. Database for Annotation, Visualisation and Integrated 
Discovery (DAVID), v6.7 was used to analyse large gene lists and perform 
comprehensive clustering to outline genes with a similar function or biological 
theme. KEGG pathway analysis on steroid biosynthesis was included in the 
DAVID output.  
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Figure 7-7 Transcription factor CREB and its extracellular signal 
pathway. Genes included in the microarray data labelled by stars. Database for 
Annotation, Visualisation and Integrated Discovery (DAVID), v6.7 was used to 
analyse large gene lists and perform comprehensive clustering to outline genes 
with a similar function or biological theme. KEGG pathway analysis on steroid 
biosynthesis was included in the DAVID output.  
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Figure 7-8 Fc gamma R-mediated phagocytosis pathway. Genes included in 
the microarray data labelled by stars. Database for Annotation, Visualisation and 
Integrated Discovery (DAVID), v6.7 was used to analyse large gene lists and 
perform comprehensive clustering to outline genes with a similar function or 
biological theme. KEGG pathway analysis on steroid biosynthesis was included in 
DAVIDoutput.
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DAVID output. 
Figure 7-9 Pathogenic Escherichia coli infection pathway. Genes included 
in the microarray data labelled by stars. Database for Annotation, Visualisation 
and Integrated Discovery (DAVID), v6.7 was used to analyse large gene lists and 
perform comprehensive clustering to outline genes with a similar function or 
biological theme. KEGG pathway analysis on steroid biosynthesis was included in 
the DAVID output.  
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